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ABSTRACT 
The aT3 -1 gonadotroph- derived cell line was used as a model system to 
study intracellular signalling systems associated with the LHRH receptor, 
with particular interest in phospholipase D (PLD) and mechanisms involved 
in its regulation, such as protein kinase C (PKC) and non -receptor tyrosine 
kinases. 
Phospholipase D activation in aT3 -1 cells proceeded after a delay 
when stimulated by LHRH, or by the phorbol ester, phorbol 12,13 -dibutyrate 
(PDBu). LHRH -stimulated PLD activity was fully resistant to desensitisation 
over a 40 min time course. The Cat+ ionophore, ionomycin was unable to 
stimulate PLD activity. LHRH -stimulated PLD activity was inhibited by PKC 
downregulation or by bisindolylmaleimide PKC inhibitors at an 
approximately 8 -fold higher concentration than that seen for the PDBu- 
stimulated PLD activity. Another PKC inhibitor, H7, inhibited PDBu- 
stimulated PLD activity in a manner that indicated multiple components to 
the inhibition and inhibited LHRH -stimulated PLD activity with a low 
potency. This is consistent with the possibility that one mediator of the 
LHRH response is a form of PKC which is relatively resistant to certain PKC 
inhibitors and insensitive to phorbol esters, or that some other unknown 
kinase is involved. The tyrosine kinase inhibitors, lavendustin A and 
genistein were able to selectively inhibit the LHRH -stimulated PLD activity. 
Phospholipase D activation stimulated by LHRH was insensitive to 
pertussis toxin pretreatment, indicating that the heterotrimeric G- proteins, Gi 
and Go are not involved. 
LHRH induced tyrosine phosphorylation of a number of proteins in 
aT3 -1 cells; a similar phosphorylation profile was also produced by 
stimulation with PDBu. Tyrosine phosphorylation of proteins in aT3 -1 cells 
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was reduced by ionomycin. Two members of the src- family of non -receptor 
tyrosine kinases, src and fyn, were detected at significant levels in these 
cells by immunoblot. Using immunoprecipitation techniques we have 
shown that the enzymic activity of fyn is increased within 10 min of LHRH 
stimulation. 
The LHRH -stimulated PLD activity could not be detectably enhanced 
by a conditioning preincubation with LHRH, such as brings about the 
priming effect of LHRH ( a phenomenon of cellular sensitisation elicited by 
LHRH receptor activation). Removal of steroids from the growth medium 
severely impaired the PLD activation due to LHRH; this response was 
largely restored by addition of oestradiol -1713 but not progesterone. This 
may have implications for the LHRH priming effect in vivo, which is 
dependent upon the level of circulating steroid hormones. 
The murine LHRH receptor was transiently expressed in COS 7 cells 
from the cDNA in a pcDNA vector using a DEAE dextran transfection 
procedure. It was demonstrated that LHRH -stimulated PLD activation 
displayed similar sensitivity to the bisindolylmaleimide PKC inhibitor, Ro 
31 -8220, to that seen in aT3 -1 cells. It was not however sensitive to 
tyrosine kinase inhibitors or pertussis toxin. Using site -directed 
mutagenesis of residues 87 and 318 in the transmembrane 2 and 7 
domains of the LHRH receptor (which represents an inversion of the 
consensus motif in the G- protein coupled receptor family), it was found that 
mutation of Asp 318 to Asn was alone sufficient to produce a rapidly 
desensitising PLD response to LHRH, in contrast to the non -desensitising 
wild type. 
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1.1 Aims of this study 
The aim of this research project has been to elucidate the 
mechanism whereby phospholipase D is activated by the LHRH receptor in 
pituitary gonadotrophs, and as far as possible to identify the intermediary 
steps involved. Experiments to address the involvement of protein kinase 
C -like enzymes and non -receptor tyrosine kinases in LHRH receptor 
signalling and site -directed mutagenesis to address the role of specific 
receptor residues in signal transduction have been key areas of research. 
These signalling systems have been investigated mainly in the 
aT3 -1 pituitary gonadotroph- derived cell line, so that a better 
understanding of their function may indicate what role, if any, they play in 
LHRH signalling and self priming in pituitary gonadotrophs (Fink, 1988). 
The use of a cell line has been necessary due to difficulty in studying 
intracellular signalling systems in a highly heterogeneous tissue, such as 
the anterior pituitary. 
In addition to phospholipids playing a structural role in the 
membrane, it is increasingly clear that they act as substrates for various 
phospholipases, phospholipase A2 (PLA2), phospholipase C (PLC) and 
phospholipase D (PLD), which generate lipid second messengers for 
signal transduction in response to extracellular stimuli (Dennis et a/, 1991). 
Lipid -derived second messengers derived from the hydrolysis of 
phosphoinositides have long been recognised as forming the basis for a 
major signalling pathway. More recently, it has been recognised that the 
hydrolysis of other phospholipids, such as phosphatidyicholine may also 
play a major role in intracellular signalling mechanisms (Billah and Anthes, 
1990). 
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1.2 Inositol phospholipids and intracellular signal transduction 
One of the earliest lipid- derived messenger pathways to be 
elucidated was that of the phospholipase C (PLC) mediated hydrolysis of 
the phosphoinositides. The phosphoinositides are a minor group of 
membrane phospholipids, with a myo- inositol head group that can be 
phosphorylated at multiple sites (Hawthorne, 1982). They form a minor 
component of most eukaryotic membranes. The three most predominant 
phosphoinositides are phosphatidylinositol (PI), phosphatidylinositol 4- 
monophosphate (PIP) and phosphatidylinositol 4,5- bisphosphate (PIP2). 
Collectively, these three lipids usually constitute less than 8% of the total 
membrane phospholipids of mammalian cells (Hawthorne, 1982). 
It was demonstrated that stimulation of cell -surface receptors initiated 
the hydrolysis of inositol phospholipids, for example it was found that in 
agonist -stimulated exocrine pancreas, an increase in lipid radiolabelling 
was confined to two lipids, PI and phosphatidic acid (PA) (Hokin and Hokin, 
1955; Hokin, 1985). It was also found that an appropriate stimulus caused 
a substantial decrease in the PI present in the membrane (Hokin - 
Neaverson, 1974). It was later realised that it was not PI that was the 
primary target of PLC hydrolysis, but its phosphorylated derivative, PIP2 
(Irvine et al, 1984). Recognition of the full importance of PIP2 came with the 
observation that in vasopressin -stimulated hepatocytes, a decrease in PIP2 
preceded changes in PI and was largely independent of Cat+ (Michell and 
Kirk 1981). When the aqueous products of phosphoinositide hydrolysis 
were examined in agonist -stimulated salivary glands, it was found that 
inositol 1,4,5 -trisphosphate (IP3) formation preceded that of PI (Berridge, 
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1983), confirming that the primary phosphoinositide cleaved by the 
receptor- mediated activation of PLC was PIP2. 
Inositol 1,4,5- trisphosphate has been shown to be capable of acting 
as an intracellular messenger by releasing Cat+ from intracellular stores 
(Streb et al, 1983). However, not all of the intracellular Cat+ stores are 
sensitive to IP3; it appears that the IP3- sensitive Cat+ pool is found in a 
perinuclear location (Ross et al, 1989). An IP3 receptor has been purified, 
which appears to act as a channel for Cat+ release upon IP3 binding; thus 
the IP3- receptor can be considered a ligand -gated ion channel 
(Suppattapone et al, 1988). 
Hydrolysis of PIP2 by PLC has been shown to directly produce two 
intracellular messengers, IP3 and diacylglycerol (DAG). It has been 
demonstrated that increased levels of DAG, derived from the agonist- induced 
hydrolysis of phosphoinositides increased the affinity for Cat+ of the Cat+ 
activated, phospholipid- dependent Ser/Thr protein kinase, protein kinase C 
(PKC), thereby activating it (Kishimoto et al, 1980). 
Phospholipase C, the enzyme responsible for the receptor mediated 
hydrolysis of PIP2, has been shown to consist of a superfamily of enzymes. 
The three main subgroups are ß, y and S (reviewed in Rhee and Choi, 
1992). It has been possible to show the widespread distribution of these 
subgroups in various tissues by protein purification, immunological 
analysis, biochemical comparison and by molecular cloning of the various 
enzymes. It has been reported that these three subtypes of PLC are 
regulated by different mechanisms, for example ß -type PLCs are regulated 
by heterotrimeric G proteins, y -type PLCs are regulated by tyrosine 
phosphorylation, and there are reports that PLC -S can be activated by free 
fatty acids (reviewed in Liscovitch and Cantley, 1994). 
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1.3 Receptor- mediated hydrolysis of phosphatidylcholine by 
phospholipases 
Hydrolysis of phosphoinositides is generally an early event following 
stimulation, however hydrolysis of other phospholipids, particularly 
phosphatidylcholine, is reported to produce DAG at a later phase. The 
hydrolysis of PC can be catalysed by distinct species of receptor linked 
phospholipases, namely PC specific PLC, PLD and PLA2 (reviewed in Dennis 
et al, 1991; Billah and Anthes 1990). 
Phosphatidylcholine (PC) is the principal phospholipid in 
mammalian cells and can account for up to 50% of the total phospholipid 
content (White, 1973). It consists of three main forms, 1,2- diacyl- sn- glycero- 
3- phosphocholine , 1 -O- alkyl -2- acyl -sn- glycero -3- phosphocholine and 1- 
alk-1'-enyl-2- acyl -sn- glycero -3- phosphocholine; 1,2- diacyl -sn- glycero -3- 
phosphocholine has been shown to be the predominant subclass in most 
mammalian cell types (Horroks and Sharma 1982). 
The major pathway of PC biosynthesis is called the CDP -choline or 
Kennedy pathway (Kent, 1990). In this pathway there is an ATP -dependent 
pohsphorylation of choline. Formation of an activated intermediate, CDP - 
choline is then catalysed by CTP: phosphocholine cytidyltransferase. The 
lipid PC is then generated by the transfer of CDP -choline to 1,2- 
diacylglycerol (Kent, 1990). 
1.3.1 Phospholipase D 
It has been reported in several systems that the production of DAG is 
temporally dissociated from the generation of IP3, often to the extent that 
DAG can be formed in the absence of IP3 formation (Farese et al, 1985). It 
has also been noted that DAG can be produced in a biphasic manner, with 
an initial first phase of DAG production associated with IP3 production. This 
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type of biphasic response has been observed in angiotensin II- or 
endothelin- stimulated vascular smooth muscle cells (Griendling et al, 1986; 
Sunako et al, 1989) and in vasopressin -stimulated fibroblasts and 
hepatocytes (Thomas et al, 1983; Huang and Cabot, 1990). The levels of 
DAG produced in the second phase are generally much larger than those 
in the initial phase, and can be seen parallel with the generation of similar 
levels of choline (Thompson et al, 1990). Studies of the fatty acid 
composition of agonist- dependent DAG production have revealed that DAG 
produced in the early phase contains predominantly those fatty acids found 
in the phosphoinositide pool (stearate, arachidonate), whereas the later 
phase contains more saturated fatty acids, typically found in 
phosphatidylcholine (Pessin and Raben, 1989; Pettit and Wakelam, 1993). 
Phospholipase D has been shown to be selective for 
phosphatidylcholine, and to a lesser extent phosphatidylethanolamine, and 
in a brain microsomal assay this activity has been shown to be selective 
only towards the head group (i.e. choline), as hydrolysis of the phospholipid 
was not dependent upon the fatty acid chain length or composition (Horwitz 
and Davis, 1993). Much of the evidence for PLD- hydrolysis of PC has 
come from the measurement of hydrolysis products, and measurements of 
the time course of PA and DAG generation. These methods were used in 
order to link agonist stimulation of a P2 purinergic receptor with PLD 
activation in endothelial cells (Martin and Michaelis, 1989). However, it is 
important not to overlook the fact that DAG kinase and phosphatidate 
phosphohydrolase (PPH) are able to interconvert DAG and PA, and that 
rapid interconversion of metabolites may obscure true relationships. This 
point is clearly demonstrated in endothelial cells, where a very high PPH 
activity in the particulate fraction means that it is not possible to detect any 
bradykinin -stimulated formation of PA (Martin and Michaelis, 1988). 
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Evidence for the presence of a receptor -coupled PLD has also come from 
the exploitation of a unique catalytic activity of the enzyme. In the presence 
of a primary alcohol, PLD catalyses a transphosphatidylation reaction, in 
which the phosphatidyl moiety is transferred to the alcohol, forming a 
phosphatidylalcohol (Dawson, 1967). Since this phosphatidylalcohol is 
stable and is not hydrolysed by PPH, this forms the basis of a selective 
assay for PLD, which can be used in whole cells (Pai et al, 1988; Randall et 
al, 1990). If a sufficiently high concentration of alcohol is used, the 
production of PA by PLD can be blocked, providing a means of determining 
the proportion of DAG generated by the PLD pathway, although the 
specificity of alcohols at these levels may limit their usefulness (Bonser et 
al, 1989). 
Phospholipase D is an enzyme found primarily in particulate cellular 
fractions of mammalian cells, having been partially purified from rat brain 
(Chalifa et al, 1990) and rat neutrophils (Olsen et al, 1991). However a 
soluble form of the enzyme has also been detected in bovine tissue (Wang 
et al, 1991). Plasma membrane PLD from rat brain synaptosomes (Chalifa 
et al, 1990) has been shown to require Cat +, but still has considerable 
activity at Cat+ concentrations less than 1 µM. So far PLD has not been 
purified to homogeneity, however the studies that have been carried out on 
partially purified PLD suggest that different PLD isoenzymes exist that vary 
in their pH optima, responses to detergents and cations, subcellular 
distribution and substrate specificity (reviewed in Exton, 1994). 
1.3.2 Mechanisms of receptor activation of phospholipase D 
Studies of PLD in mammalian systems indicate that receptor - 
mediated activation occurs through multiple pathways, such as protein 
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kinases, Cat+ and multiple types of GTP- binding proteins (Billah, 1993; 
Exton, 1994). 
In many cell types, PKC appears to be important in PLD activation, 
with phorbol esters being commonly used as an experimental means to 
stimulate PLD activity (Billah and Anthes, 1990). Strong evidence in the 
favour of PKC involvement in PLD regulation comes from studies in which 
the levels of PKC in the cells have been modified. For example, prolonged 
exposure to phorbol esters was shown to block PLD activation stimulated 
by PMA and endothelin -1 in Rat -1 fibroblasts (MacNulty et al, 1990) and by 
bradykinin in bovine pulmonary endothelial cells (Martin et al, 1989). In 
several systems, overexpression of PKC isoforms resulted in an increase in 
PLD activity. For example, over -expression of PKC -ß1 in rat fibroblasts 
resulted in facilitation of the PLD activity stimulated not only by the phorbol 
ester PMA (Pai et al, 1991a), but also through receptor- activated systems 
such as endothelin (Pai et al, 1991b), and a- thrombin (Pachter et al, 1992). 
Selective inhibitors of PKC have also been used in order to determine 
whether PKC is involved in the activation of PLD, for example in endothelial 
cells, the P2- purinergic receptor -stimulated activation of PLD is sensitive to 
the PKC inhibitor Ro 31 -8220 (Purkiss and Boarder, 1992). It has also 
been demonstrated that phorbol ester (PMA)- stimulated PLD activity in 
Swiss 3T3 cells was selectively inhibited by Ro 31 -8220, while bombesin- 
stimulated PLD activity was not significantly altered by Ro 31 -8220 (Cook et 
al, 1991). The mechanism by which PKC brings about PLD activation is 
unclear. It may be through a direct phosphorylation of PLD, or PKC may be 
acting upon an intermediary regulatory protein. It has also been reported 
that PKC may be capable of stimulating PLD activity in the absence of ATP, 
suggesting the unconventional possibility that a non- phosphorylation 
mechanism can also be involved (Conricode et al, 1992). The existence of 
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both phosphorylating and non -phosphorylating PKC mechanisms for the 
agonist- induced activation of PLD could explain why inhibitors of the ATP - 
binding site of PKC produce variable results. 
Several studies have suggested that tyrosine kinases play a role in 
the receptor- mediated activation of PLD, involving both receptor and non - 
receptor tyrosine kinases (Billah, 1993). Selective inhibitors of protein - 
tyrosine kinases have been shown to inhibit receptor -linked activation of 
PLD in many cases. For example in human neutrophils, the formyl -Met- 
Leu-Phe (fMLP) -stimulated activation of PLD is inhibited by the tyrosine 
kinase inhibitors ST271 and ST638 (Uings et al, 1992). Stimulation of the 
EGF receptor in Swiss 3T3 cells leads to the tyrosine kinase- dependent 
activation of PLD, in the absence of detectable PLC activity (Cook and 
Wakelam, 1992). The protein- tyrosine phosphatase inhibitor pervanadate 
has also been shown to stimulate PLD activity in HL -60 cells through an 
elevation in the level of tyrosine phosphorylation (Bourgoin and Grinstein, 
1991). A possibly more direct stimulation of PLD activity has been 
observed in cells overexpressing the viral form of the non -receptor tyrosine 
kinase c -src (Song and Foster, 1993). It would therefore appear that PLD 
activity can be stimulated through the activation of both receptor and non - 
receptor tyrosine kinases. 
Calcium also appears to play a critical role in PLD activation in many 
systems (Billah, 1993). lonophores of Cat +, such as ionomycin and A 
23187 have been shown to stimulate PLD in many cell types (Pai et al, 
1988). It has also been demonstrated that removal of extra- cellular Cat+ 
can attenuate PLD activation stimulated by fMLP in HL -60 granulocytes 
(Pai et al, 1988). 
It is well established that PLD can be activated by receptors which 
are coupled to their effector systems through heterotrimeric G proteins 
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(Thompson et al, 1993a). Many receptor -stimulated PLC and PLD systems 
are blocked by the microbial toxin, pertussis toxin, which acts by ADP - 
ribosylating the a- subunit of the Gi and Go subtypes of heterotrimeric G 
proteins, thus preventing their activation (Milligan, 1988). For example in 
HL -60 granulocytes, the increased activity of both PLC and PLD stimulated 
by fMLP was blocked by pertussis toxin pre- treatment (Pai et al, 1988). 
However in hepatocytes, vasopressin -, angiotensin II- and adrenaline - 
stimulated PLC and PLD activations were insensitive to pertussis toxin, 
even though they could be activated in membrane preparations by non - 
hydrolyzable analogues of GTP (Bocckino et al, 1987). An insensitivity to 
pertussis toxin does not rule out G protein involvement, but simply shows 
that there is no Gi or Go involvement. A G protein involvement in the 
activation of PLD has also been extensively demonstrated by the use of the 
non -hydrolysable GTP analogue, GTPyS, in permeablised cells (Anthes et 
al, 1991). It therefore appears that PLD can be activated by a variety of G 
protein -coupled receptors, linked to the intracellular signalling machinery 
by G proteins probably belonging to both Gq and Gi families. 
Recently evidence has come to light that members of the family of 
low molecular weight G proteins related to Ras, ARF (ADP -ribosylation 
factor) and Rho, are closely involved in the regulation of PLD (Cockroft et al, 
1994; Brown et al, 1993; Bowman et al, 1993). There is evidence that ARF 
is involved in the regulation of membrane traffic, through the formation of 
coated vesicles, and transport between the endoplasmic reticulum and cis - 
golgi (Balch et al, 1992). This raises the possibility that PLD may also play 
a role in membrane traffic and vesicle formation by changing the 
characteristics of membranes (reviewed in Kahn et al, 1993). 
It is not known if other types of low molecular weight G proteins are 
responsible for the regulation of PLD. Low molecular weight (20 -25 kDa) G 
20 
proteins related to Ras, exist as a superfamily of proteins grouped into four 
subfamilies: Ras, Rho, Rab and Ran (Lowy and Willumsen, 1993). ADP - 
ribosylation factor (ARF) is related to these other families of low molecular 
weight G protein, although it shares some properties with the heterotrimeric 
G proteins. These low molecular weight G proteins cycle between an 
inactive GDP -bound form and an active GTP -bound state. This exchange is 
normally very slow, but can be greatly accelerated by another family of 
proteins, the guanine -nucleotide exchange factors (GEFs) (Feig, 1994). 
Activity of the Ras type G proteins can also be prolonged by proteins known 
as guanine- nucleotide dissociation inhibitors, or GDIs (reviewed in Feig, 
1994). 
1.3.3 Phosphatidylcholine selective phospholipase C 
It has been demonstrated that as well as a PLC activity being 
involved in the hydrolysis of inositol phospholipids, there is a form of PLC 
which selectively hydrolyses PC. Phosphatidylcholine has been shown to 
be a substrate for PLC partially purified from dog heart cytosol (Wolf and 
Gross, 1985), bull seminal plasma (Sheikhnejad and Srivastava, 1986) and 
promonocytic U937 cells (Clark et al, 1986). These activities have been 
shown to exhibit a neutral pH optima and not detectably to hydrolyse 
inositol phospholipids. So far PC -PLC has not been extensively purified, 
but its existence is expected due to the enzymic activity that produces 
choline phosphate from PC (Nishizuka, 1992). It is thought that PLC - 
mediated PC hydrolysis is responsible for the later phase of DAG 
production, as is also thought to be the case for PLD- mediated hydrolysis of 
PC. In contrast the hydrolysis of PIP2 by PLC appers to be responsible for 
an early and transient peak of DAG (reviewed in Liscovitch, 1992). 
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1.3.4 Phospholipase A2 
As well as generating PA and DAG, PC hydrolysis also leads to the 
generation of other lipid products with distinct cellular signalling functions. 
Although not the focus of this study, PLA2- generated second messengers 
represent an important component of lipid- derived cellular signalling 
mechanisms and should not be overlooked in the consideration of agonist- 
induced alteration in cellular function. 
Phospholipase A2 has been shown to be present as a 14 kDa 
secretory PLA2, present in digestive enzymes and snake venom, requiring 
millimolar levels of Cat+ for activity (Davidson and Dennis, 1990). There is 
little evidence that this family of low molecular weight PLA2 are involved in 
intracellular signalling. In contrast, a high molecular weight (85 kDa) 
cytosolic PLA2 has been demonstrated to be activated in response to 
physiologically -relevant changes in free Cat+ (Gronich et al, 1990; Clark et 
al, 1991). Ligand- induced activation of cytosolic PLA2 selectively leads to 
the release of arachidonic acid (AA) from the sn -2 position of PC or 
phosphatidylethanolamine (PE), while inositol phospholipids are poor 
substrates (Gronich et al, 1990; Diez and Mong, 1990). The action of PLA2 
produces the products AA and lysophosphatidic acid (LPA), used in the 
further biosynthesis of cellular regulators, such as prostaglandins, 
leukotrienes and platelet activating factor (PAF) (Irvine, 1982). It has been 
demonstrated that it is possible for AA to synergistically activate Cat+ 
dependent PKC isoforms in the presence of DAG, at near basal Cat+ 
concentrations (Shinomura et al, 1991; Chen and Murakami, 1992). It is 
also possible that LPA has signalling functions, since LPA has been shown 
to enhance the activity of the a, ß and y isoforms of PKC in vitro (Sasaki et 
al, 1993). Lysophosphatidic acid is also known to act as an agonist for a G 
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protein -coupled cell surface receptor (Durieux and Lynch, 1993). It has 
also been reported that AA is capable of activating PLC -5 (Liscovitch and 
Cantley, 1994). 
1.3.5 Phosphatidate and diacylglycerol in intracellular signalling 
Several reports have suggested that the appearance of certain 
cellular responses are more closely associated with PA than with DAG 
formation. For example, in unprimed neutrophils, it is the level of PA 
generated by PLD rather than the level of DAG that correlates with the 
fMLP -stimulated respiratory burst (Koenderman et al, 1989; Rossi et al, 
1990). Similar relationships have been reported for proliferation in 
fibroblasts (Zhang et al, 1990) and insulin secretion in pancreatic islets 
(Dunlop and Metz, 1989; Konrad et al, 1991). One approach that has been 
taken in order to determine whether PA or DAG is functionally important is 
the use of propranolol, which has been described as an inhibitor of PPH at 
high concentrations, both in vitro and in vivo (Billah and Anthes, 1990). In 
unprimed human neutrophils, propanolol was shown to potentiate the 
fMLP -stimulated respiratory burst (Rossi et al, 1990), however in primed 
neutrophils in which the PLD activity is amplified, propanolol inhibited the 
respiratory burst (English and Taylor, 1991); this is consistent with the 
hypothesis that priming changes the key regulatory second messenger 
from PA to DAG. Although it has been demonstrated that propanolol can be 
a useful experimental tool, the high concentrations required to inhibit PPH 
are known to affect membrane fluidity (Barret and Cullum, 1968), which 
may affect cellular responses. There have been several in vitro 
observations which are consistent with a second messenger role for PA. 
Early evidence suggested that PA acted as a Cat +- ionophore (Putney et al, 
1980), although this was later attributed to contamination of samples by 
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oxidised lipids (Holmes and Yoss, 1983), and in A -431 carcinoma cells the 
capacity of PA to mobilise Cat+ was dependent on the generation of IP3. It 
has been reported that PA can activate PLC in membranes and soluble 
extracts from platelets (Jackowski and Rock, 1989), and also activate 
phosphatidylinositol -4- phosphate -5- kinase in synaptosomal membranes, 
thereby increasing the level of PIP2 (Moritz et al, 1992). However, these 
affects of PA do not account for its effects seen in the absence of PLC 
activity. 
There is evidence that PA- sensitive protein kinase(s) exist that are 
able to phosphorylate multiple substrates, distinct from those of DAG- 
stimulated PKC (Bocckino et al, 1991). It seems certain that PA does have 
some important second messenger functions, such as the activation of 
phosphatidylinositol 4- phosphate kinase purified from bovine brain 
membranes (Moritz et al, 1992). It has also recently been reported that PA 
is able to bind to PKC in a cell free system, bringing about a shift in its 
electrophoretic mobility and causing its activation, assessed by 
autophosphorylation and phosphorylation of exogenous PKC substrates 
(Limatola et al, 1994). 
Several observations suggest that PC- derived DAG is not capable of 
activating PKC. It was demonstrated in a- thrombin stimulated fibroblasts 
that under conditions which stimulate the production of DAG derived from 
both PI snd PC hydrolysis, there was detectable activation of PKC. 
Whereas under conditions where a- thrombin only stimulates the hydrolysis 
of PC, there was no detectable activation of PKC (Leach et al, 1991). It has 
also been shown that in IgE- stimulated RBL 2H3 mast cells the PLD- 
mediated production of DAG is not responsible for PKC activation (Lin et al, 
1992). However, the idea that DAG derived from PC is ineffective at 
activating PKC has been challenged by results which show that in a- 
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thrombin- and PDGF -stimulated fibroblasts the late phase of DAG 
production from PC hydrolysis is associated with the activation of PKC E, but 
not PKC a (Ha and Exton, 1993). This study concluded that it was the 
absence of Cat+ associated with PC hydrolysis that was responsible for this 
differential activation. It has also been demonstrated that phagocytosis in 
the human neutrophil, mediated by complement receptors, is associated 
with phosphorylation of a PKC substrate, the myristoylated alanine -rich C- 
kinase substrate (MARCKS) protein, as well as DAG generation through 
PLD (Fallman et al, 1992). It appears that in some cases, PC- derived DAG 
may be involved in the sustained activation of PKC, as the kinetics of this 
DAG formation are more prolonged than that derived form PIP2 hydrolysis 
and in the absence of a rise in cytosolic Cat +, PC- derived DAG may 
therefore be important for the activation of Cat + -independent PKCs such as 
PKC e (Ha and Exton, 1993). Sustained PKC activation may be important 
in events such as proliferation, differentiation and in cellular priming events. 
1.4 Protein kinase C 
Protein kinase C (PKC) was identified by Nishizuka and co- workers 
in 1977 (Takai et al, 1977) as a proteolytically -activated protein kinase with 
no obvious role at the time. It was later shown to be a Cat + -activated, 
phospholipid- dependent enzyme (Takai et al, 1979), which has been 
shown to be modulated by DAG, resulting in an increased affinity for Cat+ 
(Takai et al, 1979; Kishimoto et al, 1980). Activation of PKC requires 
diacylglycerol with a 1,2 -sn conformation. With respect to the side chains, 
unsaturated fatty acids have been shown to most effective and fatty acid 
chain length is not critical, although there is an optimal chain length (Mori et 
al, 1982). The consensus from a variety of studies is that protein kinase C 
activation occurs via a two step process. Firstly, inactive soluble PKC 
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(which readily reacts with MgATP) binds anionic phospholipids (especially 
phosphatidylserine) and Cat +, resulting in PKC associating with the 
membrane, but having a relatively low kinase activity. Diacylglycerols or 
phorbol esters can then induce greater PKC activity (Bazzi and Nelsestuen, 
1991). The stoichiometry for the interaction of the co- factors in vitro is 
considered to be 4 -10 phosphatidylserine molecules to one DAG/ phorbol 
ester molecule to one Cat+ ion for every monomeric PKC molecule 
(Hannun et al, 1986a; Hannun and Bell, 1990). 
1.4.1 Protein kinase C subtypes 
There are multiple discrete subspecies of PKC, each showing subtly 
different enzymic properties, differential tissue expression and specific 
intracellular localisation (Nishizuka, 1988). So far eleven subspecies of 
PKC have been identified, which can be classified into three subgroups; 
conventional, novel and atypical PKCs. The 4 conventional PKCs have 
been designated: a, ßI, ßII and y, the novel isoforms of PKC consist of 
i , µ and 0, and the atypical PKCs are and a, (Hug and Saare, 1993). 
The conventional group of PKC enzymes have four conserved (C1- 
C4) and five variable (V1 -V5) regions. The Cl domain is a putative 
membrane binding domain, containing two cysteine rich zinc finger motifs 
that bind to DAG or phorbol esters (Ono et al, 1989) and a pseudosubstrate 
sequence which inhibits the activity of the catalytic domain in the inactive 
state (Hug and Saare, 1993). The C2 domain is a Cat + -binding domain 
and appears to be required for the Cat+ sensitivity of the conventional PKCs 
(Ono et al, 1988). The C3 domain contains the catalytic site and C4 
appears to be involved in substrate recognition. The novel group of PKCs 
lack a C2 domain and do not require Cat+ to be activated (reviewed in 
Nishizuka, 1992). The atypical group of PKCs also lack a Cat+ binding 
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domain, but unlike the conventional and novel PKCs which have two 
cysteine -rich zinc -finger motifs they only have one. As a consequence they 
are reported to be unaffected by DAG or phorbol esters. The signalling 
pathway activating the atypical PKCs is unknown at present, however, there 
is evidence that PKC Ç can be activated by cis -unsaturated fatty acids and 
by PA (Nakanishi and Exton, 1992; Ways et al, 1992; Limatola et al, 1994). 
1.4.2 Activators of protein kinase C 
There is good evidence that both 1,2 -DAGs and tumour -promoting 
phorbol esters directly activate all but the atypical PKCs by binding to two 
DAG /phorbol ester binding domains and increasing the enzyme's affinity for 
Cat+ and /or phospholipid (Castagna et al, 1982; Ogita et al, 1992). It has 
been demonstrated that diacylglycerols are able to displace phorbol ester 
ligands from PKC, which suggests that phorbol esters and DAG share a 
common binding site, and that phorbol esters can activate PKC by binding 
at the DAG binding site (Leach et al, 1983). 
The phorbol ester used in the present study was phorbol 12,13 - 
dibutyrate (PDBu), which in the presence of Cat+ shows no marked 
selectivity of activation between PKCs isolated from a range of tissues. 
However, other PKC activators, such as mezerein and 1,2- dioctanoyl -sn- 
glycerol (DOG) do display a marked difference in their ability to activate 
certain isoforms (Evans et al, 1991). 
1.4.3 Inhibitors of protein kinase C 
Inhibitors of protein kinase C activity are widely used to study 
systems in which PKC may be involved. The mode of action of these 
compounds may be through interference with the Cat + / phospholipid 
interaction, DAG /phorbol ester binding or ATP or substrate binding. 
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Compounds preventing the interaction of Cat+ with PKC, such as 
melittin and polymyxin B (Huang, 1989) also block the activity of other Ca2 +- 
dependent enzymes. They are therefore not very selective PKC inhibitors and 
are rarely used as such. Compounds such as calphostin C and sphingosine 
are reported to interfere with PKC -lipid interactions. Calphostin C blocks 
DAG /phorbol ester binding with PKC and is reasonably selective for PKC over 
other protein kinases. It does however cause an irreversible inhibition of 
phorbol ester binding, which may limit its uses (Kobayashi et al, 1989). 
Sphingosine, an 18- carbon lipid, causes PKC inhibition by binding 
competitively to the DAG /Ca2+ and phosphatidylserine binding sites. However 
sphingosine also has effects on biological systems which are independent of 
PKC, limiting its use as a selective PKC inhibitor (Hannun et al, 1986b). Some 
of the compounds that inhibit PKC by interacting with the enzyme's catalytic 
domain include the isoquinolinesulphonamides, such as 1 -(5- 
isoquinolinesulphonyl)-2- methyl piperazine (H7), and substances with an 
indole carbazole structure, such as staurosporine, K252a and their structural 
congeners, the bisindolylmaleimides, such as Ro 31 -8220, which has been 
shown to potently inhibit PKC activity at ATP levels similar to those found in 
whole cells (Davis et al, 1992), and GF 109203X (Toullec et al, 1991). The 
action of H7 on PKC is reversible and competitive with ATP (Hidaka et al, 
1984). There is a considerable sequence homology for ATP binding sites 
among serine /threonine kinases. H7 therefore only displays a slight selectivity 
for PKC, over other kinases. Bisindolylmaleimides such as Ro 31 -8220 and 
GF 109203X are related to the general kinase inhibitor staurosporine. Both 
staurosporine and K252a inhibit PKC by interacting with the catalytic domain, 
perhaps competing at the ATP binding site (Davis et al, 1992). Both of these 
compounds are however not highly -selective PKC inhibitors, as they are able 
to potently inhibit other protein kinases by the same mechanism. Analogues of 
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staurosporine, of the bisindolylmaleimide family of compounds, have been 
developed by modification of the side chains, which have a much higher 
selectivity for PKC over other protein kinases (Davis et al, 1989). Two such 
compounds, Ro 31 -8220 (Davis et al, 1992), and GF 109203X (Toullec et al, 
1991), are up to 100 times more selective for PKC compared to PKA than is 
staurosporine. 
Certain groups of PKC inhibitors have been shown to possess partial 
selectivity for certain PKC isoforms. Members of the bisindolylmaleimide 
family of compounds have been shown to be more potent at inhibiting the 
Cat + -dependent PKC isoforms a and ß than the Cat + -independent PKC 
isoform s (Wilkinson et al, 1993). It has also been shown that a novel 
protein kinase inhibitor, rottlerin shows selectivity for PKC 8 over other 
isoforms of PKC (Gschwendt et al, 1994). It may be possible to utilise this 
slight selectivity in attempting to determine which isoforms are involved in a 
particular biochemical pathway in cells. There is also evidence for different 
PKC isoforms showing varying sensitivities to H7, since an uncharacterised 
PKC isoform in the anterior pituitary shows an insensitivity to inhibition by 
H7 compared to other PKC activities isolated from this tissue (Johnson and 
Mitchell, 1989). 
1.5 Non -receptor tyrosine kinases 
Tyrosine phosphorylation has recently been implicated in the action 
of several neuropeptides which act through G protein -coupled receptors, 
such as bombesin, vasopressin and endothelin (Zachary et al, 1991). This 
tyrosine phosphorylation is presumed to be mediated by the action of non - 
receptor tyrosine kinases, since G protein -coupled receptors have no 
intrinsic tyrosine kinase activity. It has been observed that non - receptor 
tyrosine kinases increase the phosphorylation of an apparently partially 
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distinct spectrum of cellular proteins compared with receptor tyrosine 
kinases (Cantley et al, 1991). 
1.5.1 Src -type tyrosine kinases 
One of the main groups of non -receptor tyrosine kinase is the src- 
family, consisting of a group of nine closely related proteins: src, fyn, Ick, 
lyn, yes, hck, blk, fgr and yck. These enzymes have been demonstrated to 
be involved with cellular transformation and in intracellular signal 
transduction (Cooper, 1990). In addition to a C- terminal tyrosine kinase 
domain, src family members share the conserved internal homology 
regions, SH2 and SH3. The SH2 domain has been shown to interact with 
specific phosphotyrosine residues (Songyang et al, 1993). It has been 
demonstrated that SH3 domains are able to bind to the proline -rich 
sequence motif X- P- X- X- P- P- P- Z -X -P, where X represents any amino acid, 
and Z represents a hydrophobic amino acid (Ren et al, 1993). It has also 
been suggested that SH3 domains may be important for localisation to the 
cytoskeleton, since SH3 containing proteins are often associated with the 
cytoskeleton (Musacchio et al, 1992). The N- terminal region of src kinases, 
which is myristoylated, appears to be primarily responsible for targeting the 
proteins to cellular membranes, particularly the inner surface of the plasma 
membrane (Resh, 1994). 
There is good evidence that this src- family of kinases are maintained 
in an inactive state through phosphorylation of a tyrosine at position 527 
near the C- terminus by CSK (C- terminal src kinase), which is believed to be 
a universal regulator of src family kinases (Okada et al, 1991). Tyrosine 
phosphatases are thought to be able to bring about the activation of src - 
family kinases by dephosphorylation of tyrosine 527 (Courtneidge, 1985). It 
is thought that the interaction of the phosphorylated tyrosine 527 with the 
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SH2 domain sterically impedes the catalytic domain (Koch et al, 1991), 
while the SH3 domain may also bind to the C- terminal tail or kinase domain 
and aid inhibition. Tyrosine phosphorylation of src at position 416 is 
thought to stabilise the catalytic domain in an active conformation, as is also 
the case for autophosphorylation of the cAMP- dependent protein kinase 
(Knighton et al, 1991). 
It has been shown in platelets (which contain particularly high levels 
of c -src) that agonists which directly or indirectly activate PKC such as the 
phorbol ester PMA, vasopressin and the Cat+ ionophore A23187 increase 
the activity of the non -receptor tyrosine kinases c -src and c -fyn. Stimulation 
of platelets by the above pathways causes the phosphorylation of c -src at 
Ser -12, and also increases the substrate affinity of c -src by two to three fold 
(Liebenhoff et al, 1993). In many cell types a rise in cytosolic Cat+ is 
sufficient to elicit tyrosine phosphorylation (Vostal et al, 1993). However, a 
clear picture of how non -receptor tyrosine kinases are activated after G 
protein -coupled receptor activation has not yet emerged. 
1.5.2 Focal adhesion kinase (p125 FAK) 
Stimulation of G protein -coupled neuropeptide receptors has also 
been shown to stimulate the activity of a 125 kDa tyrosine kinase, focal 
adhesion kinase (FAK) (Zachary et al, 1992). Focal adhesion kinase is 
interesting in that it lacks the non -catalytic domains or motifs which are 
found in other receptor and non -receptor tyrosine kinases (Schaller et al, 
1992). The catalytic domain possesses all the conserved motifs of other 
tyrosine kinases, however, this region is flanked by large amino- and 
carboxy -terminal domains lacking any significant homology to other 
tyrosine kinases. Focal adhesion kinase does not possess any acylation 
sites, which would confer membrane association, or sites for association 
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with other proteins, such as SH2 or SH3 domains (Cobb et al, 1994; Ren et 
al, 1993). 
There is evidence for the constitutively active v -src bringing about 
FAK activation when expressed in NIH 3T3 cells (Guan et al, 1990). It is 
therefore possible that src type kinases may be responsible for tyrosine 
phosphorylating FAK, downstream of G protein -coupled receptor activation. 
1.5.3 Other non -receptor tyrosine kinases 
Another type of signal- activated non -receptor tyrosine kinase is p72 
syk. This kinase possess a kinase domain, similar to other tyrosine 
kinases, and two SH2 domains (Taniguchi et al, 1991). It has also been 
demonstrated that syk can be rapidly activated following thrombin 
stimulation of platelets, which appears to be dependent upon Cat+ (Wang 
et al, 1994). It has been shown that the JAK (janus or just another kinase) 
family of tyrosine kinases, which lack SH2 or SH3 domains, are activated 
by association with cytokine receptors (Ihle et al, 1994). Another non - 
receptor tyrosine kinase c -Abl has so far not been linked with any receptor. 
It has however been shown to bind to actin filaments in the cytoplasm and 
bind to specific DNA sequences (Wang, 1993). 
1.5.4 Inhibitors and activators of tyrosine phosphorylation 
Several groups of compounds have been developed that have the 
ability to selectively inhibit protein- tyrosine kinases, and these have been 
extensively used as a method of determining the involvement of tyrosine 
kinases in a variety of purified and whole cell systems. A number of 
compounds have been particularly useful in identifying the cellular actions 
of protein- tyrosine kinases in response to receptor agonists. 
Lavendustin A has been shown to be a potent inhibitor of tyrosine 
kinases and to have little effect on cAMP- dependent protein kinase or PKC 
32 
(Hsu et al, 1991). Lavendustin A is a competitive inhibitor with respect to ATP, 
but a non -competitive inhibitor with respect to a src peptide substrate (Hsu et 
al, 1991). Binding analysis has also revealed that lavendustin A acts as a 
slow, tight binding inhibitor with a two step mechanism (Hsu et al, 1991). 
Another compound of the isoflavine family, genistein has been reported to 
inhibit the tyrosine kinase activity of the EGF receptor tyrosine kinase, pp60 v- 
src and pp110 gag -fes in vitro. This inhibition was shown to be competitive 
with respect to ATP and non -competitive to a phosphate acceptor, histone 
H2B. It has also been demonstrated that genistein has scarcely any effect on 
the serine/ threonine specific protein kinases, cAMP- dependent protein kinase 
and PKC, making it an excellent (and widely used) compound for inhibiting 
protein- tyrosine kinases (Akiyama et al, 1987). Piceatannol (3,4,3', 5'- 
tetrahydroxy- trans -stilbene), has been previously identified as an antileukemic 
agent, and has been shown to act as an inhibitor of protein- tyrosine kinase 
activity. Piceatannol inhibits the purified thymocyte protein- tyrosine kinase, 
p40, by competing for the peptide or protein binding site, due to its structural 
similarity with tyrosine. Piceatannol has also been shown to inhibit the activity 
of the p56 Ick non -receptor tyrosine kinase in LSTRA leukemic cell 
membranes or intact cells. Piceatannol did not detectably inhibit the activity of 
cAMP- dependent protein kinase (Geahlen and McLaughlin, 1989). However, 
it has been demonstrated that piceatannol will inhibit the Cat + -dependent 
activity of PKC from aT3 -1 cells, using the glycogen synthase (GS) peptide 
(10011M) as a substrate (M. Johnson, unpublished results). The mode of 
action of piceatannol differs from that of the other tyrosine kinase inhibitors 
described above, which compete at the ATP binding site, in that piceatannol 
has a structural similarity with tyrosine and binds to the substrate binding site 
(Geahlen and McLaughlin, 1989). This mode of action is similar to that of 
synthetic compounds called tyrphostins which also inhibit the activity of 
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protein- tyrosine kinases by blocking substrate binding (Yaish et al, 1988; 
Schechter et al, 1989). Another compound which is structurally related to 
piceatannol and tyrphostins and having a similar mode of action is methyl 2,5- 
dihydroxycinnamate (MDC). This compound has been shown to potently 
inhibit the EGF- receptor tyrosine kinase, although due to its polar nature it is 
unsuitable for whole cell assays (Umezawa et al, 1990). 
It has been demonstrated that peroxides of vanadate (pervanadate) 
are capable of stimulating the tyrosine phosphorylation of the insulin 
receptor in intact cell through the inhibition of tyrosine phosphatase activity 
rather than activation of the autokinase reaction. This effect of pervanadate 
was 102 -103 times more potent than that of vanadate (Fantus et al, 1989). 
Since pervanadate has been demonstrated to elevate the levels of 
phosphotyrosine in whole cells, we have also used it in this study in order 
to mimic the receptor activation of tyrosine kinases in aT3 -1 cells. 
1.6 Tyrosine phosphatases 
The level of tyrosine phosphorylation of cellular proteins can be 
controlled by the action of tyrosine kinases, which have been discussed 
above, and also by the action of tyrosine phosphatases. As is the case with 
tyrosine kinases, tyrosine phosphatases can be roughly classified into two 
subfamilies, receptor tyrosine phosphatases and non -receptor tyrosine 
phosphatases (Pot and Dixon, 1990). In common with tyrosine kinases, 
tyrosine phosphatases are a diverse group of enzymes with a large number 
of possible regulatory domains (Pot and Dixon, 1990). An example of the 
receptor tyrosine phosphatases is CD45, which has intracellular tandem 
repeats of a 200 -amino acid protein- tyrosine phosphatase domain, a single 
membrane spanning region and an extracellular domain (Alexander, 
1990). A representative of the non -receptor class of tyrosine phosphatases 
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is PTP 1 B, which has a single copy of the conserved 200 -amino acid 
tyrosine phosphatase domain with no transmembrane domain (Guan et al, 
1990). The diverse structures of non -receptor tyrosine kinases suggests 
multiple methods of regulation (Pot and Dixon, 1990). 
1.7 LHRH receptor signaling and the LHRH -self priming effect 
The present study has addressed the signalling mechanisms 
associated with LHRH- receptor activation (specifically PLD activation and 
tyrosine phosphorylation), in order to elucidate the biochemical events 
which may underlie LHRH receptor signalling, and in particular the LHRH- 
self priming mechanism occurring in gonadotrophs in the anterior pituitary. 
The anterior pituitary gland contains several distinct types of 
secretory cell, releasing at least six different circulating hormones (Denef 
and Andries, 1982). Luteinising hormone (LH) and follicle -stimulating 
hormone (FSH) are released from gonadotrophs, growth hormone (GH) 
from somatotrophs, prolactin from mammotrophs, adrenocorticotrophic 
hormone (ACTH) from corticotrophs and thyroid -stimulating hormone (TSH) 
is released from thyrotrophs, whilst somato -mammotrophs secrete both GH 
and prolactin (Denef and Andries, 1982). Release of these hormones is 
regulated mainly by peptides released into the hypophysial portal blood 
vessels from the median eminence of the hypothalamus. One such peptide 
is the decapeptide, luteinising hormone -releasing hormone (LHRH; pyro- 
Glu- His- Trp -Ser- Tyr- Gly- Leu -Arg- Pro- Gly -NH2) which is the main 
physiological stimulus for the release of LH and FSH from gonadotrophs. 
An aspect of particular interest in the gonadotroph is the self -priming 
effect of LHRH, which is the mechanism by which LHRH induces a profound 
increase in gonadotroph responsiveness (Aiyer et al, 1974a). This priming 
effect is an essential factor in bringing about the surge of LH release which 
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triggers ovulation (Fink, 1986). Priming is enabled in part by the history of 
exposure of the anterior pituitary to steroid hormones prior to the 
gonadotroph surge; that is high levels of circulating oestrogens (mainly 
oestradiol -173) and low levels of progesterone (Fink, 1986; Fink, 1988). 
The release of LHRH from the hypothalamus is of a pulsatile nature and 
although the frequency of release is increased near the LH surge, the 
additional hormone output is too small to account for the very large 
increment in LH release from the pituitary (Fink, 1988). The increase in 
pituitary responsiveness, initiated by oestrogen, is further intensified by the 
release of ovarian progesterone during the early part of the LH surge (Fink, 
1988). The effective role of the LHRH -priming effect is to co- ordinate the 
increase in LHRH release with the increased responsiveness of the 
pituitary, in order that both events result in a massive surge in LH release 
from the pituitary, and thus initiate ovulation in female mammals. 
It has been reported that LHRH- induced LH release coincides with 
an increase in 45Ca2+ efflux from pre -loaded anterior pituitary pieces 
(Williams, 1976). It has also been shown that LHRH can induce inositol 
phospholipid breakdown in dispersed anterior pituitary cells (Snyder and 
Bleasdale, 1982), and that this was followed by an increase in IP3 and DAG 
accumulation (Schrey, 1985). GTP analogues have also been shown to be 
capable of increasing inositol phosphate production and LH release from 
ATP -permeablised, dispersed rat anterior pituitary cells (Andrews and 
Conn, 1986). It therefore seems likely that IP3 production and Cat+ are 
major pathways involved in LHRH- induced LH release. The LHRH- 
mediated increase in intracellular Cat+ levels may induce LH release by 
modulating the activity of a number of different Cat + -dependent processes. 
One particular example is that LHRH treatment of ovariectomised rats 
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causes a redistribution of calmodulin from the cytosol to the plasma 
membrane (Conn et al, 1981). 
LHRH receptor activation has been shown to lead to the generation 
of DAG (Andrews and Conn, 1986), which is known to lead to the activation 
of PKC (Nishizuka, 1992). LHRH can induce PKC translocation to the cell 
membrane, with a time -course and concentration -dependence similar to 
that of LHRH- induced LH release (Naor et al, 1985). Furthermore, DAG 
and phorbol esters have been shown to induce gonadotrophin release from 
anterior pituitary cells in culture (Conn et al, 1985) and anterior pituitary 
pieces in vitro (Turgeon and Waring, 1986; Johnson and Mitchell, 1989). 
Introduction of purified rat brain PKC into permeablised anterior pituitary 
cells also induced LH release (Naor et al, 1989), consistent with a role for 
PKC in LH release responses. It has also been demonstrated that 
inhibitors of protein- tyrosine kinases are able to inhibit the LHRH- stimulated 
release of LH from anterior pituitary pieces in vitro (Johnson et al, 1994). 
It is also possible that PLA2 could play a role in LHRH signalling in 
the pituitary. Since it has been demonstrated using cultured anterior 
pituitary cells, that arachidonic acid (AA) can induce LH release, and that 
LHRH can induce an increase in [3H] -AA release from pre -labelled cells 
(Naor and Catt, 1981; Chang et al, 1986). It has also been shown that 
inhibitors of PLA2 are able block the onset of LHRH priming, but do not 
effect the immediate LHRH -stimulated release of LH from the anterior 
pituitary. The LHRH priming effect could also be partially mimicked by a 
conditioning preincubation with arachidonic acid (Thompson et al, 1994). 
It has also been demonstrated that LHRH- receptor activation can 
lead to the stimulation of PLD activity in the aT3 -1 pituitary gonadotroph 
derived cell line (Netiv et al, 1991), and in ovarian granulosa cells 
(Liscovitch and Amsterdam, 1989). 
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1.7.1 T3 -1 cell line 
Biochemical studies on pituitary cell types have been hampered by 
the heterogeneous nature of the tissue; gonadotrophs constitute 
approximately 5% of the cells in the anterior pituitary. One way of 
overcoming this problem has been the use of an established cell line. This 
has been done by producing the aT3 -1 anterior pituitary clonal cell line with 
the properties of gonadotrophs (Windle et al, 1990; Horn et al, 1991). The 
cell line was obtained by targeted tumorigenesis in transgenic mice using 
the SV40 Tag oncogene linked to the promoter region of the human 
gonadotrophin hormone a subunit. This cell line expresses high affinity 
LHRH receptors, but does not synthesise or secrete the ß subunits of LH or 
FSH ( Windle et al, 1990), limiting the usefulness of this cell line as a model 
for studying the primed release of LH. 
Despite the drawback of not being able to assay a secretory end- 
point in these cells, they have contributed importantly to progress in the 
field of LHRH signalling. Previous studies have established clearly that 
LHRH can stimulate PLC -mediated phosphoinositide hydrolysis, with an 
absence of short term homologous desensitisation (Davidson et al, 1994). 
It is also capable of mobilising calcium from intracellular and extracellular 
locations (Mitchell et al, 1988). There is now increasing evidence that 
activation of PLD (Netiv et al, 1991) and PLA2 mediated pathways also 
occur, as levels of arachidonate metabolites are elevated in pituitary cells 
as a consequence of LHRH stimulation (Dan -Cohen et al, 1992). 
The present study has examined the activation of PLD in the T3 -1 
cell line. By assessing the generation of the stable product, 
phosphatidylbutanol (PtdBut), that is produced by PLD in the presence of 
butan -1 -ol, a study has also been made of the kinetics of PLD activation by 
LHRH and the effect of various agents on the activation process. 
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CHAPTER 2 
MATERIALS AND GENERAL METHODOLOGY 
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2.1 Materials 
[9,10 -3H]- Palmitate (60 Ci/ mmol) was obtained from NEN Du Pont 
de Nemours, Germany, Ro 31 -8220 was a gift from Roche Products Ltd, 
Welwyn, Herts, UK. lonomycin , phorbol 12,13 -dibutyrate, LHRH and the 
LHRH antagonist ([Ac- D- p- CI -Phe 1,2, D-Trp3,D-Arg6,D-AIa10]-LHRH), 
sodium orthovanadate, chloroquine phosphate, geniticin, penicillin, 
streptomycin, ß- estradiol, progesterone and DL- threo -dihydrosphingosine 
were obtained from Sigma Chemical Co, Poole, Dorset, UK. Lavendustin 
A, 1-( 5- Isoquinolinesulphonyl )- 2- methylpiperazine (H7), genistein, methyl 
2,5- dihydroxycinnamate and GF 109203X were obtained from Calbiochem- 
Novabiochem, Nottingham, UK. Piceatannol and N- [1 -(2,3- Dioleoyloxy) 
propyl] -N, N, N- trimethyl ammoniummethylsulphate (DOTAP) were obtained 
from Boehringer- Mannheim UK, Lewes, East Sussex. DEAE -dextran was 
obtained from Promega. The FYN3 polyclonal rabbit antibody was 
obtained from Santa -Cruz Biotechnology, NBS Biologicals, Hatfield, 
England. The GD11 mouse monoclonal anti -src antibody and the 4G10 
mouse monoclonal anti -phosphotyrosine antibody were obtained from 
Upstate Biotechnology Incorporated (UBI), Lake Placid. Screw top glass 
vials (2 ml) were obtained from Chromacol. All other laboratory reagents 
were AnalaR grade from BDH, Merck Ltd, Poole, Dorset, UK. 
2.2 Data analysis 
All concentration -response curves were analysed by a non -linear, 
error -weighted direct fitting program, modelling on Hill kinetics (P.fit, 
Elsevier Biosoft, Cambridge). The significance of the differance between 
values was determined using the Mann -Whitney U test. 
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2.3 Cell culture 
All cultures were grown in a humidified atmosphere of 95% air/ 5% 
CO2 at a constant temperature of 37 °C, and received fresh medium every 3- 
4 days. al-3-1 cells were cultured in Dulbecco's modified eagle medium 
supplemented with 10% foetal calf serum (heat inactivated), sodium 
pyruvate (0.11 g /I), 2 mM L- glutamine, 100 U /ml penicillin and 0.1 mg /ml 
streptomycin. COS 7 and CHO cells were cultured in Hams F -12 medium 
supplemented with 10% foetal calf serum (heat inactivated), 100 U /ml 
penicillin and 0.1 mg /ml streptomycin. They also received fresh medium 
every 3 -4 days. Cell lines were split when 100% confluent and seeded at 
low density in fresh flasks. Cells were harvested by trypsin digestion: 
medium was removed and replaced with 1.5 ml of a 0.25% (v /v) trypsin 
solution and left for 10 min, the cells were then removed from flask by 
agitation with fresh growth medium. The cells were then suspended in an 
appropriate volume for transfer to a fresh flask, or to a 12 well culture plate 
for assays (1/3 of a confluent flask for each plate) and used after 2 days. 
Cell lines were frozen for storage in liquid N2 by resuspending 
harvested cells at an estimated density of 10' cells/ml in 95% foetal bovine 
serum (heat inactivated) + 5% dimethylsulphoxide. The cell suspension 
was aliquoted into cryostat tubes and placed in a closed polystyrene box 
(room temperature). The box was then placed at -70 °C for 3 -5 hrs before 
being transferred to liquid N2. Frozen cells were recovered from liquid N2 by 
thawing in water at 37 °C, after the liquid N2 had evaporated from the vial. 
The contents of the cryostat tube were then transferred to a flask with the 
appropriate volume of medium, under sterile conditions. 
Dimethylsulphoxide was removed after the cells were allowed 24 hr 
recovery, by total replacement of growth medium with fresh growth medium. 
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2.4 ANIMALS 
Adult female ( -200 g) COB Wistar rats were maintained under 
controlled lighting conditions (lights on from 05.00 to 19.00 h) and 
temperature (22 °C) with free access to food pellets (CRM, Labsure, Manea, 
Cambs, UK) and tap water. 
Female rats were assessed for a minimum of two 4 day oestrous 
cycles (determined by vaginal lavage) before being anaesthetised with 
Sagatal (30 mg /kg body weight; sodium pentabarbitone; May and Baker, 
Dagenham, Essex) by 11 am on the day of the cycle under investigation. 
The cytological characteristics of the vaginal smears in 4 -day cyclic rats 
were as follows: 
Metoestrus: Large number of leucocytes, epithelial cells and 
cornified epithelial cells. 
Dioestrus: Leucocytes, epithelial cells and cornified epithelial cells, but in 
smaller amounts than in metoestrus. 
Pro -oestrus: Mainly nucleated epithelial cells. 
Oestrus: Predominantly cornified epithelial cells. 
2.5 Assay of phospholipase D activity 
In order to label the phosphatidyl moiety of phosphatidylcholine, 
cells were incubated for 2 h with [3H] palmitate (5 piCi/ ml, 1 ml in each well) 
in minimal essential medium, at 37 °C under 5% CO2 /95% 02. Cells were 
washed twice with warm MEM (37 °C), containing 1% fatty acid free BSA. 
This was then replaced with 1 ml warm MEM containing 0.5% fatty acid - 
free BSA to each well. Butan -1 -ol was added to each to give a 
concentration of 30 mM (since previous experiments in this and other 
laboratories have shown that this concentration of butan -1 -ol provides 
optimal production of [3H]PtdBut, without adverse effects on cell viability as 
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assessed by trypan blue exclusion). Various inhibitory drugs were added, 
immediately before adding the stimulating agent which was present for 30 
min, unless otherwise stated. Reactions were terminated by removing the 1 
ml of medium and adding 0.5 ml ice -cold methanol. Cells were then 
scraped out of wells and transferred to a 2 ml screw -top glass vial. 
Chloroform was added to give a chloroform/ methanol ratio of 1:1. Tubes 
were mixed and left for 15 min, before distilled water was added to give a 
chloroform/ methanol/ water ratio of 1:1:0.8. The vials were vigorously 
shaken and centrifuged for 5min to separate the two phases. The top 
aqueous phase was carefully aspirated and discarded while the lower 
organic phase was left in the vial and dried under vacuum in a centrifugal 
evaporator (V.A. Howe, Banbury, UK) for approximately 50 min at 30 °C. 
Once the lower organic phase had evaporated it was resuspended in 50 µl 
chloroform/ methanol (19:1) and then spotted onto Whatman LK5D thin 
layer chromatography laned plates (silica 250 pm). The plates were 
developed using the organic phase of a mixture: ethyl acetate/ 2,2,4 - 
trimethylpentane/ acetic acid/ water (110: 50: 20: 100). In this system, 
phosphatidylbutanol (Rf =0.3) is well separated from phosphatidate (Rf 
=0.1), major phospholipids (Rf =0) and neutral lipids (Rf = 0.7- 0.95). The 
region containing PtdBut, and corresponding to a [14C]PtdBut standard (gift 
from R. Randall, Wellcome Research Laboratories, Kent, UK) was scraped 
off the plate and radioactivity quantified by liquid scintillation counting. 
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CHAPTER 3 
INVOLVEMENT OF PROTEIN KINASE C, AND OTHER 
MECHANISMS IN THE ACTIVATION OF PLD 
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3.1 INTRODUCTION 
There is considerable evidence that PKC plays a key role in the 
regulation of PLD in many systems (Thompson et al, 1993a). 
Phospholipase D activity can be stimulated in many tissues by phorbol 
esters (with 413 position stereospecificity), suggesting a role for PKC in 
activating the enzyme (Billah and Anthes, 1990). Not surprisingly, the 
phorbol ester -induced activation of PLD is highly sensitive to inhibitors of 
PKC. Interestingly, certain groups of PKC inhibitors, specifically the 
bisindolylmaleimides, which have been used in this study show partial 
selectivity for the Cat + -independent PKC isoforms (Wilkinson et al, 1993). 
Certain unidentified, PDBu -stimulated, PKC activities in pituitary and lung 
(Ison et al, 1993) have also been demonstrated to have a relative 
resistance to another PKC inhibitor 1- (5- isoquinolinyl sulphonyl)-2- methyl- 
piperazine (H7). It has also been postulated that this H7- resistant PKC 
activity plays an important role in the LHRH -priming effect (Johnson et al, 
1992). Thus it is conceivable that the involvement of different PKC isoforms 
in a response, such as PLD activation, could be reflected by slightly 
different sensitivities to inhibitors. 
Further strong evidence of the importance of PKC in the activation of 
PLD has been demonstrated by the over -expression of PKC a (Eldar et al, 
1993) and 131 (Pai et al, 1991a) in rat fibroblasts, in which the PLD activity 
stimulated by the phorbol ester, phorbol 12- myristate 13- acetate (PMA), and 
also that mediated by receptor- activated systems such as endothelin (Pai et 
al, 1991 b) or a- thrombin (Pachter et al, 1992) were enhanced. Another 
technique widely used in order to implicate PKC involvement, also used in 
this study, is down -regulation of PKC isoforms, brought about by prolonged 
preincubation with phorbol esters (McArdle and Conn, 1989). 
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Diacylglycerol derived from the hydrolysis of PIP2 by PLC has been 
shown to lead to the activation of protein kinase C (Nishizuka, 1992). 
However, doubts have been expressed as to whether DAG resulting from 
PLD- mediated hydrolysis of PC can be similarly effective. Several 
observations have suggested that PC derived DAG is not capable of 
activating PKC. For example it was demonstrated that in a- thrombin 
stimulated fibroblasts, DAG derived from Pl but not PC hydrolysis is 
responsible for the activation of PKC (Leach et al, 1991). In IgE- stimulated 
RBL 2H3 mast cells the PLD mediated production of DAG does not appear 
to be responsible for PKC activation (Lin et al, 1992). However, the idea 
that DAG derived from PC is ineffective at activating PKC has been 
challenged by results which show that in a- thrombin- and PDGF -stimulated 
fibroblasts the late phase of DAG production from PC hydrolysis is 
associated with the activation of PKC s, but not PKC a; this difference was 
shown to be due to the absence of a Cat+ elevation associated with PC 
hydrolysis, and not due to differences in the species of DAG produced (Ha 
et al, 1993). It has also been suggested that PLD -generated DAG is 
responsible for a sustained activation of PKC, since the kinetics of DAG 
accumulation are prolonged, compared to DAG generated from PIP2 by the 
action of PLC (Billah and Anthes, 1990). 
Studies have shown that the consensus composition of the fatty acid 
side chains is different in DAG derived from PC compared to PIP2 (Pessin 
and Raben, 1989; Pettit and Wakelam, 1993). This difference may 
conceivably influence DAG's cellular actions, such as activating PKC, 
perhaps making it more selective for certain PKC isoforms (Pettit and 
Wakelam, 1993). Nevertheless it has been demonstrated that it is the 
absence of a rise of Cat+ and not the source of DAG that is important in 
thrombin- and PDGF -stimulated fibroblasts (Ha and Exton, 1993). In Swiss 
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3T3 cells stimulated with bombesin, the fatty acid profile of DAG species 
produced is time -dependent, with DAG at early time points having a similar 
profile to that of phosphoinositides and at later time points being similar to 
PC (Pettit and Wakelam, 1993). 
Receptors coupled to heterotrimeric G proteins are widely linked to 
the activation of PLD in many types of cell (Billah, 1993). A commonly 
employed technique for demonstrating G protein involvement has been to 
use the unhydrolysable, stable GTP- analogue, guanosine 5' -(y- 
thio)triphosphate (GTPyS) in cell free preparations and permeablised cells 
(Anthes et al, 1991). This method has implicated an involvement of G 
proteins in PLD activation in many cell types, such as responses to fMLP in 
neutrophils (Olsen et al, 1991), and to endothelin in mesangial cells (Kester 
et al, 1992). In several systems, receptor -stimulated activation of PLD can 
be inhibited by pretreating the cells with the microbial toxin, pertussis toxin, 
which ADP -ribosylates the a subunit of G- proteins of the Gi and Go families, 
thus preventing their activation (Milligan, 1988). In fMLP -stimulated HL -60 
granulocytes the activation of both PLC- and PLD was blocked by pertussis 
toxin pre- treatment (Pai et al, 1988). However in hepatocytes, the activation 
of PLC and PLD by vasopressin -, angiotensin ll- and adrenaline were 
insensitive to pertussis toxin, even though these enzymes can be activated 
in membrane preparations by non -hydrolyzable analogues of GTP (Bockino 
et al, 1987). An insensitivity to pertussis toxin does not rule out G protein 
involvement, but simply shows that there is no Gi or Go involvement. It 
therefore appears that PLD can be activated by a variety of G protein - 
coupled receptors, linked to the intracellular signalling machinary by both 
Gq and Gi G proteins. 
As well as heterotrimeric G proteins being involved in the receptor 
activation of PLD, members of a group of low molecular weight G proteins, 
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ARF and Rho have also been implicated in PLD activation (Brown et al, 
1993; Cockroft et al, 1994; Bowman et al, 1993). It has been demonstrated 
that ARF plays a role in vesicle traffic and is a component of the coat of 
golgi- derived coated vesicles (Serafini et al, 1991). In cell free PLD assays 
carried out in HL -60 cells a cytosolic factor is required for PLD activity. 
Activity can be reconstituted in cytosol depleted cells by replacing cytosol, 
and the required cytosolic factors appear to be ARF1 and ARF3 (Cockroft et 
al, 1994). Activation of PLD was dependent on the concentration of ARF 
protein, indicating a stoichiometric, rather than a catalytic activation of PLD. 
Activation of PLD by ARF was observed at 100 nM Ca2 +, however this was 
greatly enhanced at 10 µM Ca2+ (Cockroft et al, 1994). The guanine 
nucleotide exchange factor protein for ARF (ARF -GEF) has been shown to 
be a target for an inhibitor of vesicle transport, brefeldin A (Donaldson et al, 
1992). This raises the possibility that brefeldin A could be used to assess 
whether PLD is activated by ARF in whole cell systems. 
Intracellular Ca2+ levels appear to be important in the regulation of 
PLD in some systems. In a wide variety of studies it has been demonstrated 
that depletion of intracellular and /or extracellular Ca2+ inhibits the activation 
of PLD (Purkiss and Boarder, 1992; Billah et al, 1989; Bockino et al, 1987; 
Cook et al, 1991), although this technique has not been used in this study. 
Calcium ionophores are also widely used in order to raise the cytoplasmic 
Ca2+ concentration, and in several cell types they have been shown to 
stimulate the activation of PLD (Billah et al, 1989; Bockino et al, 1987; Van 
Blitterswijk et al, 1991). 
The kinetics of PLD activation can vary considerably, depending on 
cell type and receptor pathway. The time course for PLD activation has 
been shown to vary from -5 sec, followed by rapid desensitisation (Briscoe 
et al, 1994), to a substantial delay after receptor activation (5 -10 min), 
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followed by a very slow desensitisation (Netiv et al, 1991). It could be 
postulated that the time course of PLD activity will be closely related to the 
cellular functions of PA and DAG. It may also reflect the action of individual 
isoforms of PLD. 
3.2 METHODS 
3.2.1 Phospholipase D assay 
Assays for phospholipase D were carried out using the standard protocol, 
as described in section 2.5. 
3.3 RESULTS 
3.3.1 PLD kinetics and activators 
The production of [3H] phosphatidylbutanol (PtdBut) in T3 -1 cells 
incubated with LHRH for 30 min showed a marked increase over the very 
low levels in control cells (approximately 60 000 dpm in stimulated cells 
compared to approximately 3000 dpm in control cells) and clear 
concentration -dependence (Figure 3.1). Under these conditions, the EC5o 
for PLD activation by LHRH was 16 ± 5 nM and reached a maximum by 
approximately 100 nM. A concentration of 100 nM LHRH was therefore 
used in most of the other experiments in this study, in order to elicit a large 
(but not supra -maximal) PLD response. 
The time course (up to 40 min) of [3H] PtdBut accumulation elicited by 
LHRH (100 nM) or PDBu (1 µM) is shown in Figure 3.2. In the LHRH- 
stimulated cells there was a lag of between 5 and 10 min before [3H] PtdBut 
production could be detected. The rate of [3H] PtdBut accumulation 
appeared to be approximately constant between 5 and 40 min. In PDBu- 
stimulated cells there was an even longer lag of between 10 and 15 min 
before [3H] PtdBut levels were detectable. The activation of PLD by PDBu 
appeared to occur at a rate comparable to the LHRH stimulated activity only 
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for around 10 min before the rate of [3H] PtdBut accumulation declined. 
Thus at all times, especially the longer time points, PDBu (1 µM) caused a 
much lower level of [3H] PtdBut accumulation than LHRH (100 nM). 
The LHRH receptor antagonist [Ac-D-p-Cl-Phe1,2,D-Trp3,D- Arg6,D- 
Ala10] -LHRH (Neckola et al, 1982) (1 µM),completely prevented activation of 
PLD by LHRH (100 nM), whilst the antagonist itself caused no detectable 
activation of PLD (Table 3.1). The biologically- inactive phorbol ester 
isomer, 4a- phorbol 12,13 -dibutyrate (4a -PDBu, 1 µM) elicited no increase 
in PLD activity at a concentration of 1 µM. The Cat+ ionophore, ionomycin 
(30 µM) caused no significant activation of PLD by itself, although it did 
slightly augment the PDBu -stimulated PLD activity (Table 3.1). A 
combination of LHRH (100 nM) and PDBu (1 µM) elicited approximately 
additive levels of [3H] PtdBut production (Table 3.1), even though the large 
accumulation due to 100 nM LHRH was maximal on its own concentration - 
response curve. To address the possibility that the lag in [3H] PtdBut 
production was due to a requirement for protein synthesis in the mechanism 
of PLD activation, experiments were carried out in the presence of 
cycloheximide (300), but this clearly had no effect on LHRH- induced PLD 
activity (Table 3.1). 
Sphingosine and its metabolite, sphingosine -1- phosphate have 
been reported to increase phosphatidic acid levels by PLD activation 
(Desai et al, 1992). DL- threo -dihydrosphingosine (30 µM) did cause a 
slight activation of PLD, 12 ± 2.5 % of that observed for LHRH (100 nM) 
stimulation (Table 3.1). 
3.3.2 PKC involvement 
Two approaches were used to assess the role of PKC in LHRH- 
induced PLD activation; firstly by employing a number of selective PKC 
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inhibitors and secondly, down -regulation of PKCs in aT3 -1 cells by 
prolonged preincubation with a phorbol ester prior to LHRH stimulation 
(McArdle and Conn, 1989). Over a 30 min incubation with LHRH (100 nM), 
the selective bisindolylmaleimide PKC inhibitor Ro 31 -8220 (Davis et al, 
1992) completely inhibited the evoked PLD activity with an IC50 of 460 ± 
180 nM (Figure 3.3). In cells stimulated for 30 min with PDBu (1 µM), Ro 31- 
8220 again completely inhibited PLD activity but with an ICSÓ of 62 ± 30 nM 
(Figure 3.3). This represents an approximately eight fold greater potency of 
Ro 31 -8220 when PDBu was used as a stimulus instead of LHRH. Another 
highly -selective bisindolylmaleimide PKC inhibitor GF 109203X (Toullec et 
al, 1991) completely inhibited the PLD activity stimulated by LHRH (100 
nM), with an IC50 of 1.0 ± 0.2 p.M (Figure 3.4). PDBu -stimulated PLD activity 
was more potently inhibited by GF 109203X, with an IC50 of 161 ± 19 nM 
(Figure 3.4). 
A PKC inhibitor of another structural class, 1 -(5- isoquinolinyl 
sulphonyl) -2- methyl -piperazine (H7) (Hidaka et al, 1984) inhibited LHRH- 
stimulated activation of PLD with an IC50 of 232 ± 25 µM (Figure 3.5). The 
slope factor of the concentration -inhibition curve (1.27 ± 0.15) was 
consistent with a single component to the inhibition. However in cells 
stimulated with PDBu (1 µM) (Figure 3.5), H7 inhibited the response over a 
very wide concentration range (slope factor = 0.56 ± 0.05). This is 
consistent with multiple components being involved in the inhibition. The 
concentration -inhibition curve gave a much better fit to a 2 component Hill 
equation than to a one site model with component parameters of IC50(i) = 
12.5 ± 1.9 µM (45% of sites) and IC50(ii) = 635 ± 85 gM (55% of sites). 
Down -regulation of PKC isoforms using 300 nM PDBu caused no 
significant reduction of the LHRH -stimulated PLD activity after 1 hr. 
However after 16 hrs it resulted in a 74 ± 3% reduction in the LHRH- 
f:\ ''' 
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stimulated PLD activity, and after 24 hrs of phorbol treatment the LHRH- 
stimulated activation of PLD was attenuated by 82 ± 9% (Figure 3.6). 
3.3.3 G- protein involvement 
The LHRH -stimulated activation of PLD was insensitive to pertussis 
toxin up to a concentration of 300 ng /ml, the highest concentration used. 
The aT3 -1 cells were pretreated with pertussis toxin for approximately 16 
hrs prior to the assay, which represents a fully adequate time for the 
inactivation of any G- proteins sensitive to ADP -ribosylation by pertussis 
toxin (Milligan, 1988). 
Brefeldin A, a compound which has been demonstrated to inhibit the 
guanine nucleotide exchange on the low molecular weight G protein ARF 
(Donaldson et al, 1992), inhibited the LHRH -stimulated PLD activity with an 
IC50 of 320 ± 1150 (Figure 3.7), however this inhibition was not complete 
by 1 mM brefeldin A, the highest concentration used. 
3.4 DISCUSSION 
Despite being clearly coupled via G proteins to phosphoinositide 
hydrolysis (Snyder and Bleasdale, 1982; Schrey, 1985; Anderson et al, 
1992, Davidson et al, 1994), the LHRH receptor is an atypical member of 
the family of such receptors since it lacks an extended C- terminal tail 
(Tsutumi et al, 1992). There is evidence that phosphorylation of the C- 
terminal tail of several G protein -coupled receptors contributes importantly 
to receptor desensitisation (Probst et al, 1992). Therefore the lack of a C- 
terminal tail on the LHRH receptor may contribute to the complete lack of 
desensitisation seen in the PLD response to LHRH over the 40 min time 
course used in this study (Figure 3.2). Desensitisation may also be altered 
by virtue of the unusual sequence differences in consensus sequences of 
52 
the transmembrane 2 and transmembrane 7 domains (Zhou et al, 1994); 
this topic will be discussed further in Chapter 6. 
LHRH -stimulated activation of PLD proceeded after a lag of about 5 
min (Figure 3.2). This result is similar to that of a previous study carried out 
on aT3 -1 cells, in which it was proposed that PLD activation required a 
particularly high receptor occupancy, thus dictating a lag before PLD activity 
could be detected (Netiv et al, 1991). However, the observation of an even 
more pronounced lag in activation by PDBu suggests that the delay is 
mainly due to some factor other than the rate of receptor occupancy by an 
agonist. The experiments with cycloheximide also indicate that the lag in 
activation of PLD by LHRH was not due to the synthesis of an intermediary 
activating protein. 
It is unclear why the mechanism through which PDBu causes 
activation of PLD becomes so markedly attenuated after 10 min of 
detectable activity. It is known that even quite short incubations of cells 
(including aT3 -1 cells) with high concentrations of phorbol esters can lead 
to down -regulation of many PKC isoforms (Johnson et al, 1993a), and as 
has been previously shown, phorbol esters will have a more profound 
down -regulatory effect on PKC than receptor agonists (Lutz et al, 1993). 
However, a 1 hr preincubation with PDBu (300 nM) did not result in any 
detectable reduction of the LHRH -stimulated activation of PLD (Figure 3.6). 
The prolonged delay before PDBu caused PLD activation compared to 
LHRH is also unexplained. It is of course possible that PDBu is activating 
isoforms of PKC not normally involved in the LHRH receptor activation of 
PLD, or that a different isoform of PLD may be activated through the PDBu- 
stimulated pathway. The additive effect of LHRH and PDBu on the PLD 
response supports the theory that these two stimuli do use different 
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biochemical pathways at least to some degree in order to bring about the 
activation of PLD. 
Calcium ionophores are in general good activators of PLD 
(Thompson et al, 1991). However, increasing the concentration of 
intracellular calcium with ionomycin, which has been reported to release 
Cat+ from intracellular stores (Morgan and Jacob, 1994), was not sufficient 
by itself to activate PLD in this study. Furthermore ionomycin was not able 
to potentiate to any great extent the PLD response elicited by PDBu. Both a 
and ß isoforms of PKC have been implicated in PLD activation in different 
systems. It was demonstrated in membane preparations from Chinese 
hamster lung fibroblasts that addition of purified PKC a, and to a lesser 
extent PKC ß stimulates PMA and Cat + -induced PLD activity (Conricode et 
al, 1994). Overexpression of PKC ß in fibroblasts has also been shown to 
lead to an elevation in the phorbol- stimulated PLD activity (Eldar et al, 
1993; Pai et al, 1991a). It is therefore entirely possible that Cat + -dependent 
PKCs are also involved here, since it is known that LHRH receptor 
activation increases intracellular Cat+ levels within the cells (Limor et al, 
1987; Anderson et al, 1992), which could contribute to activation of such 
Cat + -dependent PKC isoforms. Receptor systems that activate PLD in a 
PKC- independent manner, such as the angiotensin II- stimulated activation 
of PLD in vascular smooth muscle cells have been shown to be blocked by 
chelation of intracellular and /or extracellular Cat+ (Lassegue et al, 1991; 
Billah et al, 1989), whereas the activation of PLD in aT3 -1 cells appears to 
be highly dependent on PKC. Interestingly a report has described the 
inhibition by Cat+ of guanosine 5'- 0- (3- thiotriphosphate) -induced PLD 
activation in permeablised NG 108 -15 neuroblastoma X glioma cells 
(Liscovitch and Eli, 1991). 
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Sphingosine has previously been reported to be an inhibitor of PKC 
(Hannun and Bell, 1990). Further studies have also demonstrated that 
sphingosine has complex biological effects, many of which seem to be 
independent of PKC (Faucher et al, 1988), such as the activation of 
sphingosine- activated protein kinase (Pushkareva et al, 1993), illustrating 
the complex modulation of signalling systems by these lipids. It has also 
recently been reported that sphingosine, and its metabolite, sphingosine 1- 
phosphate are able to stimulate PLD activity (Desai et al, 1992). It was also 
found that sphingosine caused a modest increase in PLD activity in this 
study. It is therefore possible that sphingosine and sphingosine 1- 
phosphate produced within the cell are able inhibit the activity of PKC, while 
at the same time increasing the activity of PLD. This might be important if 
DAG and PA were needed for cellular functions not involving PKC. 
The present results provide strong evidence for an obligatory role of 
PKC in the LHRH -stimulated activation of PLD, since this response was 
greatly attenuated by PKC down -regulation and fully blocked by selective 
PKC inhibitors. The bisindolylmaleimide PKC inhibitors Ro 31 -8220 and 
GF 109203X were about eight times more potent against PDBu -stimulated 
PLD activation than against LHRH -stimulated PLD activation. Since all 
phorbol ester -sensitive PKC isoforms are likely to be strongly activated by 
the relatively high concentration of PDBu used (11.1M), it is possible that a 
form of PKC relatively resistant to Ro 31 -8220 may be activated in response 
to LHRH, in contrast to the consensus of those, more sensitive, isoforms 
activated by PDBu. It has been reported that a bisindolylmaleimide related 
to Ro 31 -8220 shows selectivity for the Cat + -dependent PKCs compared to 
PKC E (Wilkinson et al, 1993). It has been demonstrated that aT3 -1 cells 
express the PKC isoforms a, E and at high levels (Johnson et al, 1993b). 
Interestingly, the atypical Cat + -independent isoform, PKC - only has one 
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cysteine -rich zinc finger domain, and is therefore not activated by phorbol 
esters which require two zinc finger domains. this PKC isoform also shows 
a relative resistance to bisindolylmaleimides and related indolocarbazoles 
compared to other PKC isoforms (Martiny -Baron et al, 1993). It is therefore 
possible that PKC , or a related species may be involved in the LHRH- 
stimulated PLD pathway, since this response is less sensitive to 
bisindolylmaleimides than the PDBu -stimulated response. The relatively 
high potency of Ro 31 -8220 and GF 109203X on LHRH responses, 
compared to other studies in whole cells does however suggest that some 
form of PKC is involved in PLD activation. For example Ro 31 -8220 was 
able to attenuate the LHRH -stimulated PLD activity at a two -fold lower 
concentration than that seen for PMA- stimulated PLD activity in Swiss 3T3 
cells (Cook et al, 1991). It has also been demonstrated that Ro 31 -8220 
potently inhibits the P2 receptor- or PMA -stimulated activation of PLD in 
endothelial cells at a concentration of less than 10 (Purkiss and Boarder, 
1992). The other bisindolylmaleimide PKC inhibitor used in this study, GF 
109203X, has been shown to inhibit platelet aggregation stimulated by a- 
thrombin and collagen with IC5Ós of 875 ± 216 and 760 ± 250 nM 
respectively, and to inhibit the phosphorylation of major cellular substrates 
of PKC (Toullec et al, 1991). The concentrations required in all of the above 
studies in whole cells compare favourably with our own results for the 
bisindolylmaleimide inhibition of LH RH- and phorbol- stimulated PLD 
activity, although it is of course possible that an unknown kinase with some 
sensitivity to bisindolylmaleimides (other than a PKC isoform) is mediating 
the LHRH -stimulated activation of PLD. 
Another PKC inhibitor, H7, also inhibited both the LHRH- and PDBu- 
induced increases in PLD activity. LHRH -stimulated PLD activity was 
inhibited in a monophasic fashion, suggesting either that only one PKC 
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isoform was involved, or that all those involved had the same low sensitivity 
to H7. Compared to the potency of inhibition of various PKC isoforms by H7 
in cell -free assays, the LHRH- induced PLD activity was markedly 
insensitive to H7 (Schapp and Parker, 1990). However, H7 competes for 
ATP binding, and in a whole cell system it has been shown that H7 blocks 
the release of LH from LHRH -stimulated anterior pituitaries with an IC50 of 
71 ± 13 RM (Johnson et al, 1992), while the H7 inhibits the PDBu- induced 
release of LH from anterior pituitaries in vitro with an IC50 of 1.7 ± 1.5 µM 
(Thompson et al, 1993b). It has also been reported that there is a distinct 
H7- resistant form of PKC in the rat anterior pituitary gland, that may 
represent either a novel or modified PKC isoform, although it is clear that 
this species is phorbol ester -activated and can be clearly separated from 
PKC -4 by ion -exchange and hydroxyapatite chromatography (Ison et al, 
1993). 
There appear to be multiple components to the inhibition by H7 of 
PDBu- evoked PLD activity. Interestingly this suggests that PLD activation 
by stimulation with phorbol esters involves more than one isoform of PKC, 
and whilst it has already been shown using overexpression studies that the 
Ca2 +- dependent PKC isoforms a and 131 can participate in PLD activation 
(Eldar et al, 1993; Pai et al, 1991 a), it now seems likely that further species 
of PKC may also be able to contribute. 
The fact that compounds which inhibit the activity of PKC by 
competing with the ATP -binding site are capable of inhibiting the LHRH- 
and PDBu -stimulated PLD activity suggests that the mechanism by which 
PKC brings about PLD activation involves protein phosphorylation. This 
contrasts with one study which concluded that PKC activates PLD though a 
phosphorylation- independent mechanism, since there was no ATP 
requirement (Conricode et al, 1992). 
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PDBu -stimulated activation of PLD activity was almost completly 
desensitised over 16 hrs exposure to PDBu, consistent with the activator - 
induced down- regulation of PDBu- sensitive PKC isoforms (Hug and Saare, 
1993), which has been reported to result in a faster down -regulation of the 
Cat + -dependent PKC a, compared to the Cat + -independent PKC (Huwiler 
et al, 1991). In contrast, although apparently blocked by highly -selective 
PKC inhibitors, LHRH- induced PLD activation showed no desensitisation 
through 40 min, thus suggesting that a PKC isoform resistant to down - 
regulation (perhaps 0) was playing a significant role, in contrast to the 
PDBu -stimulated PLD activation. However, it may be that other, more 
complex mechanisms may be responsible for the results observed. In fact 
the loss of the vast majority of LHRH- induced PLD activation following 
down -regulation of PDBu- sensitive PKCs may count against the major 
involvement of a PDBu- insensitive PKC such as , since it has been 
observed that PKC was not down -regulated as a result of long term 
phorbol ester treatment (Ways et al, 1992; Chen and Murakami, 1992). 
However there appears to be some controversy as to whether PKC Ç can be 
down -regulated by phorbol ester treatment, since it has been reported PKC 
translocates to the membrane as a result of PMA treatment in human 
platelets (Crabos et al, 1992) and has been shown to be down -regulated as 
a result of PDBu -treatment in T3 -1 cells (Johnson et al, 1993a). 
Nevertheless, since the down -regulation protocol involves intense 
activation of PDBu- sensitive isoforms in the initial stages (which could lead 
to profound secondary effects within the cell), the interpretation of the down - 
regulation result must require a degree of caution. It has also been 
reported that other proteins have Cys -rich motifs, responsible for phorbol 
binding, such as Raf, myosin heavy chain kinase, DAG kinases, and the low 
molecular weight G- proteins Vav and n- chimerin (reviewed in Liscovitch 
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and Cantley, 1994). It is therefore likely that these, and other proteins will 
be affected by long -term phorbol ester treatment. 
LHRH- stimulated PLD activation was insensitive to inhibition by 
pertussis toxin (up to 300 ng /ml), which would suggest that the G- protein 
involved is not a member of the Gi or Go family which are sensitive to 
pertussis toxin (Milligan, 1988). This result is similar to recent evidence that 
inositol phosphate production in aT3 -1 cells is also insensitive to pertussis 
toxin, where it was postulated that the G protein involved was a member of 
the Gq /G11 family (Anderson et al, 1992). It therefore seems likely that the 
activation of both PLC and PLD are linked to the LHRH receptor in the 
intracellular signalling pathway by a pertussis toxin -insensitive G protein, 
possibly Gq. Although the involvement of both PKC (Chapter 3) and 
tyrosine kinases (Chapter 4) in the activation of LHRH -stimulated PLD 
suggests that there is no direct interaction between the subunits of 
heterotrimeric G proteins and PLD. 
Brefeldin A, an inhibitor of vesicle transport in the golgi, was clearly 
able to inhibit LHRH -stimulated PLD activation, although at a slightly higher 
concentration than that used to prevent the formation of coated vesicles on 
golgi cisternae in a cell free system, which was 150 µM (Orci et al, 1991). 
The cellular target of brefeldin A appears to be the guanosine nucleotide 
exchange factor for the low molecular weight G- protein ARF (Donaldson et 
al, 1992). It has recently been reported that ARF is able to activate PLD in a 
GTP- dependent manner in HL60 cells (Cockroft et al, 1994; Brown et al, 
1993). These results raise the possibility that PLD may be involved in 
vesicle formation within the cell, possibly by the formation of an area of 
polar phospholipids on the membrane, or by the generation of lipid second 
messengers which control other components of the veisicle formation or 
fusion mechanism. This pathway also demonstrates a possible means by 
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which the vesicle formation machinery could be under direct receptor -linked 
second messenger control. It has also been postulated that another low 
molecular weight G- protein, Rho, may also be involved in the activation of 
PLD in neutrophils, since the Rho -GDP dissociation inhibitor (Rho -GDI), a 
regulatory protein that specifically inhibits the functions of the Rho family of 
small G- proteins was able to inhibit GTPyS- stimulated PLD activity 
(Bowman et al, 1993). It is possible that the low molecular weight G protein 
ARF may be involved as a direct activator of PLD in the LHRH- stimulated 
activation of PLD, downstream of other components in the activation 
pathway. It must however be noted that the use of brefeldin A is not proof of 
the involvement of ARF, and can only be used as a pointer. 
The results presented in this chapter provide strong evidence for an 
obligatory involvement of PKC (possibly a phorbol ester insensitive isoform, 
such as PKC ) in the LHRH -stimulated activation of PLD at some point in 
the signalling pathway. However, this does not mean that PKC brings 
about PLD activation through a direct phosphorylation, since there appear 
to be other components to the activation process downstream of PKC, such 
as tyrosine kinase (Chapter 4) and possibly ARF. It is apparent that the 
LHRH receptor is coupled to the downstream signalling machinery, in the 
case of PLD activation through a pertussis toxin -insensitive G- protein, 
possibly a member of the Gq family. It is also possible that a low molecular 
weight G- protein, such as ARF is involved in the LHRH- mediated activation 
of PLD, since an inhibitor of the GTP- exchange factor for ARF, brefeldin A, 
is able to attenuate the LHRH -stimulated activation of PLD. It is interesting 
that additivity is observed in the PLD response when stimulated by both 
LHRH and PDBu; this suggests that these two stimuli activate PLD through 
different pathways, further consistent with the possible involvement of a 
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phorbol ester- unresponsive PKC isoform in the LHRH- stimulated pathway. 
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Table 3.1 
Compounds effecting the activity of PLD in aT3 -1 cells 
Effect of various compounds on the accumulation of [3H] PtdBut in aT3 -1 
cells over a 30 min time course from three separate experiments. Values 
are expressed as a % of the LHRH (100 nM)- stimulated PLD activity, with 
the basal level of [3H] PtdBut accumulation (3000 dpm) subtracted, and 
are means ± SEM from 4 -8 separate determinations. 
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Table 3.1 
Induced Response dpm x 103 (mean % 
response to LHRH 
parentheses) 
a 
LHRH (100 nM) 
LHRH antagonist (1 µM) 




± 5.5 (100 ± 9) 
±1.2( -1 ±2) 
± 1.2 (1 ± 2) 
b 
LHRH (100 nM) 
4ß-PDBu (1 µ.M) 
4a-PDBu (1 µM) 
61.2 ±6.2(100 ±10) 
33 ± 4.8 (54 ± 4) 
1.2 ± 1.2 (0 ± 2) 
LHRH (100 nM) + 4ß-PDBu (1 µM) 79.1± 5.5 (131 ± 9) 
lonomycin (30 uM) 1.8 ± 3.8 (1 ± 2.1) 
4ß-PDBu (1 µM) + ionomycin (30 uM) 39 ± 2.4(64 ± 4) 
C 
LHRH (100 nM) 61 ± 6 (100 ± 10) 
LHRH (100 nM) + cycioheximide (30 µM) 60 ± 2.4 (98 ± 4) 
DL-threo-dihydrosphingosine (30 µM) 7.3 ± 1.5 (12 ± 2.5) 
in 
Figure 3.1 
Concentration response curve for LHRH -stimulated activation in 
aT3 -1 cells 
Concentration -response curve for LHRH -stimulated activation of PLD (ie 
[3H]PtdBut accumulation) over a 30 min incubation with the basal value 









































Time course of LHRH- and PDBu -stimulated activation of PLD in 
aT3 -1 cells 
Time course of PLD activation by LHRH (100 nM) and PDBu (1 pM) with the 
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Figure 3.3 
Concentration response curve for the inhibition of LHRH -and 
PDBu -stimulated PLD activity by Ro 31 -8220 in aT3 -1 cells 
The effect of the protein kinase C inhibitor Ro 31 -8220 on stimulus- induced 
PLD activation. Concentration- dependent inhibition of responses to LHRH 
(100 nM)and and to PDBu (1 µM) with the basal values subtracted. 
Stimulation was for 30 min, and values are means ± SEM from 4 -8 
separate determinations. Values above and including 0.01 µM Ro 31 -8220 
for LHRH -stimulated PLD activity and above and including 0.03 µM Ro 31- 
8220 for PDBu -stimulated PLD activity are significantly different from the 
stimulus- induced PLD activity (p <0.05, Mann -Whitney U test). There was 






/ 0 0.01 0.1 
4. 
I I 
Ro 31-8220 (µ,M) 
i 
1 
-f- LHRH- stimulated PLD activity 
---4.--- PDBu -stimulated PLD activity 
10 
Figure 3.4 
Concentration response curve for the inhibition of LHRH- and 
PDBu -stimulated PLD activity by GF 109203X in aT3 -1 cells 
The effect of the protein kinase C inhibitor GF 109203X on stimulus - 
induced PLD activation. Concentration -dependent inhibition of responses 
to LHRH (100 nM)and and to PDBu (1 pM), with basal values subtracted. 
Stimulation was for 30 min, and values are means ± SEM from 4 -8 
separate determinations. Values above and including 0.3 pM GF 109203X 
for LHRH -stimulated PLD activity and 0.030 GF 109203X for PDBu- 
stimulated PLD activity are significantly different from the stimulus- induced 
PLD activity (p <0.05, Mann -Whitney U test). There was no effect of GF 
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concentration response curve for the inhibition of LHRH- and 
PDBu -stimulated PLD acrivity by H7 in aT3 -1 cells 
The effect of the protein kinase C inhibitor 1-(5-isoquinolinesulphonyl)-2- 
methylpiperazine H7 on stimulus- induced PLD activation. Concentration - 
dependent inhibition of responses to LHRH (100 nM)and and to PDBu (1 
µM). Stimulation was for 30 min, and values are means ± SEM from 4 -8 
separate determinations. Values above 10 µM H7 for the LHRH -stimulated 
PLD activity and 100 p.M for the PDBu -stimulated PLD activity are 
significantly different from the stimulus- induced PLD activity (p <0.05, Mann - 
Whitney U test). Curve fitting analysis indicated an unusually low Hill 
coefficient (0.56 ± 0.05; consistent with the contribution of multiple 
components) in the case of H7 inhibition of PDBu -stimulated PLD activity 
but not for LHRH- stimulated PLD activity. There was no effect of H7 on the 
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Figure 3.6 
LHRH -stimulated activation of PLD in aT3 -1 cells treated for 
varying periods of time with PDBu (300 nM) 
LHRH -stimulated activation of PLD in aT3 -1 cells treated with the phorbol 
ester PDBu (300 nM) for different lengths of time over a 24 hr period. LHRH 
(100 nM) stimulation of PLD activity was for 30 min, and values are means 
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Figure 3.7 
Concentration response curve for the inhibition of LHRH- 
stimulated PLD activity by brefeldin A 
Inhibition of LHRH -stimulated PLD activity by an inhibitor of ARF guanine 
nucleotide exchange factor, brefeldin A. Stimulation was for 30 min, and 
values are means ± SEM from 4 -8 separate determinations with the basal 


































































PHARMACOLOGICAL EVIDENCE FOR THE 




It is becoming increasingly clear that tyrosine kinases are involved in 
the receptor linked activation of phospholipase D in many cell types, 
including those receptors acting through G protein -coupled receptors, as 
well as receptors with intrinsic tyrosine kinase activity (Thompson et al, 
1993a). It has been demonstrated that tyrosine phosphorylation is involved 
in fMLP -, platelet activating factor (PAF)- and leukotriene- stimulated 
activation of PLD in human neutrophils, and that this receptor stimulated 
PLD activity can be attenuated by the tyrosine kinase inhibitors, ST271, 
ST638 and erbstatin, although they had no effect on the phorbol ester - 
stimulated PLD activity. In parallel it was also demonstrated that tyrosine 
phosphorylation was not involved in the fMLP -stimulated activation of PLC 
(Uings et al, 1992). In another example of a G protein -coupled system, it 
was demonstrated that in cells derived from vascular smooth muscle, 
endothelin -1 was able to stimulate PLD activity through a PKC- and 
tyrosine kinase- dependent mechanism, and that the PMA- stimulated PLD 
activity was insensitive to tyrosine kinase inhibitors (Wilkes et al, 1993). 
Tyrosine kinase inhibitors have also been shown to inhibit the EGF- 
stimulated activation of PLD in Swiss 3T3 cells, indicating that receptors 
with intrinsic tyrosine kinase activity can also couple to PLD activation 
(Cook and Wakelam, 1992). 
The level of tyrosine phosphorylation of cellular proteins can be 
controlled by the action of tyrosine kinases, and by the action of tyrosine 
phosphatases, which remove phosphate groups from phosphotyrosine 
residues (Pot and Dixon, 1990). Cell permeable peroxides of vanadate are 
capable of inhibiting the activity of tyrosine phosphatases, thus increasing 
the level of tyrosine phosphorylation within the cell and enhancing the 
effect of tyrosine kinases (Grinstein et al, 1990). This effect of pervanadate 
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has been reported to be 102 -103 times more potent than that of vanadate in 
cell free assays (Fantus et al, 1989). It was demonstrated in HL -60 cells 
that peroxides of vanadate were able to stimulate the activation of PLD, and 
that this PLD stimulation can be blocked by selective inhibitors of tyrosine 
kinases (Bourgoin and Grinstein, 1991). Strong evidence for the 
involvement of a non -receptor tyrosine kinase in the activation of PLD has 
also been demonstrated by an increase in PLD activity in BALB /c 3T3 cells 
transformed by constitutively active v -src. The evoked PLD activity in this 
system has been shown to be independent of PKC and distinct from the 
PLD activity stimulated by phorbol esters (Song and Foster, 1993). 
However, the results of this study do not necessarily mean that the 
physiologically relevant activation of PLD is caused by c -src or other src - 
type kinases in normal cells. 
In the present study we have assessed the effects of a number of 
selective tyrosine kinase inhibitors on both the LHRH receptor -stimulated, 
and the phorbol ester -stimulated PLD activity. We have also used the 
tyrosine phosphatase inhibitor pervanadate in order to bring about a more 
direct elevation of tyrosine phosphorylation by the inhibition of tyrosine 
phosphatases (Grinstein et al, 1990). 
4.2 METHODS 
4.2.1 Phospholipase D assay 
Assays for phospholipase D were carried out using the standard protocol, 
as described in section 2.5. 
4.2.2 Preparation of Pervanadate 
Pervanadate was prepared as previously described, with minor 
modifications (Fantus et al, 1989). Na3VO4 was added to divalent cation - 
free Earle's balanced salt solution containing HEPES (30 mM) to give a 
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final concentration of 5 mM. The pH was adjusted to 7.4 with NaOH, then 
H2O2 (1 M) was added to give a concentration of 1 mM and the solution was 
left for 15 min before 4 mg of catalase was added, in order to remove 
excess H2O2. The solution remained clear throughout the above procedure. 
4.3 RESULTS 
In order to assess whether tyrosine phosphorylation was involved in 
LHRH -stimulated activation of PLD, a number of compounds were used 
which are known to inhibit or enhance cellular tyrosine phosphorylation. 
Over a 30 min stimulation with LHRH (100 nM) the highly -selective 
tyrosine kinase inhibitor lavendustin A, which has been demonstrated to be 
a competitor with respect to ATP, but a non -competitive inhibitor with 
respect to a src- peptide substrate (Hsu et al, 1991). Binding analysis has 
also revealed that lavendustin A acts as a slow, tight binding inhibitor with a 
two step mechanism (Hsu et al, 1991). Lavendustin A inhibited 
approximately 60% of the LHRH -stimulated PLD activity with an IC50 of 133 
± 17 nM (Figure 4.1). Even at concentrations up to 20 µM, lavendustin A 
caused no further inhibition of PLD. In contrast lavendustin A had no effect 
on PLD activity elicited by the PKC activator PDBu (1 µM) over a 30 min 
stimulation (Figure 4.1). The inactive isomer of lavendustin A, lavendustin 
B (Hsu et al, 1991), had no detectable effect on the LHRH -stimulated PLD 
activity at a concentration of 10 µM. 
Another tyrosine kinase inhibitor investigated was piceatannol. This 
compound has been shown to inhibit the purified thymocyte protein - 
tyrosine kinase, p40, by competing for the peptide or protein binding site 
(Geahlen and McLaughlin, 1989). It has been shown that piceatannol does 
not inhibit the activity of cAMP- dependent protein kinase (Geahlen and 
McLaughlin, 1989). However, it has also been demonstrated that 
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piceatannol will inhibit the Cat + -dependent activity of PKC from aT3 -1 cells, 
using glutamate synthase (GS)- peptide (100 µM) as a substrate with an IC50 
of 163 ± 12 (M. Johnson, unpublished results). In this study piceatannol 
inhibited the LHRH -stimulated activation of PLD with an IC50 of 35 ± 5 fiM. 
Piceatannol also caused inhibition (albeit with a somewhat lower potency) 
of PDBu -stimulated PLD activity, with an IC50 of 155 ± 50 
is a further tyrosine kinase inhibitor investigated here, 
which has been shown to be competitive inhibitor with respect to ATP and 
non -competitive to a phosphate acceptor, histone H2B (Akiyama et al, 
1987). These authors also demonstrated that genistein has scarcely any 
effect on the serine/ threonine specific protein kinases, cAMP- dependent 
protein kinase and PKC. Genistein inhibited the LHRH (100 nM)- stimulated 
activation of PLD with an IC50 of 92 ± 34 µM (Figure 4.2), whilst causing no 
significant inhibition of PDBu (1 µM)- stimulated PLD activation up to 300 
µM (Figure 4.2). Although the above tyrosine kinase inhibitors were able to 
inhibit the LHRH -stimulated PLD activity, another tyrosine kinase inhibitor 
MDC was unable to inhibit the LHRH- or PDBu -stimulated PLD (results not 
shown) at 1 mM, the highest concentration used. It was not assessed 
whether MDC was able to enter the cells here, although MDC is a polar 
compound and its anticipated low ability to enter cells may explain this 
result (Umezawa et al, 1990). 
The tyrosine phosphatase inhibitor pervanadate (1 mM) was able to 
stimulate PLD activity over a 30 min period (Table 4.1) to a level similar to 
that evoked by PDBu (1 µM), whilst pervanadate and PDBu had an additive 
effect on [3H] PtdBut accumulation (Table 4.1). The Cat+ ionophore 
ionomycin which has been reported to release Cat+ from intracellular stores 
(Morgan and Jacob, 1994), markedly attenuated the PLD response elicited 
by pervanadate (Table 4.1). In order to determine whether PKC was 
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involved in the pervanadate- stimulated pathway of PLD activation (i.e. 
downstream of tyrosine kinase activation), we used the selective PKC 
inhibitor Ro 31 -8220 (Davis et al, 1992), which had no detectable effect on 
pervanadate- induced PLD activation (Table 4.1), in contrast to its potent 
inhibition of the corresponding response to LHRH (Chapter 3). 
4.4 DISCUSSION 
The present results strongly suggest the involvement of tyrosine 
kinases in the activation of PLD by LHRH, in addition to the previous 
evidence for an involvement of PKC in the same mechanism (Chapter 3). 
Lavendustin A was able to inhibit with high potency the majority of 
the LHRH- induced PLD response, leaving a residual PLD activity that was 
unaffected by further elevating the lavendustin A concentration. The portion 
of the LHRH- induced response insensitive to lavendustin A may represent 
a separate pathway of PLD activation. Lavendustin A had no effect on the 
PDBu- activated PLD activity, which raises the possibility that PDBu utilises 
the same pathway as the lavendustin A- insensitive portion of the LHRH 
response, or a totally separate pathway to that involving tyrosine 
phosphorylation. Both LHRH and PDBu responses were fully sensitive to 
PKC inhibitors (albeit with somewhat different potencies), which is 
consistent with the idea that the lavendustin A- sensitive, presumably PDBu- 
insensitive component of LHRH action may be mediated by a PDBu- 
insensitive PKC isoform, such as PKC . Alternatively, the incomplete 
inhibition of the LHRH -stimulated PLD activity by lavendustin A may be due 
to the slow initial binding of the inhibitor to its target (Hsu et al, 1991). 
Another tyrosine kinase inhibitor, piceatannol was able to completely 
inhibit the LHRH- evoked PLD activity, and was also able to inhibit the 
PDBu -stimulated activation of PLD at a slightly higher concentration. 
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However this concentration was very similar to that required for inhibition of 
Cat + -dependent PKC activity by piceatannol in aT3 -1 cells (M. Johnson; 
unpublished results), and may therefore represent the inhibition of PKC 
stimulated by piceatannol. Care should be taken in the interpretation of the 
piceatannol results, since piceatannol is reported to block the substrate 
binding site (Geahlen and McLaughlin, 1989), therefore the inhibition may 
be dependent on the substrate as well as the kinase. The tyrosine kinase 
inhibitor genistein displayed greater than 10 fold selectivity towards LHRH- 
stimulated PLD activity, compared to the PDBu- induced response, 
indicating that any inhibition of the PDBu -stimulated PLD activity was 
probably non -specific, possibly involving the inhibition of PKC or other 
Ser/Thr protein kinases. Another tyrosine kinase inhibitor MDC, did not 
cause any detectable inhibition of the LHRH- or PDBu -stimulated activation 
of PLD. It has been reported that this compound is poorly able to enter 
cells, due to its polar nature, making it unsuitable for whole cell assays 
(Umezawa et al, 1990). However, these results do indicate that the 
conditions used in the PLD assay do not disrupt the integrity of the cells. 
These results with tyrosine kinase inhibitors on the LHRH- and 
PDBu -stimulated PLD activity are wholly consistent with the idea that the 
mechanism for the LHRH -stimulated activation of PLD involves a tyrosine 
kinase, and since piceatannol and genistein were able to completely inhibit 
the LHRH -stimulated PLD activity, it is likely that tyrosine phosphorylation is 
an obligate requirement for PLD activation by LHRH in this system. 
The PDBu- evoked PLD activity was only inhibited at higher doses of 
some of the tyrosine kinase inhibitors, indicating the probable lack of 
involvement of tyrosine kinases using this mechanism. This information 
further reinforces the evidence from studies with PKC inhibitors (Chapter 3) 
that LHRH and PDBu stimulate PLD activation using independent 
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mechanisms in aT3 -1 cells, as has been proposed in previous studies for 
the activation of PLD by G protein -coupled receptors (Uings et al, 1992; 
Wilkes et al, 1993). However, we have observed that PDBu is able to elicit 
tyrosine phosphorylation in aT3 -1 cells through an unidentified mechanism 
(see Chapter 5). 
In the present study, pervanadate (1 mM) caused a marked 
stimulation of PLD activity, further supporting the evidence that tyrosine 
phosphorylation participates in the pathway of activation of PLD by LHRH. 
The pervanadate- stimulated activation of PLD was unaffected by the PKC 
inhibitor Ro 31 -8220, indicating that the tyrosine kinase in the LHRH- 
stimulated PLD activation pathway, which has its effect enhanced by 
pervanadate, is downstream of PKC, since Ro 31 -8220 has no effect on this 
activity. The additive effect on [3H]PtdBut accumulation of co- stimulation 
with pervanadate and PDBu points towards these two stimuli leading to the 
activation of PLD through two separate pathways, although the level of PLD 
activation with pervanadate and PDBu co- stimulation was not as high as 
the LHRH -stimulated PLD activity. If PDBu were activating the PKC 
upstream of the tyrosine kinase involved in the LHRH -stimulated activation 
of PLD, it would be expected that the PDBu -stimulated PLD activity would 
be attenuated by protein- tyrosine kinase inhibitors with the same potency 
as for the LHRH -stimulated response. The results presented in this Chapter 
demonstrate that this is clearly not the case, lending further support to the 
theory that the PKC involved in the LHRH -stimulated activation of PLD is a 
species not activated by phorbol esters, such as PKC . 
lonomycin markedly reduced the PLD activation elicited by 
pervanadate, as indeed it prevented the LHRH agonist- induced tyrosine 
phosphorylation of aT3 -1 cellular proteins (Chapter 5). This is consistent 
with the theory that Cat+ is capable of inducing activation of tyrosine 
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phosphatases, possibly similar to PTP 1B which is a widespread tyrosine 
phosphatase that is activated through the cleavage of its membrane 
localisation domain by the Cat + -activated protease calpain (Frangioni et al, 
1993). Another phosphatase which has been shown to have some protein - 
tyrosine phosphatase activity, calcineurin, can be activated by the Cat+ 
binding protein, calmodulin (Pallen and Wang, 1985). It is unlikely that 
these effects of ionomycin are the result of any cytotoxic effects, since 
ionomycin was unable to significantly effect the PDBu -stimulated activation 
of PLD in aT3 -1 cells (Chapter 3). The effects of Cat+ on tyrosine 
phosphorylation may depend on cell type since an increase in intracellular 
Cat+ has been reported to increase tyrosine kinase activity in angiotensin -Il 
stimulated GN4 liver epithelial cells (Huckle et al, 1992). In Swiss 3T3 
cells, depletion of intracellular Cat+ did not affect lysophosphatidic acid 
(LPA)- induced tyrosine phosphorylation (Seufferlein and Rozengurt, 1994). 
In contrast, PKC rather than Cat+ appears to be a necessary (though not 
solely sufficient) intermediary in endothelin- stimulated tyrosine 
phosphorylation and mitogenesis in kidney glomerular mesangial cells 
(Simonson and Hermar, 1993). Interestingly, elevation of Cat+ levels in 
epidermal keratinocytes leads to activation of the non -receptor tyrosine 
kinase c -src, through a mechanism involving tyrosine dephosphorylation 
(consistent with Cat + -activation of a tyrosine phosphatase) but leads 
concomitantly to the inactivation of the related c -yes tyrosine kinase activity 
(Zhao et al, 1992). 
It was not within the scope of this study to evaluate whether tyrosine 
kinases directly phosphorylate PLD in response to LHRH stimulation, since 
PLD has not been isolated, and there are no specific antibodies which are 
able to recognise PLD. However, one way this might be done would be to 
immunoprecipitate cellular proteins from aT3 -1 cells, pre -stimulated with 
78 
LHRH, with an anti -phosphotyrosine antibody and assay the 
immunoprecipitated proteins for PLD activity. This experiment might 
determine whether PLD is directly tyrosine phosphorylated in response to 
LHRH. It would not however determine which tyrosine kinase was involved 
and it is possible that any immunoprecipitated PLD would not be tyrosine 
phosphorylated itself, but bound to tyrosine phosphorylated regulatory 
proteins. 
It has been shown in platelets, which contain particularly high levels 
of c -src, that agonists directly or indirectly activating PKC, such as the 
phorbol ester, phorbol 12- myristate 13- acetate (PMA), vasopressin and the 
Cat+ ionophore A23187 increased the activity of the non -receptor tyrosine 
kinases c -src and c -fyn. Stimulation of platelets by the above pathways 
causes the phosphorylation of Ser -12 on c -src, which is a potential 
phosphorylation site for PKC, and consequently increases the substrate 
affinity of c -src by two to three fold (Liebenhoff et al, 1993). Similarly 
another member of the src family of tyrosine kinases fgr, has been shown 
to be activated in response to fMLP -stimulation in neutrophils (Gutkind and 
Robbins, 1989), and c -src can also be activated as a result of endothelin -1 
receptor activation in mesangial cells (Simonson and Hermar, 1993). 
Phospholipase D activity has been shown to be elevated in BALB /c 3T3 
cells transformed by v -src, although this activation was shown to 
independent of PKC (Song and Foster, 1993). As src -type kinases have 
been shown to be activated through G protein -coupled receptors in 
previous studies, and also to bring about PLD activation, a member of the 
src family of non -receptor tyrosine kinases is currently the most likely 
candidate for the tyrosine kinase participating in LHRH receptor signalling. 
Low molecular weight G proteins such as Ras, Rho and ARF have 
been shown to be regulated by another group of proteins which change the 
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G proteins between an active, GTP -bound state and an inactive GDP - 
bound state (Barbacid, 1987). Agonists which stimulate G protein -coupled 
receptors, such as thrombin and LPA have been shown to lead to the 
activation of Ras through a process that involves a pertussis toxin -sensitive 
heterotrimeric G- protein, and which can also be blocked by the tyrosine 
kinase inhibitor, genistein (Van Corven et al, 1993). It has also been 
reported that proteins which stimulate the intrinsic GTPase activity of Ras by 
up to 100 -fold, Ras GTPase activating proteins (Ras -GAP), can act as a 
substrate for v -src (Park and Jove, 1993). Another protein involved in the 
regulation of Ras -type low molecular weight G- proteins is Vav, a guanosine 
nucleotide releasing factor, which mediates the exchange of GDP for GTP, 
thus activating Ras -type G- proteins (Downard, 1992). It has been shown 
that Vav shows increased activity when tyrosine phosphorylated, and is 
also a substrate for the src -type non -receptor tyrosine kinase p56 Ick 
(Gulbins et al, 1993). A non -receptor tyrosine kinase has also been shown 
to inhibit the GTPase activity of another low molecular weight G- protein, 
p21 cdc 42, which is related to Rho (Manser et al, 1993). It therefore 
appears that the activity of low molecular weight G proteins can be both 
positively and negatively controlled by the action of non -receptor tyrosine 
kinases. Both Ras -GAP and Vav have SH2 and SH3 domains, which 
mediate protein -protein interactions (Vogel et al, 1988; Bustelo et al, 1992; 
Songyang et al, 1993; Ren et al, 1993). It is interesting that GTP- exchange 
on low molecular weight G proteins can be regulated by non -receptor 
tyrosine kinases, since low molecular weight G proteins have also been 
implicated in the regulation of PLD in several systems (Cockroft et al, 1994; 
Brown et al, 1993; Bowman et al, 1993). It has also been demonstrated 
here that an inhibitor of ARF guanine nucleotide exchange factor, brefeldin 
A is able to inhibit the LHRH -stimulated activation of PLD in aT3 -1 cells 
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(Chapter 3). The exact mechanism whereby tyrosine kinases regulate PLD 
is not clear at present, however, in the case of LHRH- stimulated PLD, it is 
possible that a non -receptor tyrosine kinase modulates the activity of a low 
molecular weight G protein, which in turn activates PLD. 
It is difficult to conclude exactly how non -receptor tyrosine kinases fit 
into the PLD activation pathway stimulated by LHRH, although there is a 
clear case for their involvement. It can be ascertained from the results 
presented in this Chapter that there is no pervanadate- enhanced tyrosine 
kinase activity upstream of PKC involved in the activation of PLD. A 
possible explanation of the results is that a non -receptor tyrosine kinase is 
involved downstream of PKC. This may be similar to a proposed 
mechanism in thrombin -stimulated human platelets, whereby PKC 
phosphorylation of src has been proposed to increase the substrate affinity 
of src (Liebenhoff et al, 1993). Another possibility is that the tyrosine kinase 
involvement in LHRH -stimulated PLD activation is independent of PKC, and 
that both the tyrosine kinase pathway and PKC are needed in order to fully 
activate PLD. The fact that PKC inhibitors and the tyrosine kinase 
inhibitors, genistein and piceatannol totally inhibit LHRH -stimulated PLD 
activation is consistent with the idea that both tyrosine kinases and PKC are 
involved in the same pathway, and that the non -receptor tyrosine kinase is 
downstream of PKC. 
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Table 4.1 
Modulators of tyrosine phosphorylation, PKC and Cat+ 
mobilisation on PLD activity in aT3 -1 cells 
Effect of various compounds on PLD activity in aT3 -1 cells. Time course of 
the assay was 30 min in each case. Values are expressed as a % of the 
LHRH (100 nM)- stimulated PLD activity, with the basal level of [3H]PtdBut 




Induced Response dpm x 103 (mean % of 
response to LHRH in 
parentheses) 
LHRH (100 nM) 61 ±5.5(100 ±9) 
Pervanadate (1 mM) 13.4 ± 2.4 (22 ± 4) 
4f3-PDBu (1 jiM) 33 ± 2.4 (54 ± 4) 
Ionomycin (30 uM) 0.6 ± 1.2 (1 ± 2) 
Pervanadate (1 mM) + ionomycin (30 uM) 4.3 ± 1.8 (7 ± 3) 
Pervanadate (1 mM) + 4ß-PDBu (1 uM) 47.6 ± 4.2 (78 ± 7) 
Pervanadate (1 mM) + Ro 31-8220 (1 uM) 12.8 ±2.4 (21 ±4) 
Figure 4.1 
Concentration response curve for the inhibition of LHRH- and 
PDBu -stimulated PLD activity by lavendustin A in aT3 -1 cells 
The effect of the tyrosine kinase inhibitor lavendustin A on stimulus - 
induced PLD activation. Concentration -dependent inhibition of responses 
to LHRH (100 nM)and PDBu (1 pM). Stimulation was for 30 min, and 
values are means ± SEM from 4 -8 separate determinations. Values for 
LHRH -stimulated PLD activity are significantly different form the LHRH- 
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Figure 4.2 
Concentration response curve for the inhibition of LHRH- and 
PDBu -stimulated PLD activity by genistein in I3 -1 cells 
The effect of the tyrosine kinase inhibitor genistein on stimulus- induced 
PLD activation. Concentration -dependent inhibition of responses to LHRH 
(100 nM)and PDBu (1 µM). Stimulation was for 30 min, and values are 
means ± SEM from 4 -8 separate determinations. Values above 300 
genistein for the LHRH- stimulated PLD activity and 3000 genistein for the 
PDBu -stimulated PLD activity are significantly different from the stimulus - 
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CHAPTER 5 
THE INVOLVEMENT OF TYROSINE 




There is considerable evidence that stimulation of cells with 
compounds through G protein -coupled receptors linked to 
phosphoinositide hydrolysis, such as bombesin, vasopressin, endothelin, 
lysophosphatidic acid, bradykinin and thrombin (as is also the case with 
LHRH), can lead to the tyrosine phosphorylation of cellular proteins through 
the activation of non -receptor tyrosine kinases (Zachary et al, 1992; 
Seufferlein and Rozengurt, 1994; Offermanns et al, 1993; Hordijk et al, 
1994; Lundberg and Song, 1991; Force et al, 1991). Receptor -stimulated 
tyrosine phosphorylation is more commonly associated with receptor 
tyrosine kinases, such as growth factor receptors, which have intrinsic 
tyrosine kinase activity in their cytoplasmic domains, although activation of 
receptor tyrosine kinases has also been shown to activate src -type non - 
receptor tyrosine kinases (Kypta et al, 1990). Tyrosine phosphorylation has 
also been reported upon activation of T -cell receptors, which also have no 
intrinsic protein- tyrosine kinase activity (Wang et al, 1994). Members of the 
src- family of non -receptor tyrosine kinases are reported to be activated 
following association with T -cell receptors, and this tyrosine kinase 
activation can in turn result in the activation of PLC -y (reviewed in Mustelin 
and Burn, 1993). However, no such direct interaction between non - 
receptor tyrosine kinases and G- protein coupled receptors has been 
reported. 
The level of tyrosine phosphorylation within cells can be regulated 
by the activity of protein tyrosine phosphatases, as well as tyrosine kinases, 
and these can be roughly divided into two families, receptor tyrosine 
phosphatases and non -receptor tyrosine phosphatases. Non -receptor 
tyrosine phosphatases represent a diverse group of enzymes, which are 
potentially regulated by intracellular signalling mechanisms. For example, 
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it has recently been demonstrated that a ubiquitously expressed tyrosine 
phosphatase, PTP -PEST, can be inactivated as a result of phosphorylation 
by cAMP- dependent protein kinase and PKC (Garton and Tonks, 1994). 
Another abundant non -receptor tyrosine phosphatase, PTP -1 B, is normally 
localised to the cytoplasmic face of the endoplasmic reticulum by a C- 
terminal targeting sequence. It has been found that the Cat + -activated 
phosphatase, calpain, is able to cleave the C- terminal membrane targeting 
sequence of PTP -1 B, resulting in a 2 -fold increase in the activity of PTP -1 B 
and resulting in its subcellular relocation, probably bringing it into close 
proximity with its substrates (Frangioni et al, 1993). Another Ser/Thr and 
tyrosine phosphatase, calcineurin (PP2B), can be activated in a Cat+ 
dependent manner after its association with calmodulin, a major 
intracellular receptor for Cat+ ions (Pallen and Wang, 1985). It is possible 
that there may be important messenger activated tyrosine phosphatases as 
well as tyrosine kinases in aT3 -1 cells, which play a role in regulating the 
level of tyrosine phosphorylation. 
It has been demonstrated that agonists which activate PKC, either 
directly or indirectly in platelets can increase the substrate affinity of the 
c -src non -receptor tyrosine kinase (Liebenhoff et al, 1993). Stimulation of G 
protein -linked systems with the non -hydrolysable analogue of GTP, GTPyS, 
has also been reported to stimulate tyrosine phosphorylation (Nasmith et al, 
1989). Similarly another member of the src family of tyrosine kinases, fgr, 
has been shown to be activated in response to fMLP -stimulation in 
neutrophils (Gutkind and Robbins, 1989). There is also evidence that c -src 
can be activated as a result of endothelin -1 receptor activation in mesangial 
cells (Simonson and Hermar, 1993), and by LPA receptor stimulation in NIE 
115 neuroblastoma cells (Jalink et al, 1989). It has recently been reported 
that one of the potential substrates of c -src and to a lesser extent fyn in vitro, 
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is the activated form of the Cat + -independent PKC 8 from porcine spleen. 
This tyrosine phosphorylation increased the specificity of PKC 8 for certain 
substrates (Gschwendt et al, 1994). 
Bombesin, vasopressin and endothelin have been shown to 
stimulate the rapid tyrosine phosphorylation of the tyrosine kinase p125 
focal adhesion kinase (FAK) in Swiss 3T3 cells (Zachary et al, 1991). All of 
these neuropeptides have receptors that signal via heterotrimeric G 
proteins, and have seven hydrophobic transmembrane domains. It has 
been demonstrated that neuropeptide receptor stimulation often results in 
the rapid tyrosine phosphorylation of a group of proteins of 110 -130 kDa, as 
well as minor components of 90 and 70 -80 kDa (Zachary et al, 1991). 
Following neuropeptide receptor stimulation, there has also been shown to 
be phosphorylation of a src transformation -associated substrate, p130, 
possibly FAK, or other target proteins of a similar molecular weight 
(Schaller et al, 1992). There is also strong evidence that v -src is able to 
phosphorylate p125 FAK (Schaller et al, 1992), and that a stable 
association can be formed between p125 FAK and two src -type tyrosine 
kinases, src and fyn (Cobb et al, 1994). This raises the possibility that 
cellular src -type tyrosine kinases are also involved in the regulation of p125 
FAK in other signalling systems activated by G protein -coupled receptors. It 
has been reported that FAK may be an important early step in intracellular 
signalling pathways, triggered in response to cell interactions with the 
extracellular matrix (Hanks et al, 1992). Focal adhesion kinase has also 
been reported to phosphorylate components of the cytoskeleton in 
response to integrin activation (Schaller et al, 1992). 
In studying non -receptor tyrosine kinases associated with the LHRH 
signalling pathway we have concentrated on the src -type tyrosine kinases, 
since these were the most highly characterised at the time of starting the 
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study, and have also been implicated in the activation of PLD (see chapter 
4). We have used variety of immunoblot and immunoprecipitation 
techniques in order to investigate the LHRH- and PKC- induced tyrosine 
phosphorylation of cellular proteins in the aT3 -1 cell line. 
5.2 METHODS 
5.2.1 SDS- polyacrylamide gel electrophoresis and 
immunoblotting with Phast system 
Confluent cultures of T3 -1 cells were incubated with the LHRH 
receptor agonist buserelin (100 nM; [D- Ser(tBu)6, DesGIy10] LHRH 
ethylamide), 300 nM PDBu, 30 µM ionomycin or saline (control). Reactions 
were terminated after 20 min by scraping cells into a buffer containing 20% 
(w /v) sodium dodecyl sulphate and 5% (v /v) 2- mercaptoethanol, then 
heating to 100 °C for 5 min. Cellular proteins were separated on 7.5% 
homogeneous microgels which were run on a PhastSystem 
electrophoresis apparatus (Pharmacia, Milton Keynes, UK), then 
electroblotted onto Immobilon -P polyvinylidene membranes (Millipore). For 
the antiphosphotyrosine blots the Immobilon was then probed with the 
4G10 mouse monoclonal antibody (UBI), which recognises 
phosphotyrosine, or with the 4G10 antibody blocked with o- phospho -L- 
tyrosine (1 mM) (Sigma). A horseradish peroxidase (HRP)- labelled 
secondary antibody (Scottish Antibody Production Unit) was used to bind to 
the primary 4G10 antibody. Enhanced chemiluminescence (ECL; 
Amersham, UK) was employed to visualise antibody binding; this method 
uses the principal of the conversion of a non -luminescent chemical to a 
highly luminescent one by horseradish peroxidase bound to the secondary 
antibody. This chemiluminescence can then be detected on photographic 
film. 
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For the immunodetection of fyn, the Immobilon was probed with the 
FYN3 rabbit polyclonal antibody (Santa Cruz), or with antibody blocked 
with the peptide used to generate the antibody. A secondary HRP- linked 
anti -rabbit antibody was then used to bind to the primary antibody; antibody 
binding was then visualised by ECL- detection. For immunodetection of src, 
the Immobilon was probed with a mouse monoclonal antibody (GD 11) 
(UBI). A secondary HRP- linked anti -mouse antibody was then used to bind 
to the primary antibody; antibody binding was visualised with the ECL- 
detection system. 
5.2.2 Tyrosine kinase immunoprecipitation and kinase 
assay 
aT3 -1 cells were grown to confluency in tissue culture dishes (10 cm 
diameter), and were then quiesced using serum -free medium for 
approximately 24 hrs prior to the assay. The cells were then stimulated with 
LHRH (100 nM) for 10 min, while control cells were left unstimulated. After 
this stimulation the cells were scraped in 1.8 ml ice -cold phosphate 
buffered saline (PBS), plus protease inhibitors (aprotinin (50 µg /ml), 
leupeptin (200 µg /ml and PMSF (2 mM)) and orthovanadate (100 µM). The 
cell debris was pelleted by centrifugation and resuspended in 1 ml NP -40 
lysis buffer (see below). This was then left to stand on ice for 20 min. 
Non -solubilised debris was then pelleted by spinning at 14000 g in a 
benchtop centrifuge for 15 min at 4 °C, the pellet was then discarded. The 
supernatant was incubated, with mixing, with protein A- sepharose (100 pl) 
at 4 °C for 2 hrs in order to clear the supernatant of any proteins non- 
specifically binding to protein A- sepharose. The protein A- sepharose was 
then pelleted for 15 min at 4 °C. The pellet was then discarded and the 
supernatant transferred to a fresh tube. Antibody (FYN3; 10 pg /ml) and 
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protein A- sepharose were then added to the supernatant and incubated for 
2 hrs at 4 °C. At the end of this incubation the protein A- sepharose- 
antibody- protein complex was pelleted (4 °C), and the supernatant 
discarded. The pellet was then washed three times in NP 40 lysis buffer 
plus inhibitors, then once with Tris -HCI (50 mM) pH 7.2, NaCI (150 mM). 
NP -40 Lysis Buffer: 5 mM Tris-HCI pH 8.0 
150 mM NaCI 
1% NP-40 
Na3VO4 (200 µM) 
leupeptin (200 µg/ml) 
aprotinin (50 µg/ml) 
PMSF (2 mM) 
Inhibitors were added fresh daily from stock solutions. PMSF was added 
immediately prior to assay, as it is extremely unstable. 
Kinase assay 
The tyrosine kinase substrate used in the assay of tyrosine kinase activity 
was acid -denatured enolase (200 p.g /ml) (Cooper, 1984). 
Reaction Buffer: HEPES pH 7.5 (20 mM) 
MgCl2 (10 mM) 
MnCl2 (10 mM) 
Na3VO4 (100 µM) 
Leupeptin (200 µg /ml) 
Aprotinin (50 µg /ml) 
The immunoprecipitate was resuspended in 100 p.I reaction buffer. 
Reaction was started by the addition of 20 pi ATP solution (511M ATP + 
[y33P] ATP (5jCi)) to the reaction buffer and immunoprecipitate. The time 
course of the kinase assay was 5 min (37°C), and was terminated by the 
addition of ice cold Tris -HCI pH 7.5 (50 mM), NaCI (150 mM). This was 
then centrifuged for 15 min (4 °C) in order to pellet the protein A- 
sepharose. The supernatant containing the enolase was then boiled in 
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SDS -PAGE sample buffer and the samples run on 7.5% homogenous 
polyacrylamide gels, with enolase running as a broad band at 
approximately 50 kDa. The phosphorylation of the enolase substrate was 
assessed by the use of a phosphorimager. 
5.2.3 Resolution of products from the 
immunoprecipitation -kinase assay by SDS - 
polyacrylamide gel electrophoresis 
Polyacrylamide gels (7.5 %) were prepared in a BioRad gel former 
(20 cm x 20 cm x 1.5 mm) according to manufacturers instructions and 
allowed to set for 45 -60 min with a layer of iso -butyl alcohol on top to level 
the surface and exclude air. The top of the gel was then extensively 
washed and the inner surface of the glass plates dried with filter paper. The 
stacking gel was prepared according to the manufacturers instructions and 
poured on top of the separating gel. Well formers were carefully placed in 
top of the stacking gel, being careful to exclude air bubbles. The gel was 
then allowed to set for 35 -45 min. Well formers were carefully removed and 
the wells carefully rinsed out with distilled water. Gels were then clipped 
into a BioRad gel tank and the upper and lower reservoirs filled with tank 
buffer. 
Previously prepared protein samples were then thawed out and 
warmed up in order to aid pippeting. 150 pl of protein sample was added to 
each well, an equal volume of lx SDS sample buffer was added to marker 
lanes which had concentrated radiolabeled protein standards (Rainbow 
markers, Amersham). A voltage was then applied and the gels run to the 
bottom (2 hrs at 25 mA for the stacking gel, then 3 hrs at 40 mA for the 
running gel). 
Tank buffer: 25 mM Tris base, pH 6.8 
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192 mM glycine 
0.1% SDS 
5.3 RESULTS 
5.3.1 Anti -phosphotyrosine immunoblotting 
In order to determine whether protein- tyrosine phosphorylation 
occurs in aT3 -1 cells in response to LHRH stimulation (100 nM), cellular 
proteins were separated using SDS -PAGE on a 7.5% homogeneous 
polyacrylamide gel (section 5.2.1) with an antibody which recognised 
phosphotyrosine (4G -10). The LHRH- receptor agonist, buserelin was 
observed to induce tyrosine phosphorylation on many proteins of molecular 
mass -60 to >170 kDa, but especially notable was a broad band at around 
128 kDa and a diffuse band at around 76 kDa (Figure 5.1). A time course of 
tyrosine phosphorylation in response to buserelin and PDBu was assessed 
(Figure 5.2), with time points at 3, 10, and 60 min in order to determine at 
what point the tyrosine phosphorylation of cellular proteins was maximal. It 
would appear that the protein- tyrosine phosphorylation induced by the 
LHRH receptor agonist buserelin was maximal by the 10 min minute time 
point, and did not appear to have reduced by 60 min (Figure 5.2). By 
varying exposure conditions during development of the immunoblot 
reaction, it could be seen that each of these bands consisted of a minimum 
of two proteins (Figure 5.1). Similar phosphorylations of protein- tyrosine 
were also evoked with the activator of PKC, PDBu (1 µM) (Figure 5.1). The 
Cat +- ionophore, ionomycin(30 µM), reduced the level of tyrosine 
phosphorylation in all the target proteins below that observed in 
unstimulated aT3 -1 cells. 
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5.3.2 Immunodetection of src- family tyrosine kinases 
It is apparent that the tyrosine kinase or kinases activated by LHRH 
receptor stimulation are non -receptor tyrosine kinases, since the LHRH 
receptor has no intrinsic tyrosine kinase activity (Tsutsumi et al, 1992). 
Although other families of non -receptor tyrosine kinases exist, what little 
evidence is available suggests that src- family tyrosine kinases may well be 
activated downstream of G protein -coupled receptors (Liebenhoff et al, 
1993). Therefore we have concentrated here on the src family of tyrosine 
kinases. 
Cellular proteins were separated by SDS -PAGE on 7.5% 
homogenous polyacrylamide gels and blotted onto lmmobilon-P 
membranes (Millipore) for immunodetection. In aT3 -1 cells, two of the src 
family of non -receptor tyrosine kinases were detectable with the antibodies 
used. Using the mouse monoclonal antibody to src (GD 11), and an HRP- 
linked secondary anti -mouse antibody, a single band was detected at 
approximately 60 kDa, using the ECL detection system (Amersham) (Figure 
5.3). The rabbit affinity -purified polyclonal antibody FYN3 (Santa Cruz), 
with a secondary HRP -liked anti -rabbit antibody and using the ECL 
detection system, detected fyn as single specific band at approximately 60 
kDa, non -specific antibody binding was detected by blocking the FYN3 
antibody with the peptide used to generate the antibody prior incubating 
with the Immobilon membrane (figure 5.3). Other members of the src family 
of non -receptor tyrosine kinases; lyn, yes, hck, and fgr were not detectable 
in aT3 -1 cells using the technique described in the methods section, 
although src, fyn, lyn, yes, hck and fgr were detectable by the same 
technique, using the same antibodies in human neutrophils (results not 
shown). This provides a positive control with which to compare the 
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negative results in the aT3 -1 cells. All of the above polyclonal antibodies to 
the src-type kinases, except the src antibody, GD 11, which is a monoclonal 
antibody, were raised against peptides corresponding to the N- terminal 
region of the protein, which has been reported to be highly variable 
between different members of the src -type tyrosine kinase family (Cooper 
and Howell, 1993). It was reported in the product literature for the above 
antibodies that there is no detectable cross -reactivity with other members of 
the src family of tyrosine kinases. 
5.3.3 Fyn immunoprecipitation 
Confluent 10 cm diameter dishes of aT3 -1 cells were stimulated for 
10 min with LHRH (100 nM) in order to attempt to bring about activation of 
p59 fyn. An immunoprecipitation was then carried out as described in 
section 5.2.2, using the FYN 3 antibody (10 µg /ml) in order to recover p59 
fyn in a state where its activity could be assessed in a partially- purified 
state, free of other tyrosine kinases which may have a high constitutive level 
of activity, or which may also be activated by LHRH. Stimulation of aT3 -1 
cells for 10 min with LHRH (100 nM) resulted in approximately a 50% 
increase in [33P] incorporation into an acid -denatured enolase substrate 
(Figure 5.4). It has been demonstrated that enolase can be phosphorylated 
on a single tyrosine and is an effective substrate for pp60 v -src; the extent of 
enolase phosphorylation by tyrosine kinases in vitro can be increased by a 
brief prior exposure of the substrate to pH 4 (Cooper et al, 1984). 
5.4 DISCUSSION 
Since many of the tyrosine phosphorylations induced here by LHRH 
could also be elicited by PDBu (Figure 5.1), it is possible (if there is only 
one tyrosine kinase step involved) that LHRH and PDBu are both able to 
activate this component of the signalling mechanism. The protein- tyrosine 
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phosphorylations induced in aT3 -1 cells by the LHRH- receptor agonist, 
buserelin, appear remarkably similar to those induced by lysophosphatidic 
acid (LPA), bombesin and endothelin in Swiss 3T3 cells and in Rat -1 
fibroblasts, with proteins of 70 -80 kDa and 110 -130 kDa being the main 
phosphorylation targets (Seufferlein and Rozengurt, 1994). In each of the 
above cases, as well as in the present study, the administration of a phorbol 
ester appears to induce protein- tyrosine phosphorylations similar to those 
observed with the receptor ligands, indicating that PKC may be an 
important regulator of intracellular tyrosine phosphorylation. It is not known 
if any if the proteins phosphorylated in response to LHRH are the tyrosine 
kinase p125 FAK. In Swiss 3T3 cells, stimulation of FAK activity can be 
induced by direct activation of PKC with PDBu (Sinnett -Smith et al, 1993). 
However, evidence has been put forward that bombesin stimulation leads 
to the activation of FAK through a PKC- independent pathway, and that the 
integrity of the cytoskeleton is essential for both the PKC- dependent and 
independent activation of FAK (Sinnett -Smith et al, 1993). It is therefore 
possible that in the present study, the similar tyrosine phosphorylation 
induced by PDBu and LHRH could involve different signalling pathways. 
Indeed, it has recently been demonstrated that the PDBu -stimulated 
tyrosine phosphorylation of proteins in aT3 -1 cells is almost completely 
blocked by the protein kinase C inhibitor GF 109203X (3 pM), while LHRH- 
stimulated tyrosine phosphorylation is only partially blocked by GF 
109203X (3 mM) (Johnson et al, 1994). This suggests that the PDBu- 
stimulated tyrosine phosphorylation in aT3 -1 cells is dependent upon PKC, 
while the LHRH -stimulated tyrosine phosphorylation is only partially 
dependent upon PKC. 
Only two of the src family of non -receptor tyrosine kinases were 
detectable using immunoblotting techniques in aT3 -1 cells. We were also 
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able to confirm that lyn, yes, hck, and fgr were not detectable with the 
antibodies used, although the sensitivity of the technique does not exclude 
their presence at very low levels. All of the above src -type kinases were 
detectable using these antibodies in human neutrophils, which were used 
as a positive control. It has been reported that there are central nervous 
system (CNS) and peripheral forms of c -src, and that the CNS form of c -src 
has an increased kinase activity, and contains six additional amino acids in 
its regulatory domain, generated by alternative splicing (Brugge et al, 
1985). While both forms of c -src are expressed in the CNS, only the 
unmodified form of c -src can be detected in peripheral tissues (Brugge et al, 
1985). It has also been reported that there are two different forms of fyn 
mRNA that arise from the mutually exclusive splicing of alternative seventh 
exons; one of these products is found at high levels in the brain (Cooke et 
al, 1991), the other form is preferentially expressed in T lymphocytes 
(Cooke and Purlmutter, 1989). The presence of src and fyn together in the 
same cell has also been noted in platelets, in which the level of fyn is 
approximately 5 -10 fold lower than that of src (Liebenhoff et al, 1993). This 
does not necessarily imply that fyn only plays a minor role in tyrosine 
phosphorylation events. Indeed, it has been demonstrated that both src 
and fyn are potentially phosphorylated by PKC in response to thrombin 
stimulation, leading to an increase in substrate affinity (Liebenhoff et al, 
1993). This step could also be crucial to the mechanism whereby LHRH- 
and PDBu -stimulated PKC activity in aT3 -1 cells increases the level of 
tyrosine phosphorylation of cellular proteins. It is also possible that src -type 
tyrosine kinases may then activate FAK, or other related tyrosine kinases. 
When fyn was partially purified from aT3 -1 cells by 
immunoprecipitation, using the FYN3 polyclonal antibody (section 5.3.3), it 
was found that prior stimulation of the cells with LHRH for 10 min increased 
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the ability of such immunoprecipitates to bring about phosphorylation of a 
denatured enolase substrate by approximately 50 %. This indicates that this 
non -receptor tyrosine kinase may be responsible for some of the tyrosine 
phosphorylation resulting from LHRH- receptor stimulation. It was not 
possible to assess whether src was similarly stimulated in response to 
LHRH, although it is conceivable that src will also be activated by LHRH, 
although redundancy of function between src and fyn has not been 
ascertained in this system. However it has been demonstrated that long 
term potentiation (LTP) is impaired in fyn mutant mice, while src, yes or abl 
mutants show no impairment in LTP (Grant et al, 1992). It is not possible to 
conclude from the increased phosphorylation of enolase by 
immunoprecipitated fyn whether LHRH -stimulation results in an increase in 
kinase activity or in an increase in substrate affinity. 
A potential target for non -receptor tyrosine kinases such as src or 
FAK are regulatory proteins associated with low molecular weight G 
proteins, which have been shown to activate another important signalling 
enzyme investigated in this study, PLD (discussed in Chapter 3). For 
example, in B cells, activation of the B cell receptor, possessing no intrinsic 
tyrosine kinase activity, has been shown to stimulate the activity of src -type 
kinases. These kinases have also been shown to phosphorylate the Grb2 
adapter protein, which can then interact with Sos, the guanine nucleotide 
exchange factor for the low molecular weight G protein Ras (Smit et al, 
1994). It has also been reported that Vav, a protein with homology to 
guanine nucleotide releasing factors that activate Ras is phosphorylated by 
p56 lck, a src -type non -receptor tyrosine kinase, activated by the T cell 
receptor. This is reported to inhibit the activity of Vav and thus maintain the 
low molecular G- protein in an active state (Gulbins et al, 1993). A non - 
receptor tyrosine kinase has also been shown to inhibit the GTPase activity 
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of another low molecular weight G protein, p21 cdc 42, related to Rho 
(Manser et al, 1993). 
In platelets (which contain particularly high levels of c -src), agonists that 
directly or indirectly activate PKC such as the phorbol ester PMA, vasopressin 
and the Cat+ ionophore A23187 have been shown to bring about an increase 
in the activity of the non -receptor tyrosine kinases c -src and c -fyn. Stimulation 
of platelets by the above pathways can lead to the phosphorylation of Ser -12 
on c -src, which is thought to be responsible for an increase in the substrate 
affinity of c -src by two to three fold (Liebenhoff et al, 1993). It is therefore 
conceivable that src -type non -receptor tyrosine kinases are activated by the 
same pathway in aT3 -1 cells stimulated with LHRH. This would also explain 
how PDBu is capable of stimulating tyrosine phosphorylation in a similar 
fashion to the receptor stimulation. 
A feature of src -type non -receptor tyrosine kinases is that they have 
SH2 and SH3 domains which allow them to interact with other proteins 
involved in the intracellular signalling mechanism. For example it has 
recently been demonstrated that both src and fyn are able to form a stable 
association with p125 FAK, through interaction of the SH2 domain on src 
and fyn with phosphotyrosine residues on FAK (Cobb et al, 1994). It has 
also been demonstrated that the SH3 domain of fyn can mediate binding to 
phosphatidylinositol 3- kinase in T cells, which is thought to play an 
important role in T cell signalling (Prasad et al, 1993). It is known that SH3 
domains are able to bind to the proline -rich sequence motif X- P- X- X- P -P -P- 
Z-X-P, where X represents any amino acid, and Z represents a hydrophobic 
amino acid (Ren et al, 1993). It has also been suggested that SH3 domains 
may be important for localisation to the cytoskeleton, since SH3 containing 
proteins are often associated with the cytoskeleton (Musacchio et al, 1992). 
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As well as enzymes mediating protein- tyrosine phosphorylation, 
tyrosine dephosphorylation is also an important event in intracellular signal 
transduction pathways. It is apparent from the aT3 -1 cells treated with the 
Cat +- ionophore ionomycin, that an increase in intracellular Cat+ levels 
reduced the level of phosphotyrosine seen on intracellular proteins. It is 
likely that this has occurred through the activation of a Cat + -activated 
tyrosine phosphatase, such as PTP-1B, which can be activated by cleavage 
of its C- terminal membrane localisation domain by the Cat + -activated 
protease, calpain (Frangioni et al, 1993). Another possibility is the 
Cat + /calmodulin- dependent phosphatase, calcineurin, which has some 
tyrosine phosphatase activity (Pallen and Wang, 1985), or another related 
tyrosine phosphatase. It has also been demonstrated that in pancreatic 
acini, protein tyrosine dephosphorylation (probably mediated by PTP 1) is 
involved in the Cat + -dependent secretion of amylase, suggesting that Cat+ 
is responsible for activating a tyrosine phosphatase in this case as well 
(Jena et al, 1991). 
So in conclusion, both LHRH and PDBu appear to capable of 
inducing tyrosine phosphorylation in aT3 -1 cells, making it likely that the 
tyrosine kinase involved in LHRH -signalling is downstream of PKC. The 
major LHRH- and PDBu- induced tyrosine phosphorylations are seen on 
proteins of 70 -80 kDa and 110 -130 kDa. It is also apparent that raising the 
intracellular Cat+ concentration with ionomycin reduces the level of tyrosine 
phosphorylation in aT3 -1 cells, probably through the activation of an 
unidentified Cat + -stimulated tyrosine phosphatase. There were two 
members of the src- family of tyrosine kinases detectable by immunoblotting 
in T3 -1 cells; src and fyn. Using immunoprecipitation to partially purify fyn 
we found that LHRH- stimulation increased the phosphorylation by anti -fyn 
immunoprecipitates of an exogenous enolase substrate. 
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Figure 5.1 
Anti -phosphotyrosine immunoblots of buserelin, PDBu and 
ionomycin treated aT3 -1 cells 
Anti -phosphotyrosine immunoblots of aT3 -1 cells from 2 separate 
experiments, using the 4G10 anti -phosphotyrosine mouse monoclonal 
antibody. Lanes 1 and 8, control (saline); 3 and 6, the LHRH receptor 
agonist buserelin ([D- Ser(tBu)6, DesGly10] LHRH ethylamide; 100 nM); 
lane 2, PDBu (300 nM); lane 7, ionomycin (30 µM). Lanes 4 and 5 are 
buserelin- treated cells immunostained with phosphotyrosine -blocked 
antibody, in order to detect non -specific antibody binding. The incubation 
time of the cells in all conditions before solublisation was 20 min. 2.5 µg of 
protein was loaded per lane, determined by Bradford method (Pierce). 
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Figure 5.1 
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Time course of buserelin- stimulated tyrosine phosphorylation in 
aT3 -1 cells 
Time course of protein tyrosine phosphorylation induced by the LHRH 
receptor agonist buserelin ([D- Ser(tBu)6, DesGly10] LHRH ethylamide; 100 
nM) assessed by anti -phosphotyrosine immunoblotting, over two separate 
experiments, which compare the tyrosine phosphorylations induced at 3 












Immunoblot of the non -receptor tyrosine kinases src and fyn in 
aT3 -1 cells 
Immunoblot of protein samples from aT3 -1 cells. src was detected with the 
monoclonal mouse antibody GD 11 (UBI) (lanes 1 and 2). Fyn was 
detected with the FYN3 rabbit polyclonal antibody (Santa Cruz 
Biotechnology) (lanes 3 and 4). In order to detect non -specific binding 
associated with the FYN3 antibody, the antibody was blocked with the 
peptide used to produce the antibody before incubating with the blots (lane 
5). Antibody binding was visualised using a peroxidase -linked secondary 
antibody and chemiluminescence detection system (ECL; Amersham). 
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Figure 5.3 
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Figure 5.4 
Phosphorylation of an exogenous substrate by partially purified 
fyn 
Phosphorylation of an acid -denatured enolase substrate by the fyn non - 
receptor tyrosine kinase, immunoprecipitated using FYN3 polyclonal rabbit 
antibody (Santa Cruz). T3 -1 cells were either stimulated with LHRH (100 
nM) for 10 min prior to lysis, or they were left unstimulated (n = 1). 
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CHAPTER 6 
ACTIVATION OF PHOSPHOLIPASE D BY LHRH IN 
HOST CELLS EXPRESSING MUTANT AND WILD 
TYPE LHRH RECEPTORS 
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6.1 INTRODUCTION 
The main experimental model used in this study has been the 
activation of PLD in aT3 -1 cells stimulated with LHRH. Studies have also 
been carried out to determine whether the LHRH receptor will bring about 
the activation of PLD though the same pathway when transfected into COS 
7 and CHO cells. Using site -directed mutagenesis of the LHRH receptor a 
preliminary examination has been made of the importance of certain 
domains of the receptor protein in mediating PLD activation. 
It is becoming increasingly apparent that distinct cytoplasmic and 
transmembrane domains of G protein -coupled receptors have distinct 
cellular functions. For example, in the 132 adrenergic receptor, 
phosphorylation of serine and threonine residues in the C- terminal 
cytoplasmic tail by the ß adrenergic receptor kinase results in receptor 
desensitisation (Hausdorff et al, 1991). It has also been demonstrated that 
ionic interactions between residues of different transmembrane domains on 
G protein -coupled receptors are critical for their structure and function 
(Cohen et al, 1992; Khorana, 1992). The intracellular cytoplasmic loops of 
G- protein coupled receptors are also important for their function, as has 
been demonstrated with G protein interactions with the 3rd intracellular 
loop (Cheung et al, 1992). A characteristic shared by most G protein - 
coupled receptors is that continued stimulation results in their activity 
becoming rapidly attenuated, referred to as receptor desensitisation 
(reviewed in Wilson and Applebury, 1993). Receptor desensitisation has 
been shown to be dependent on the actions of receptor kinases, 
homologous to the [3-adrenergic receptor kinase, which phosphorylate 
activated receptors primarily on the receptors carboxyl -terminal tail, and 
possibly also in the 3rd intracellular loop of the muscarinic M1 receptor 
(Palczewski and Benovic, 1991; Lameh et al, 1992). It is also possible that 
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PKC and cAMP dependent protein kinase also play a role in receptor 
desensitisation (Lohse, 1993). Other proteins called arrestins are also 
responsible for the attenuation of G protein -coupled receptor activity. It has 
been shown that arrestins are able to bind to the activated and 
phosphorylated receptors, terminating receptor activity by blocking the sites 
of interaction with G proteins (Wilson and Applebury, 1993). 
Hydrophobicity analysis of the LHRH- receptor sequence has 
demonstrated seven stretches of highly hydrophobic amino acids with 20- 
30% sequence similarity to other G protein -coupled receptors, with the 
highest degree of homology to the interleukin -8 receptor (Tsutsumi et al, 
1992). Several features of the LHRH receptor are however unusual. The 
LHRH receptor is the smallest characterised member of the G protein linked 
receptor superfamily, and unlike any other G protein -coupled receptor it 
lacks a polar C- terminal cytoplasmic tail. Phosphorylation of the C- terminal 
tail has been shown to contribute to desensitisation of several G protein - 
coupled receptors (Probst et al, 1992). The first cytoplasmic loop of the 
LHRH receptor is also longer than in any other G protein -coupled receptor 
(Tsutsumi et al, 1992). Another important feature of the LHRH receptor is 
the substitution of serine for the conserved tyrosine, located adjacent to the 
transmembrane 3 domain, creating a potential, but not ideal 
phosphorylation site in a domain that has been shown to be important in 
the signal transduction mechanisms of other G protein -coupled receptors 
(Tsutsumi et al, 1992). 
An unusual feature of the LHRH receptor, likely to be important for 
receptor function are two residues, one is asparagine (Asn) 87 in the 
transmembrane 2 domain (TM 2), the other is aspartate (Asp) 318 in the 
transmembrane 7 domain (TM 7) (Zhou et al, 1994). In most other G protein 
linked- receptors, these residues are reversed (Probst et al, 1992). 
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Interestingly, most G protein -coupled receptors show a relatively rapid 
desensitisation of their inositol phosphate responses (Probst et al, 1992), in 
contrast to the LHRH receptor which is remarkably resistant to this 
phenomenon (Davidson et al, 1994; R. Mitchell, unpublished observations). 
Murine LHRH receptor mutants generated by site -directed mutagenesis 
and transiently transfected into COS 7 cells have been used in order to 
assess whether the kinetics of PLD activation, or the intracellular signalling 
pathways leading to PLD activation are affected. The mutant receptors 
used had Asp 318 changed to Asn (mutant 99), and Asn 87 changed to Asp 
as well as Asp 318 changed to Asn (mutant 101), which is the consensus 
found in virtually all other characterised G protein -coupled receptors. It has 
been reported that the 99 mutant can bind LHRH receptor ligands to 
approximately 70% of the level of the wild type receptor, while the 101 
mutant binds LHRH receptor ligands to about 40% of the capacity of the 
wild type receptor (Zhou et al, 1994). It has also been reported that LHRH- 
induced inositol phosphate production is greatly reduced in both the 99 and 
101 mutants (Zhou et al, 1994). It was also been found that the inositol 
phosphate production in both of the above mutants transfected into COS 7 
cells appears to be non -desensitising, as observed with the wild -type 
receptor (R. Mitchell, unpublished observations). 
Another aim of this study was to establish whether PKC and tyrosine 
kinases are involved in the LHRH -stimulated activation of PLD in CHO cells 
stably transfected with the wild -type LHRH receptor, using inhibitors of PKC 
and of protein- tyrosine kinases. 
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6.2 METHODS 
6.2.1 Phospholipase D assay 
Assays for phospholipase D were carried out using the standard protocol, 
as described in section 2.5. 
6.2.2 Transfection of COS 7 cells with receptor cDNA 
COS 7 cells were grown as described in Chapter 2. For transfection, 
cells were washed twice with OptiMEM (Gibco) supplemented with 100 
U /ml each of streptomycin and penicillin at 37 °C before exposure to the 
transfecting medium for 4 hr. The transfecting medium consisted of 
OptiMEM, penicillin/ streptomycin (100 U /ml each), 400 µg /ml DEAE 
dextran (Promega), 10011M chioroquine phosphate (Sigma) and 20 µg 
plasmid per 75 cm2 flask. This was then replaced with 10% DMSO in PBS 
for 2 min, then DMEM/ 2% UltraSer G/ penicillin/ streptomycin. Cells were 
then grown for 24 hr before being trypsinised and replated into 12 well 
plates. Phospholipase D assays were then carried out 48 hr later as 
described in Chapter 2. 
DEAE -Dextran mediated transfection 
This is an efficient technique for introducing DNA into cultured cells. 
In general DEAE -dextran mediated transfection is successful for transient, 
but not stable transfection of cells (Gluzman, 1981). The transfection 
efficiency can be increased by adding DMSO (10 %) to the cells for a short 
period. The exact mechanism through which it acts is unknown, but it may 
modify membrane structure to enhance the uptake of DNA. Chloroquine is 
applied to cells simultaneously with DNA, and appears to enhance 
transfection by binding to DNA and inhibiting intracellular DNA degradation 
by lysosomes. 
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6.2.3 Transfection of CHO cells with receptor cDNA 
Cells for transfection were cultured in Hams F12 medium with 10 % 
foetal calf serum, supplemented with 100 U /ml each of streptomycin and 
penicillin at 37 °C until they were 60 -80% confluent in cell culture dishes (10 
cm diameter). The cells were incubated overnight in the transfection 
medium (OptiMEM, penicillin /streptomycin (100 U /ml each), DOTAP 
(Boehringer Mannheim), 20 µg pcDNA with neomycin resistance gene per 
dish). Next day the medium was changed for Hams F12 with 2% Ultra Sera 
G and penicillin /streptomycin (100 U /ml each). The following day the 
medium was changed again, to the same as above, plus the neomycin 
analogue geniticin (500 µg /ml). Selection of cells took place 1 month later 
by placing cloning rings over individual colonies in order to remove and re- 
plate them. Selection of cells expressing functional LHRH receptors was 
carried out by equilibrium binding of [1251] buserelin (an LHRH- receptor 
agonist), according to previously described procedures (Mitchell et al, 
1988). 
DOTAP Transfection- reagent 
The transfection reagent DOTAP (N- [1- (2,3- dioleoyloxy) propyl] -N, N, 
N- trimethyl- ammonium \methylsulphate) is suitable for the transfection of 
DNA into mammalian cells for stable or transient gene expression. Mixing 
DOTAP with DNA results in spontaneously formed stable complexes, which 
can be added directly to serum -containing tissue culture medium. The 
DNA/DOTAP complexes fuse directly with the cell surface, releasing DNA 
into the cytoplasm. This method of transfection is also reported not to be 
cytotoxic (Stamatatos et al, 1988; Leventis and Silvius, 1990). 
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6.3 RESULTS 
Levels of buserelin binding were determined by [1251] buserelin 
binding (Mitchell et al, 1988). The Kd for [1251] buserelin binding to wild type, 
99 mutant and 101 mutant receptors in COS 7 cells were 1.03 nM, 0.89 nM 
and 0.79 nM respectively. The Bmax values for [1251] buserelin binding to wild 
type, 99 mutant and 101 mutant receptors in COS 7 cells were 506, 263 
and 141 fmol /mg protein respectively ([1251] buserelin binding expriments 
were carried out by R. Mitchell). 
It is apparent from the time course of LHRH- (100 nM) stimulated 
PLD activation in COS 7 cells transiently transfected with the wild -type 
LHRH receptor that activation of PLD proceeds without any detectable 
delay (Figure 6.1), which was seen in the case of LHRH -stimulated PLD 
activity in aT3 -1 cells (Chapter 3). The LHRH -stimulated PLD activity in 
COS 7 cells transfected with the wild type LHRH receptor does not appear 
to desensitise within 60 min (Figure 6.1), which is also the case for the 
LHRH -stimulated PLD activation in aT3 -1 cells (Chapter 3). 
In COS 7 cells transiently transfected with the 99 and 101 mutant 
LHRH receptors, LHRH -stimulation of PLD activity initially occurs at a 
higher rate than is the case for the wild type receptor in COS 7 cells, 
although the LHRH -stimulated PLD activity appears to be fully desensitised 
within 5 min (Figure 6.1); no time points less than 5 min were studied. It 
should be remembered that figure 6.1 represents an accumulation of a 
stable product (phosphatidylbutanol), therefore the stable plateau observed 
with the 99 and 101 mutant LHRH receptors represents a lack of further 
detectable PLD activity. 
In order to assess whether PKC is involved in the LHRH -stimulated 
activation of PLD in CHO cells stably expressing the wild type LHRH 
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receptor (Chapter 6.2), we used the selective bisindolylmaleimide PKC 
inhibitor Ro 31 -8220 (Davis et al, 1992). It was found that Ro 31 -8220 
completely inhibited the LHRH -stimulated PLD activity with an IC50 of 670 
+/- 160 nM (Figure 6.2). This was very similar to Ro 31 -8220 inhibition of 
LHRH -stimulated PLD activity in aT3 -1 cells, which was 460 ± 180 nM (see 
Chapter 3). 
In order to assess whether non -receptor tyrosine kinases are 
involved in LHRH receptor activation of PLD in transfected CHO cells in a 
similar manner to that seen in aT3 -1 cells, we used the tyrosine kinase 
inhibitors, lavendustin A (Hsu et al, 1991) and genistein (Akiyama et al, 
1987). Neither of these compounds had any effect on the LHRH -stimulated 
PLD activity in CHO cells stably transfected with the wild type LHRH 
receptor. Lavendustin A was used at 3 µM and genistein was used at 100 
µM. These concentrations are well above the IC50s observed for the 
inhibition of LHRH stimulated PLD activity in aT3 -1 cells (see Chapter 4). 
Pertussis toxin (100 ng /mI) did not cause any significant attenuation of the 
LHRH -stimulated activation of PLD in CHO cells stably transfected with the 
wild type LHRH receptor (as was also the case in LHRH -stimulated PLD 
activity in aT3 -1 cells (Chapter 3), indicating that the G proteins Gi and Go 
are not involved in coupling the LHRH receptor to PLD activation. 
6.4 DISCUSSION 
The results presented above indicate that both the single mutation of 
Asp 318 to Asn (99 mutant) and the double mutation of Asp 318 to Asn and 
Asn 87 to Asp (101 mutant) result in the reversion of the non -desensitising 
LHRH -stimulated PLD response seen with the wild type receptor in both 
COS 7 cells and aT3 -1 cells, to a desensitising response, characteristic of 
other G protein -coupled receptors, which have the same TM 2 Asp and TM 
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7 Asn as the double mutant (Probst et al, 1992). The wild type murine 
LHRH receptor displayed a complete lack of desensitisation in the LHRH- 
stimulated PLD response over a 60 min time course, which may be 
functionally significant for the cell. This is in contrast to the LHRH- 
stimulated production of inositol phosphates in COS 7 cells transfected with 
the 99 and 101 mutant LHRH receptors, in which there was no detectable 
desensitisation, although the levels of inositol phosphates produced are 
lower than that observed with the wild -type receptor (R. Mitchell, 
unpublished observations). These results raise the possibility that the 
activation of PLC and PLD are not coupled to the LHRH receptor by the 
same mechanism, possibly involving different G proteins. A similar non - 
desensitising response has recently been reported for inositol phosphate 
production stimulated by the murine LHRH receptor in aT3 -1 cells 
(Davidson et al, 1994). Furthermore in GH3 cells transfected with LHRH- 
receptor cDNA the hydrolysis of inositol phospholipids was also non - 
desensitising (Davidson et al, 1994). The absence of desensitisation in 
both cell types in this, and the present study suggests that the lack of 
desensitisation is likely to be due to an intrinsic property of the receptor. 
It is interesting that in most other G protein -coupled receptors, in 
which the TM 2 Asp and TM 7 Asn are conserved, agonist- induced enzyme 
activation is rapidly desensitised (Probst et al, 1992). In contrast, in the 
LHRH receptor there appears to be a natural reciprocal mutation between 
the transmembrane 2 and 7 domains(Zhou et al, 1994). It is possible that 
one or both of these residues is responsible for the lack of desensitisation 
observed in LHRH -stimulated PLD activity, or that these residues may 
interact with other loci on the receptor to influence desensitisation, since 
mutating these residues back to the consensus seen in other G protein - 
coupled receptors resulted in the LHRH -stimulated PLD activity reverting to 
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a desensitising response. It has also been demonstrated that it is likely that 
these two residues lie in close proximity when the receptor is inserted in the 
membrane, and that there may be hydrogen bonding between them (Zhou 
et al, 1994). It has been postulated that the mutation of Asp 318 to Asn is 
able to maintain the hydrogen bonding between the two residues, and that 
Asn is able to act as both a hydrogen bond acceptor and donor in this site 
(Zhou et al, 1994). It is therefore likely that in both the single and double 
mutant the structural integrity of the receptor is maintained, with the function 
of the natural reciprocal mutation being lost, resulting in a desensitisation of 
the PLD response following LHRH -stimulation. The fact that a single 
mutation of Asp 318 to Asn has the same result as the double mutation in 
reverting LHRH -stimulated PLD activity to a desensitising response 
suggests that this residue in TM 7 plays the more important role in the non - 
desensitising response, or interacts with other important loci on the 
receptor. It has been reported that a single mutation of Asn 87 to Asp 
results in a complete loss of agonist binding, suggesting that this mutation 
results in loss of hydrogen binding between TM 2 and TM 7, leading to the 
loss of a functional structure and agonist binding (Zhou et al, 1994). A 
previous study carried out in COS -1 cells implicated the Asp 318 residue of 
the rat LHRH receptor in receptor coupling to the hydrolysis of inositol 
phospholipids, since mutation of Asp 318 to Asn resulted in a loss of IP 
hydrolysis as a result of LHRH- receptor stimulation (Cook et al, 1994). 
However, other studies have demonstrated that this mutant receptor is 
capable of stimulating inositol phosphate production (Zhou et al, 1994; R. 
Mitchell, unpublished observations). The Asp 318 may be located very 
close to the end of the TM 7 domain and may therefore be able to interact 
directly with cytoplasmic proteins, or to influence residues which do. It is 
therefore possible that mutating Asp 318 to Asn allows the receptor to 
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interact with intracellular components normally involved in bringing about 
receptor desensitisation, as is the case with other G protein -coupled 
receptors. Another study has been carried out using site -directed 
mutagenesis of the conserved Asn in TM 7 and Asp in TM 2 in the 5HT1A 
receptor (Chanda et al, 1993). It was found that mutation of Asn 396 in the 
TM 7 domain to Ala, Phe or Val resulted in a loss of agonist binding. In 
contrast mutation of Asn 396 to Gln did not effect agonist binding. It is 
therefore possible that the mutation to Gln retains hydrogen bonding with 
another domain, possibly TM 2 as has been previously postulated (Zhou et 
al, 1994), while this interaction is disrupted by the other mutations. 
It is clear that the initial rate of LHRH -stimulated PLD activation was 
lower in the wild type LHRH receptor than with the mutant LHRH receptors. 
Therefore, it may be that Asp in position 318 is less efficient at coupling to 
intracellular components involved in PLD activation than with Asn in 
position 318, or the interaction of this residue with other loci on the receptor 
may be altered, resulting in a lower initial rate of LHRH -stimulated PLD 
activation. 
Although it was demonstrated in this study that residues in the 
transmembrane 2 and 7 domains are important factors in defining the 
LHRH -stimulated PLD activity as a non -desensitising response, it is still 
possible that other factors, such as the lack of a C- terminal tail (Tsutsumi et 
al, 1992) are also important in this effect, since it has been demonstrated 
that phosphorylation of the C- terminal tail can be an important factor in 
receptor desensitisation (Probst et al, 1992). 
It is interesting that the LHRH -stimulated PLD activity in COS 7 cells 
transfected with the wild type LHRH receptor proceeds without a detectable 
delay in the formation of PtdBut, while in aT3 -1 cells there was a significant 
delay in LHRH -stimulated PLD activation (Chapter 3). It therefore seems 
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likely that the delay in PLD activation may be due to intracellular 
components in the signalling pathway and not as a result of any function of 
the receptor, since no delay was observed in COS 7 cells. It has already 
been demonstrated that the delay observed in aT3 -1 cells was not due to a 
necessity for protein synthesis (Chapter 3). 
It was also demonstrated in this study that the selective PKC 
inhibitor, Ro 31 -8220 was able to inhibit the LHRH -stimulated PLD activity 
in CHO cells stably expressing the LHRH receptor at a very similar 
concentration to that seen for LHRH -stimulated PLD activity in aT3 -1 cells 
(Chapter 3). It is therefore possible that the PKC(s) involved in the LHRH- 
stimulated activation of PLD in CHO cells are the same or similar to those in 
aT3 -1 cells, which shows an approximately 8 -fold lower sensitivity to Ro 31- 
8220 than the PDBu- stimulated PLD activity in aT3 -1 cells (see Chapter 3). 
This concentration of Ro 31 -8220 represents a potent inhibition of PKC; the 
selectivity of the bisindolylmaleimide PKC inhibitors on the responses 
observed in the present study is discussed in greater depth in Chapter 3. 
From immunoblot analysis it has been shown that CHO cells contain a high 
level of PKC , and also PKC a, although it has not been able to rule out the 
presence of other isoforms (J. Simpson, unpublished results). 
It would appear that non -receptor tyrosine kinases are not involved 
in the activation of LHRH -stimulated activation of PLD in CHO cells 
transfected with the wild type LHRH receptor, as they are in aT3 -1 cells 
(Chapter 4). Neither lavendustin A or genistein had any detectable effect 
on the LHRH -stimulated activation of PLD. Since it is not known exactly 
which non -receptor tyrosine kinase is involved in the LHRH -stimulated PLD 
activation in aT3 -1 cells, it has not been possible to ascertain whether CHO 
cells contain the kinase or kinases involved. 
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The absense of desensitisation of second messenger systems in 
response to LHRH- receptor desensitisation may not be out of keeping with 
the pulsatile nature of LHRH release in vivo (Fink, 1988). The physiological 
response may be frequency modulated, and the receptor could function as 
an amplifier of the frequency- encoded signal. In fact, it may be 
innapropriate for a frequency -modulated sytem to display desensitisation 
over a time -frame which is short compared with the duration of the LHRH- 
pulse, since this would limit the duration of the pulse. It is therefore 
possible that the LHRH- receptor has evolved to be maximally active over a 
period of hours prior to ovulation, when a rapidly desensitised response 
would be inappropriate. 
In conclusion, it would appear that the natural reciprocal mutation 
between the TM 2 and TM 7 domains and in particular Asp 318 in TM 7 is 
significantly responsible for the lack of desensitisation in the LHRH- 
stimulated PLD activity. Mutating Asp 318 to Asn, which is the residue 
found in this position in most other G protein -coupled receptors (Probst et 
al, 1992), resulted in the LHRH -stimulated PLD activity having a higher 
initial rate, followed by complete desensitisation within 5 min. A double 
mutation of Asp 318 to Asn in TM7 as well as Asn 87 to Asp in TM 2, which 
is reported to interact though hydrogen bonding with Asp 318 in TM 7 (Zhou 
et al, 1994) had the same result as the single mutation. It appears that PKC 
is involved in the LHRH -stimulated activation of PLD in CHO cells stably 
expressing the wild type LHRH receptor, since the sensitivity to Ro 31 -8220 
is similar to that of LHRH -stimulated PLD activation in T3 -1 cells. The wild 
type LHRH receptor -stimulated PLD activity in transfected CHO cells was 
unaffected by tyrosine kinase inhibitors, or by pertussis toxin. 
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Figure 6.1 
Time course of LHRH -stimulated PLD activation in COS 7 cells 
transiently transfected with LHRH receptor cDNA 
Time course of [3H] PtdBut accumulation in COS 7 cells stimulated with 
LHRH (100 nM). The cells were transiently transfected with cDNA for the 
wild -type, 99 mutant and 101 mutant receptors. All values are means ± 
SEM from 4 -8 separate determinations with the basal level of [3H]PtdBut 
accumulation subtracted. Basal values were not significantly different 
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Figure 6.2 
Concentration response curve for the inhibition of LHRH- 
stimulated PLD activity by Ro 31 -8220 in COS 7 cells 
transiently transfected with wild type LHRH receptor cDNA 
The effect of the protein kinase C inhibitor Ro 31 -8220 on the LHRH- (100 
nM) stimulated activation of PLD on CHO cells stably transfected with cDNA 
for the wild -type LHRH receptor. Stimulation was for 30 min, and values are 
means ± SEM from 4 -8 separate determinations with the basal level of 
[3H]PtdBut accumulation subtracted. There was no effect of Ro 31 -8220 on 
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CHAPTER 7 
THE INVOLVEMENT OF PHOSPHOLIPASE D IN 
THE LHRH PRIMING PHENOMENON AND THE 
MODULATION OF PHOSPHOLIPASE D ACTIVATION 
BY GONADAL STEROIDS 
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7.1 INTRODUCTION 
One of the key reasons for investigating LHRH- activated intracellular 
signalling mechanisms in the aT3 -1 cell line has been to try to derive 
insights into mechanisms underlying the LHRH -priming phenomenon. This 
is a unique mechanism in pituitary gonadotrophs, in which LHRH 
significantly increases the responsiveness of gonadotrophs to itself; prior 
exposure of gonadotrophs to LHRH leads to a substantial augmentation of 
the LH and FSH release that is caused by a second exposure to LHRH 
(Aiyer and Fink, 1974b). The role of the LHRH priming effect would appear 
to be to co- ordinate the surge of LHRH and the increase in pituitary 
responsiveness to LHRH so that both events reach a peak simultaneously, 
and as a consequence produce a massive surge of LH release from 
gonadotrophs in the anterior pituitary (Fink, 1988). It has also been 
demonstrated that this priming effect is enabled in part by the history of 
exposure of the anterior pituitary to steroid hormones. The plasma 
concentrations of gonadotrophins are maintained at relatively low levels for 
most of the oestrous cycle by the negative feedback of low concentrations 
of oestrogen and high plasma concentrations of progesterone acting on the 
hypothalamus and the anterior pituitary (Fink, 1988). The LH surge is 
preceded by a surge of oestrogen and is accompanied and further 
intensified by a significant increase in the plasma concentration of 
progesterone (Fink, 1988). This priming effect of LHRH is also dependent 
upon protein synthesis, demonstrated by the ability of the inhibitor of protein 
synthesis, cycloheximide, to block the initiation of the LHRH -priming effect. 
The priming effect is also dependent upon the integrity of microfilaments 
(Fink, 1988). 
Several intracellular signalling mechanisms have been shown to be 
important in the LHRH priming effect. For example, it has been 
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demonstrated in the anterior pituitary that prior exposure to LHRH resulted 
in an enhanced LHRH- induced production of inositol phosphates, as well 
as an enhanced release of Cat+ from intracellular stores (Mitchell et al, 
1988). As well as this elevation in the level of inositol phosphates there will 
also be an increase in DAG production, which could lead to an enhanced 
activation of PKC. Indeed it has been demonstrated that inhibitors of PKC 
are able to inhibit the onset of priming, and in particular a partially H7- 
insensitive isoform of PKC may be involved in the priming effect (Johnson 
et al, 1992). The phospholipase, PLA2, also appears to be specifically 
involved in the LHRH priming phenomenon, since inhibitors of PLA2 are 
able block the onset of LHRH priming, but do not effect the immediate 
LHRH -stimulated release of LH from the anterior pituitary. The LHRH 
priming effect can also be partially mimicked by a conditioning 
preincubation with arachidonic acid (Thompson et al, 1994). An enzyme 
which is reported to phosphorylate PLA2, mitogen activated protein kinase 
(MAPK) (Lin et al, 1993) is also thought to play some role in the LHRH 
priming effect, since it has been shown to be activated by LHRH in a 
concentration dependent manner after 5 -10 min, continuing up to 60 min 
after stimulation, and has the highest activity in pro- and di- oestrus, when 
priming occurs (Mitchell et al, 1994). Elevation of cAMP levels, and the 
activation of cAMP- dependent protein kinase may also additionally be 
important in the LHRH priming effect (Turgeon and Waring, 1994). Tyrosine 
phosphorylation has also been demonstrated to be important in the release 
of LH from the anterior pituitary in response to LHRH, although not 
specifically in the primed release, by the use of protein tyrosine kinase 
inhibitors (Johnson et al, 1994). 
It is possible that PA or DAG produced by the action of PLD on PC 
might somehow be involved in increasing the responsiveness of pituitary 
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gonadotrophs to LHRH by activating the PKC or PKC -like kinases which 
have been shown to play a key role in priming (Johnson et al, 1992). 
Indeed, it was recently demonstrated that PA is capable of strongly 
activating PKC in a cell free system (Limatola et al, 1994). In the present 
study it has been shown that the LHRH -stimulated activation of PLD 
appears to be non -desensitising over a time course of 40 min (Chapter 3), 
which is similar to the time course needed to elicit the LHRH priming 
phenomenon. Phospholipase D has previously been closely linked to the 
control of cellular events, such as mitogenesis (reviewed in Boarder, 1994 
and Thompson et al, 1993a), and also in neutrophil priming, which results 
in the enhanced production of superoxide (Babior, 1984). Phospholipase 
D activity in resting, or unprimed neutrophils is poorly stimulated by fMLP, 
but in neutrophils that have been primed by pretreatment with granulocyte - 
macrophage colony stimulating factor, platelet activating factor, or 
cytochalasin B, there is a 5 -10 fold higher responsiveness observed in the 
fMLP -stimulated activation of PLD (Mullmann et al, 1990; Anthes et al, 
1991). Preliminary experiments indicated that it was not going to be 
possible to assess whether there is any involvement of PLD in LHRH- 
priming in anterior pituitary tissue, due to variability of the signal, 
presumably as a result of the heterogeneous nature of the tissue. Therefore 
attempts have been made to establish in the aT3 -1 cell line whether a 
conditioning preincubation with LHRH will result in an augmented PLD ' 
response upon subsequent LHRH exposure. It has been demonstrated that 
this type of initial LHRH -stimulus, followed by a second LHRH stimulus is 
capable of bringing about a significant augmentation in the release of LH 
from hemisected pituitaries in vitro (Fink,1986). The release of LH cannot 
be measured from the aT3 -1 cell line, since it does not synthesise or 
secrete the ß subunit of LH ( Windle et al, 1990). 
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Another area of particular interest has been the role of steroid 
hormones such as oestrogen and progesterone in modulating LHRH- 
stimulated PLD activity in aT3 -1 cells, since they have been shown to play 
such a critical role in the control of the LHRH -priming effect in vivo (Fink, 
1988). Oestrogen and progesterone bind to nuclear receptors, which act as 
trans -acting transcription factors (reviewed in Weisz and Bresciani, 1993). 
These steroid receptors are capable of binding to specific cis -acting 
enhancer elements on the DNA, usually located within the 5'- flanking 
regions of the target genes. Oestrogen has also been reported to regulate 
gene expression by influencing mRNA stability or via interaction with 
transcription regulation factors (Weisz and Bresciani, 1993). 
Steroids have also been shown to modulate the activity and 
expression of enzymes involved in intracellular signalling pathways. For 
example, it has been demonstrated that oestrogen can modulate PKC 
levels in pituitary cells, by regulating the mRNA levels of Cat + -dependent 
and -independent forms of PKC (Maeda and Lloyd, 1993). It has also been 
observed that in human endometrial fibroblasts, PLC activity can be 
enhanced by oestrogen in a Cat + -dependent manner (Imai et al, 1990), and 
that oestrogen can regulate the expression of a secretory form of PLA2 in 
the quail oviduct (Fayard et al, 1994). The level of the heterotrimeric G 
protein, Gil, which inhibits the activity of adenylate cyclase has been shown 
to be upregulated during gestation in the rat by the high levels of oestrogen 
(Tanfin et al, 1991). Progesterone independent trans -activation of the 
progesterone receptor has also been reported to occur as a result of LHRH- 
priming; this is suggested to be as a result of cAMP- dependent protein 
kinase activation, following an elevation of cAMP levels associated with 
LHRH receptor activation (Turgeon and Waring, 1994). 
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7.2 METHODS 
7.2.1 Phospholipase D assay 
Assays for phospholipase D were carried out using the standard protocol, as 
described in section 2.4. 
7.2.2 Pre -stimulating aT3 -1 cells with LHRH 
Quiescent aT3 -1 cells were pre -labelled and washed as described 
in section 2.4. They were then stimulated with 10 nM LHRH in the absence 
of butan-l-ol, in order to stimulate PLD without forming stable 
phosphatidylbutanol, for 15 min and then washed again as previously 
described (section 2.4). After a period of 1 hr they were stimulated again 
with 10 nM LHRH for a period of 30 min in the presence of butan -1 -ol (30 
mM). The remainder of the assay was as described in section 2.4. Controls 
were carried out with no pre -stimulus in order to determine whether an 
increment in the LHRH -stimulated PLD response had occurred as a 
consequence of a prior LHRH stimulus (i.e. was there evidence for priming 
of the PLD response ?). 
7.2.3 Steroid hormone treatment of aT3 -1 cells 
aT3 -1 cells were plated out in 12 well culture plates (Costar) and grown for 
approximately 24 hrs, as described in section 2.3. The growth medium was 
then changed for DMEM with no phenol red, 10% steroid free (charcoal 
stripped) foetal calf serum, 2 mM L- glutamine, 100 U /ml penicillin and 0.1 
mg /ml streptomycin, approximately 48 hrs prior to the assay. In order to 
determine the effect on LHRH -stimulated PLD of specific steroid hormones, 
oestrogen (1 nM) was added to the growth medium 16 hrs prior to the assay 
and progesterone (200 nM) was added 3 hrs prior to the assay. It has been 
demonstrated that the growth rate of aT3 -1 cells grown in steroid stripped 
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growth medium is not reduced, as assessed by 5- bromo -2'- deoxyuridine 
incorporation (M. Johnson, unpublished observations). 
7.2.4 Hormone secretion assay 
Female COB Wistar rats were maintained as described in section 
2.4. Female rats were killed at approximately 13.00 h on pro- oestrus 
(assessed as described in section 2.4). Pituitary glands were removed and 
the anterior lobes separated from the posterior pituitary. The anterior lobes 
were then bisected. These hemipituitaries were allocated one /flask, such 
that hemipituitaries from the same rat were in different treatment groups. 
The hemipituitaries were then incubated in 2 ml of pre- warmed and 
gassed (95% 02/5% CO2) HEPES- buffered minimal essential medium 
(MEM) with Earle's salts at 37 °C in a shaking water bath under an 
atmosphere of 95% 02/5% CO2. The hemipituitaries were then washed in 2 
ml of fresh medium for approximately 15 min after which the medium was 
changed before adding a stimulus of LHRH (1 nM) and the drug to be 
studied. All the medium was removed from the flasks and then replaced 
along with the drug and LHRH at the end of the 1st, 2nd and 3rd hour. The 
medium removed at the end of each hour was stored at -20 °C, until 
assayed for LH by radioimmunoassay (Daane and Parlow, 1971). 
7.3 RESULTS 
It was set out to deduce whether or not the LHRH -stimulated PLD 
activity could be enhanced by an initial exposure to LHRH, as has been 
shown to occur with the release of LH from the pituitary (Fink, 1986). The 
effect of the removal of steroid hormones from the growth medium on the 
LHRH -stimulated activation of PLD, and their subsequent readdition was 
also studied. 
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An LHRH (10 nM) pre -stimulus (15 min), in the absence of butan -1 -ol 
(to ensure that no PtdBut is formed), was applied to the T3 -1 cells, 1 hr 
prior to the cells being stimulated with LHRH (10 nM) for 30 min, in the 
presence of butanol (see section 7.2.2). The level of LHRH -stimulated PLD 
activity in cells which received a pre -stimulation was 95 ± 5% of the LHRH- 
stimulated PLD activity in cells which were not pre -stimulated (Figure 7.1). 
An LHRH concentration of 10 nM was used for both the pre -stimulus and 
the stimulus in order to ensure that the LHRH -stimulated PLD response was 
not maximal, in which case it might not have been possible to observe any 
further augmentation of the LHRH- stimulated activity that might have 
occurred. No change was observed in the basal PLD activity in cells 
receiving a pre -stimulus, but no further stimulus, compared to cells 
receiving no prestimulus with LHRH. 
In order to determine whether or not oestrogen plays a role in 
modulating LHRH -stimulated PLD activity, aT3 -1 cells were grown in a 
steroid -free growth medium. To determine the effect of oestrogen alone on 
the LHRH -stimulated PLD activity, oestrogen was added back to the growth 
medium approximately 16 hrs prior to the assay (see section 7.2.3 for 
experimental details). The LHRH -stimulated PLD activity in the cells grown 
in steroid -free growth medium was taken as the basal level (Figure 7.2). In 
the cells which had oestrogen (1 nM) added back 16 hrs prior to the assay, 
LHRH -stimulated PLD activity was 132 ± 6% of that seen in aT3 -1 cells 
grown in steroid stripped growth medium, while the LHRH -stimulated PLD 
activity in cells grown in normal growth medium was 125 ± 5% of the basal 
level (Figure 7.2). The LHRH -stimulated PLD activities in T3 -1 cells grown 
in normal growth medium, and with the readdition of oestrogen are 
significantly different from the LHRH -stimulated PLD activity in cells grown 
in steroid stripped medium (p <0.05; Mann Whitney U- test). 
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In order to determine the involvement of progesterone in the 
regulation of LHRH -stimulated PLD activity, we cultured T3 -1 cells in the 
absence of steroid hormones, as described in section 2.3, then added 
progesterone (200 nM) back to the growth medium approximately 3 hrs 
prior to the assay. In cells pre- treated with progesterone the LHRH- 
stimulated PLD activity was 110 ± 5% of that seen in cells grown in the 
absence of steroid hormones (Figure 7.2). In T3 -1 cells pretreated with 
both oestrogen (1 nM) and progesterone (200 nM), the LHRH- stimulated 
PLD activity was 129 ± 4% of that seen in cells grown in steroid free growth 
medium (Figure 7.2), which is significantly different from cells grown in 
steroid -stripped medium (p<0.05; Mann Whitney U- test). It therefore seems 
that oestrogen is needed for maximal PLD activation by LHRH. There was 
no detectable difference in the basal PLD activity between cells grown in 
normal growth medium, in steroid -stripped medium or in cells grown in 
stripped medium with the readdition of oestrogen or progesterone. 
In order to assess whether PLD plays a role in the release of LH from 
the anterior gland in vitro, we have used the primary alcohol, butan -1 -ol, 
which at high concentrations will lead to the production of 
phosphatidylbutanol, instead of PA from the hydrolysis of PC by PLD, and 
has been used as a pharmacological inhibitor of PLD responses in 
neutrophils (Bonser et al, 1989). We have also used demethoxyviridin 
(DMV), a derivative of the fungal metabolite wortmannin, which has been 
reported to inhibit PLD activity in the human neutrophil at a site between the 
activated receptor and PLD (Bonser et al, 1991). It is apparent that butan -l- 
ol was able to inhibit both the initial and the primed release of LH from the 
anterior pituitary, stimulated by LHRH (1 nM), while not affecting the basal 
release (Figure 7.3). It also appears that DMV also had a similar effect on 
both the initial and primed release of LHRH, with no apparent effect on the 
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basal release (Figure 7.4) (experiment with DMV carried out by F.J. 
Thompson). 
7.4 DISCUSSION 
It is apparent that with the conditions used this study (i.e. pretreating 
aT3 -1 cells with LHRH (10 nM) 1 hour prior to a further LHRH (10 nM) 
stimulus) there was no detectable enhancement of the LHRH -stimulated 
activation of PLD. If PLD were closely involved in controlling the LHRH 
priming effect, it is conceivable that the LHRH -stimulated PLD activity would 
be enhanced by a previous exposure to LHRH, since it has already been 
shown that there is a facilitation of the LHRH -stimulated activation of PLC in 
pro- oestrous anterior pituitaries by conditions which lead to the primed 
release of LH (Mitchell et al, 1988). This increased PLC activity may then 
lead to an increase in PKC activity. An enhanced production of PA and 
DAG derived from the hydrolysis of PC by PLD might also activate kinases, 
such as PKC, involved in modulating the priming response, since it has 
been demonstrated that an unidentified H7- resistant isoform of PKC, or a 
PKC -like enzyme is closely involved in the LHRH- priming effect (Johnson et 
al, 1992). An enhanced stimulation of PLD as well as PLC by LHRH during 
the priming phenomenon might cause a massive stimulation of PKC, while 
the activation of PLD would not result in the release of Cat+ from 
intracellular stores. The fact that the LHRH -stimulated PLD activity was not 
enhanced by the conditions used in this study does not necessarily mean 
that PLD has no role to play in the LHRH priming effect, only that a 
potentiation of the PLD response does not appear to be mediated directly 
by LHRH, and is probably not augmented in the same way as PLC. 
It has been previously noted that there is ovarian steroid -dependent 
modulation of pituitary responsiveness to different hypothalamic factors, 
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such as somatostatin, dopamine, LHRH and TRH (Drouva et al, 1988; Aiyer 
and Fink, 1974). It has also been shown that there is an increase in PKC 
activity in the pituitary following exposure to oestrogen (Thomson et al, 
1993b), and that this increase in PKC activity is not mediated by oestrogen - 
evoked changes in hypothalamic secretion of LHRH, TRH, dopamine or 
somatostatin, which might have indirectly triggered enzyme activation 
(Drouva et al, 1990). It is significant that the LHRH -stimulated PLD activity 
is lower in aT3 -1 cells grown in the absence of steroid hormones and that 
the full response can be regained by the readdition of oestrogen, but not 
progesterone to the growth medium. One possibility is that the level of 
expression of PKC, which is required for LHRH- induced PLD activation is 
normally under steroidal control, and is thus reduced in cells grown in the 
absence of steroids. It has been reported that oestrogen treatment of 
normal rat pituitary tissue and pituitary tumours can increase mRNA levels 
of the PKC isoforms, a, 13, 8, e and (Maeda and Lloyd, 1993). It has been 
demonstrated by immunodetection that aT3 -1 cells express the PKC 
isoforms a, E and at high levels (Johnson et al, 1993), therefore it is 
possible that one, or all of these isoforms could be modulated by the level 
of oestrogen in the growth medium, as has already been demonstrated in 
the anterior pituitary (Maeda and Lloyd, 1993). It is also possible that other 
components of the intracellular signalling pathway, as well as PKC, are 
regulated by steroids. Previous studies have demonstrated that oestrogen 
is capable of increasing the apparent activity of phospholipases, for 
example the PLC activity in human endometrial fibroblasts was apparently 
enhanced by oestrogen in a Cat + -dependent manner (Imai et al, 1990). It 
has also been shown that the LHRH -stimulated release of AA from the 
anterior pituitary is enhanced in pro- oestrus, and that the LHRH -stimulated 
release of AA is higher in ovariectomized /oestradiol -1713- replaced rats, 
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compared with ovariectomized rats (Thomson et al, 1994). Furthermore the 
level of expression of a secretory form of PLA2 appears to be regulated by 
oestrogen in the quail oviduct, this expression of PLA2 also appears to 
correlate with the proliferation of oviduct cells (Fayard et al, 1994). The 
question of PLD expression being increased by prior exposure to 
oestrogen cannot be approached at the present time, due to the lack of 
mRNA and protein sequence information for mammalian PLD. An 
observation has also been made that a high dose of oestrogen (10 nM) can 
stimulate a rapid (maximal in 10 sec) activation of a src -type non -receptor 
tyrosine kinase in human breast cancer MCF -7 cells under conditions of 
oestradiol- stimulated cell growth, suggesting a possible non -genomic 
effect. This effect was also blocked by anti -oestrogens, suggesting that this 
was a specific effect (Migliaccio et al, 1993). 
It is clearly not possible to assess from the results presented here the 
mechanism by which oestrogen enhances the LHRH -stimulated PLD 
activity, or which components of the signalling pathway it is affecting. 
Studying the level of expression of components of the signalling pathway 
as a result of steroid removal might provide some insights into the 
mechanism involved. However, if the effect of oestrogen is the same as that 
observed in most other systems, it is likely to be a consequence of 
increased expression of critical proteins. It is a possibility that the level of 
PLD expression, or components of its regulatory mechanism, are 
modulated with respect to the concentration of circulating oestrogens on 
different days of the oestrous cycle. It would therefore be possible that an 
increased level of LHRH -stimulated PLD activity might play a role in altering 
the level of gonadotroph responsiveness on different days of the oestrous 
cycle, with the highest level in pro- oestrus, when LHRH priming occurs and 
the level of cell responsiveness is at its highest. If this theory is correct, 
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oestrogen would most likely have a long term genomic effect. We have 
attempted to determine whether PLD activity in the anterior pituitary, 
labelled in vitro with [3H] palmitate for 2 hrs before being stimulated for 30 
min with LHRH (100 nM), is higher on any particular day of the oestrous 
cycle in female COB wistar rats. However, the high degree of variability in 
the LHRH -stimulated PLD activity between animals made it impossible for 
any conclusions to be drawn (results not shown). 
In order to try and assess whether PA or DAG produced by the action 
of PLD on PC are important for the initial or primed release of LH from the 
anterior pituitary in response to LHRH, high concentrations of butan -1 -ol 
were used in order to prevent bioactive PA being formed due to the 
formation of PtdBut by a transphosphatidylation reaction (Dawson, 1967). 
However it appears that butanol affected both the initial and the primed 
release of LH stimulated by LHRH (Figure 7.3). It may be that PLD is 
important in the LHRH -stimulated release of LH from pituitary 
gonadotrophs, since it has already been postulated that PLD may play a 
role in regulating vesicle fusion, possibly by creating an area of charged 
phospholipids on the inner surface of the cell membrane and enabling 
vesicle fusion (reviewed in Kahn et al, 1993). It is also possible that the 
high concentration of butanol is affecting the cell membranes or 
cytoskeleton, thus attenuating the LHRH -stimulated release of LH. 
Demethoxyviridin, a derivative of the fungal metabolite wortmannin, which 
has been reported to inhibit PLD activity in the human neutrophil at a site 
between the activated receptor and PLD (Bonser et al, 1991), inhibited both 
the initial and primed LHRH- induced release of LH from the anterior 
pituitary, without affecting the basal release. This is similar to the effect of 
butanol on LHRH- induced LH release, further implicating PLD in the 
regulated release of LH from pituitary gonadotrophs, but not specifically in 
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the primed release of LH, as has been demonstrated with PLA2 (Thomson 
et al, 1994), and to certain extent PLC (Mitchell et al, 1988). 
So in conclusion, it would appear that under the conditions 
investigated, the LHRH -stimulated activation of PLD was not enhanced by a 
previous LHRH stimulus in T3 -1 cells. However, LHRH -stimulated PLD 
activity was reduced in T3 -1 cells grown in the absence of steroid 
hormones, and readdition of oestrogen resulted in a recovery of the LHRH- 
stimulated PLD response. Although the mechanism by which oestrogen 
modulates PLD activity is not known, it is possible that the level of 
expression of components of the signalling machinery, such as PKC or PLD 
are regulated by oestrogen. It is also possible that oestrogen- enhanced 
expression of key signalling proteins plays an important role in the 
increased level of responsiveness observed in the LHRH priming effect in 
pro- oestrus pituitaries (Fink, 1988). It also appears that PLD is important in 
the regulated release of LH from pituitary gonadotrophes, since both high 
levels of butanol and DMV are able to attenuate the initial and primed 
release of LH from hemisected pituitaries in vitro. It may therefore be that 
PLD is required as part of regulated secretory mechanism of pituitary 
gonadotrophs, and that the LHRH -stimulated activation of PLD can be 
augmented by high circulating levels of oestrogen at pro- oestrous as part of 
a general priming of the regulated secretory mechanism. 
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Figure 7.1 
LHRH -stimulated activation of PLD in al-3-1 cells following an 
LHRH prestimulus 
10 nM LHRH- stimulated activation of PLD over 30 min in cT3 -1 cells 
pretreated with LHRH (10 nM) for 15 min, 1 hr prior to the assay (a). This is 
compared to aT3 -1 cells which did not receive a prior LHRH stimulus, but 
were stimulated with LHRH (10 nM) for 30 min (b). Values are expressed 
as a % of the PLD activity in cells which were not prestimulated, with the 
basal level of [3H] PtdBut subtracted, and are means ± SEM from 4 -6 
separate determinations. The basal level of [3H] PtdBut accumulation in 
these experiments was approximately 2000 DPM, while in cells stimulated 













































Effect of steroid hormones on LHRH -stimulated activation of 
PLD in aT3 -1 cells 
LHRH- (100 nM) stimulated activation of PLD in aT3 -1 cells (over 30 min) 
grown in the absence of steroid hormones, or with the readdition of 
oestrogen (1 nM) 16 hrs prior to the assay, progesterone (200 nM) 3 hrs 
prior to the assay, or both oestrogen (1 nM) and progesterone (200 nM). 
The LHRH (100 nM) stimulated PLD activity in aT3 -1 cells grown in normal 
growth medium (section 2.3) is also shown. All results are expressed as a 
of the LHRH- stimulated PLD activity in aT3 -1 cells grown in the absence 
of steroid hormones, and are means ± SEM of 4 -6 separate determinations 
( *p <0.05). The basal levels of PLD were constant for all of the conditions 
used. The basal level of [3H] PtdBut accumulation in these experiments 
was approximately 2000 DPM, while in cells stimulated with LHRH (100 






















































































































































The effect of butan -1 -ol on LHRH- induced LH release from pro - 
oestrous rat hemipituitaries 
Control treatments were incubated for consecutive hours in the presence of 
medium only (basal), followed by consecutive periods (1st and 2nd hr) in 
the presence of LHRH (1 nM). Different concentrations of butan -1 -ol were 
used in order to assess the effect on the basal, 1st and 2nd hours of LH 
release. Points are the average release from 2 determinations, which 
















































































































































The effect of demethoxyviridin (DMV) on LHRH- induced LH 
release from pro- oestrous rat hemipituitaries 
Control treatments were incubated for consecutive hours in the presence of 
medium only (basal) followed by consecutive periods (1st and 2nd hr) in 
the presence of LHRH (1 nM). A concentration range of DMV was used in 
order to assess the effect on the basal, 1st and 2nd hours of LH release. 


















































































































































The present studies show that the activation of PLD as a result of 
LHRH receptor -stimulation in T3 -1 cells proceeds after a delay of 5 -10 
min, and does not desensitise within 40 min. It was also found that the 
PDBu -stimulated activation of PLD proceeded after a similar delay, but then 
appeared to desensitise over a period of 10 -15 min. 
The results presented provide strong evidence for an obligatory 
involvement of PKC in the LHRH- stimulated activation of PLD in T3 -1 
cells, with a slightly lower sensitivity to bisindolylmaleimide PKC inhibitors 
than seen for the inhibition of the PDBu -stimulated PLD activity in the same 
cell type, indicating the possible involvement of a phorbol- insensitive 
isoform of PKC, such as PKC Ç. This does not signify that PKC necessarily 
brings about PLD activation through a direct phosphorylation, indeed it is 
likely that there are other components to the activation process downstream 
of PKC. It is apparent that the LHRH receptor is coupled to the downstream 
signalling machinery, leading to PLD activation, through a pertussis toxin 
insensitive G protein, possibly a member of the Gq family of heterotrimeric G 
proteins (Milligan, 1988). It is also possible that a low molecular weight G 
protein, such as ARF may also be involved in the LHRH- mediated activation 
of PLD, since an inhibitor of the ARF guanine nucleotide exchange factor, 
brefeldin A, was able to attenuate LHRH -stimulated PLD activity. It is 
interesting that additivity was observed in the PLD responses when 
stimulated by both LHRH and PDBu, suggesting that these two stimuli are 
able to activate PLD through different pathways, further implicating a PKC 
isoform which is not phorbol ester -activated in the LHRH -stimulated 
pathway. 
There appears to be an involvement of non -receptor tyrosine kinases 
in the activation of PLD stimulated by LHRH, since this response was 
potently blocked by inhibitors of protein- tyrosine kinases. In contrast PDBu- 
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stimulated PLD activity was not blocked by tyrosine kinase inhibitors at 
equivalent low concentrations. There was no apparent inhibition of the 
pervanadate- stimulated PLD activity by selective inhibitors of PKC; a 
possible explanation being that a non -receptor tyrosine kinase is involved 
downstream of PKC, and that PKC is able to bring about the activation of 
the tyrosine kinase, as has been proposed in the case in thrombin - 
stimulated human platelets, where PKC phosphorylation of c -src has been 
proposed to increase the substrate affinity of c -src (Liebenhoff et al, 1993). 
The fact that PKC inhibitors and the tyrosine kinase inhibitors, genistein and 
piceatannol totally inhibited the LHRH -stimulated PLD activity does 
indicate, although not conclusively, that tyrosine kinases and PKC are 
involved in the same pathway, with the non -receptor tyrosine kinase being 
downstream of PKC. It is possible that a low molecular weight G- protein 
might also be activated by non -receptor tyrosine kinases in aT3 -1 cells, as 
this has been previously demonstrated in other systems, possibly through 
the modulation of activating or inhibitory proteins (Downard, 1992; Manser 
et al, 1993, Gulbins et al, 1993). Low molecular weight G proteins have 
also been shown to be closely involved in the activation of PLD (Cockroft et 
al, 1994; Brown et al, 1993; Bowman et al, 1993), as well as possibly being 
involved in the activation of PLD in LHRH -stimulated aT3 -1 cells. Therefore 
it is possible that in aT3 -1 cells stimulated by LHRH, a phorbol ester - 
insensitive isoform of PKC is activated, which can then activate a non - 
receptor tyrosine kinase, which in turn activates a low molecular weight G 
protein, which then may be able to bring about the activation of PLD (Figure 
8.1). 
Both LHRH and PDBu appear to capable of inducing tyrosine 
phosphorylation in aT3 -1 cells, further indicative of there being a tyrosine 
kinase involved in LHRH -signalling mechanisms, downstream of PKC. It 
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was also demonstrated in this study that PDBu -stimulation of PLD activity 
was not attenuated by protein- tyrosine kinase inhibitors, in comparison to 
the LHRH -stimulated activation of PLD, suggesting that the PKC upstream 
of tyrosine kinase in the LHRH -stimulated pathway is not activated by 
phorbol esters. The major LHRH- and PDBu- induced tyrosine 
phosphorylations are seen on proteins of 70 -80 kDa and 110 -130 kDa. It 
has been demonstrated that the PDBu- induced tyrosine phosphorylations 
are almost totally blocked by the PKC inhibitor GF 109203X, while the 
tyrosine phosphorylation induced by LHRH can only be partially blocked by 
this PKC inhibitor (Johnson et al, 1994). This would suggest that not all the 
tyrosine phosphorylation induced by LHRH is dependent upon the 
activation of PKC. Raising the intracellular Cat+ concentration with the Cat+ 
ionophore ionomycin, reduced the level of tyrosine phosphorylation in T3- 
1 cells, probably through the activation of an unidentified Cat + -stimulated 
tyrosine phosphatase. 
It was shown that there are two members of the src- family of non - 
receptor tyrosine kinases detectable by western blotting in aT3 -1 cells; src 
and fyn. Using immunoprecipitation to partially purify fyn, it was 
demonstrated that prior LHRH -stimulation increased the phosphorylation of 
an exogenous denatured enolase substrate. It is possible that src and fyn 
may be involved in the LHRH -stimulated activation of PLD, although we 
have not studied the activation of any other non -receptor tyrosine kinase by 
LHRH. 
A natural reciprocal mutation appears to be present between the TM 
2 and TM 7 domains of the LHRH receptor (compared to the majority of 
other G protein -coupled receptors). Residue Asp 318 in TM 7, which is 
replaced by an Asn in this position in most other G protein -coupled 
receptors (Probst et al, 1992), appears to be an important factor in the lack 
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of desensitisation of the LHRH -stimulated activation of PLD. Mutating Asp 
318 to Asn and transient expression of this mutant cDNA in COS 7 cells, 
resulted in the LHRH -stimulated PLD activity having a higher initial rate, 
followed by complete desensitisation within 5 min. A double mutation of 
Asp 318 to Asn and Asn 87 to Asp in TM 2, which is reported to interact 
though hydrogen bonding with Asp 318 in TM 7 (Zhou et al, 1994), had the 
same result as the single mutation. It therefore appears that Asp 318 in TM 
7 is an important factor in the lack of desensitisation observed in the LHRH- 
stimulated activation of PLD, although the mutation of Asp 318 to Asn did 
not effect the non -desensitising hydrolysis of inositol phospholipids in the 
same cell type (R. Mitchell, unpublished observation). 
Protein kinase C appears to be involved in the LHRH -stimulated 
activation of PLD in CHO cells stably transfected with the wild type LHRH 
receptor, with a similar sensitivity to Ro 31 -8220 as was observed for the 
LHRH -stimulated activation of PLD in T3 -1 cells. The wild type LHRH 
receptor stimulated activation of PLD in CHO cells was unaffected by 
pertussis toxin, or by tyrosine kinase inhibitors, suggesting that tyrosine 
phosphorylation is not important for the activation of PLD by this route in 
CHO cells. 
It would appear that LHRH -stimulated PLD activity cannot be 
enhanced by a previous LHRH stimulus in T3 -1 cells, as is the case for the 
primed release of LH from the anterior pituitary (Aiyer et al, 1974b). 
However it was demonstrated that LHRH -stimulated PLD activity was 
reduced in T3 -1 cells grown in the absence of steroid hormones, and that 
the re- addition of oestrogen brought about a recovery in the LHRH- 
stimulated PLD response. Although the mechanism by which oestrogen 
modulates PLD activity is not known, it is possible that the level of 
expression of components of the signalling machinery, such as PKC, or 
145 
PLD itself are regulated by oestrogen. It may be that oestrogen- enhanced 
expression of components involved in the activation of PLD plays an 
important role in the increased level of responsiveness observed in the 
LHRH priming effect in pro- oestrous pituitaries, which appears to be 
dependent on an increase in the level of circulating oestrogen prior to the 
surge in LH release (Fink, 1988). Phospholipase D does not appear to be 
specifically involved in the primed release of LH from the anterior pituitary, 
since both butanol and DMV were able to inhibit the initial and primed 
release of LH in response to LHRH in vitro. 
The present study has examined the mechanism of PLD activation 
via the LHRH, G protein -coupled receptor, in a cell line derived from 
pituitary gonadotrophs. The exact physiological role of PLD in this and 
similar systems will be difficult to asertain until PLD has been characterised 
at molecular level, and the development of selective pharmacological and 
molecular probes has occured. 
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Figure 8.1 
Overview of the probable mechanism of activation of PLD by 
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SHORT TITLE: Protein kinase C and tyrosine kinases in phospholipase D activation 
SYNOPSIS 
The mechanisms of phospholipase D (PLD) activation by the luteinising hormone -releasing 
hormone (LHRH) receptor were investigated in the T3 -1 gonadotroph cell line. After a 5 -10 
min delay, LHRH- induced activation of PLD was detectable and continued unattenuated for 
up to 40 min. Phospholipase D activation by 4ß phorbol- 12,13 -dibutyrate (PDBu) also 
appeared only after a lag, but thereafter was attenuated within 10 min. LHRH- and PDBu- 
induced PLD activation was inhibited by down -regulation of protein kinase C (PKC) and by 
PKC inhibitors. However, Ro 31 -8220, GF 109203X and H7 showed lower potency on LHRH 
than on PDBu responses. Effects of the tyrosine kinase inhibitors lavendustin A, genistein 
and piceatannol implicated tyrosine phosphorylation in the PLD response to LHRH but not 
PDBu. Furthermore, the tyrosine phosphatase inhibitor pervanadate increased PLD activity. 
This response was, however, unaffected by Ro 31 -8220 (suggesting that PKC was not 
downstream of tyrosine phosphorylation in the mechanism), but was attenuated by 
ionomycin. Anti -phosphotyrosine immunoblots revealed both LHRH- and PDBu- induced 
tyrosine phosphorylation of a number of proteins, with bands at around 76 and 128 kDa being 
particularly prominent. lonomycin reduced the level of tyrosine phosphorylation below that 
seen in unstimulated cells. LHRH- induced activation of PLD in T3 -1 cells thus appears to 
involve both tyrosine kinases and PKC; distinct isoforms of PKC acting at separate sites may 
contribute to receptor- induced PLD activation. 
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INTRODUCTION 
Phospholipase D (PLD) is a phospholipid- hydrolysing enzyme (EC 3.1.4.4.) whose main 
substrate is phosphatidylcholine (PtdCho),the principal phospholipid in mammalian cells[1, 2, 
3, 4]. The products of the action of PLD on PtdCho are phosphatidic acid (PtdOH) and 
choline[4]. Phosphatidic acid can be further hydrolysed to diacylglycerol (DAG) by the 
enzyme phosphatidate phosphohydrolase (EC 3.1.3.4.) [2]. 
Diacylglycerol (DAG) derived from the hydrolysis of phosphatidylinositol 4,5- 
bisphosphate (PtdInsP2) by phospholipase C (PLC) can lead to the activation of protein 
kinase C (PKC) [4, 5, 6], although it is not entirely certain that DAG resulting from PLD - 
mediated hydrolysis of PtdCho is similarly effective. Nevertheless it has been suggested that 
PLD -generated DAG may be responsible for a sustained activation of PKC, since the kinetics 
of such DAG accumulation are prolonged, compared to DAG generated from PtdInsP2 by the 
action of PLC [4]. Since the consensus composition of the fatty acid side chains is different 
in DAG derived from PtdCho compared to PtdInsP2 [7] this may conceivably influence its 
effectiveness at activating PKC, perhaps making it more selective for certain PKC isoforms. 
There is evidence from several cell types that G- proteins [4, 8], PKC [4, 8, 9], Cat+ [4, 
10, 11 ] and tyrosine phosphorylation [4, 10, 12, 13] can be involved in the receptor -linked 
activation of PLD. This may indicate a general versatility of the enzyme, in being able to be 
activated by a large number of biochemical signalling pathways, or it is possible that multiple 
PLD isoforms exist, each activated by a different pathway. 
In the present study we have investigated the activation of PLD in the aT3 -1 cell line, 
which is a clonal pituitary gonadotroph cell line that was obtained by targeted oncogenesis in 
transgenic mice [14]. By assessing the generation of the stable product, phosphatidylbutanol 
(PtdBut), that is produced by PLD in the presence of butan -1 -ol, we have been able to study 
the kinetics of PLD activation by luteinising hormone -releasing hormone (LHRH) and the 
effect of various pharmacological agents on the activation process. Previous studies have 
established clearly that LHRH can activate PLC -mediated phosphoinositide hydrolysis and 
mobilise calcium from intracellular and extracellular locations [15, 16], whilst there is now 
increasing evidence that activation of both phospholipase A2 (PLA2) and phospholipase D 
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(PLD) mediated pathways can also occur in pituitary cells as a consequence of LHRH 
stimulation [9, 17]. 
EXPERIMENTAL 
Materials 
[9,10 -3H]- Palmitate (60 Ci/ mmol) was obtained from NEN Du Pont de Nemours, 
Germany. Ro 31 -8220 was a gift from Roche Products Ltd, Welwyn, Herts, UK. lonomycin , 
4ß- phorbol 12,13 -dibutyrate (PDBu), LHRH and the LHRH antagonist ([Ac- D- p- Cl- Phe1,2, D- 
Trp3,D- Arg6,D- A1a10] -LHRH) were obtained from Sigma Chemical Co, Poole, Dorset, UK. 
The LHRH receptor agonist, buserelin, ([D- Ser(tBu)6, DesGly10] -LHRH ethylamide) was 
obtained from Hoechst, Milton Keynes, Bucks. Lavendustin A, 1-(5-Isoquinolinesulphonyl)-2- 
methylpiperazine (H7), genistein and GF 109203X were obtained from Calbiochem- 
Novabiochem, Nottingham, UK. Piceatannol was obtained from Boehringer- Mannheim UK, 
Lewes, East Sussex. All other laboratory reagents were Analar grade from BDH, Merck Ltd, 
Poole, Dorset, UK. 
Cell Culture 
The aT3 -1 cells were cultured in Dulbecco's modified Eagle medium with 0.11 g/I Na 
pyruvate (pyruvate -DMEM; Gibco BRL, Paisley, Scotland, UK), containing 10% foetal calf 
serum, penicillin/ streptomycin (100 U/ ml each) and 2 mM L- glutamine [14]. The cells were 
quiesced in serum -free pyruvate -DMEM for approximately 24 hours prior to the experiments. 
Phospholipase D assays were carried out in 12 well tissue culture plates (Costar). 
Assay of Phospholipase D Activity 
In order to label the phosphatidyl moiety of PtdCho, cells were incubated for 2 h with 
[3H] palmitate (5 pCi/ ml, 1 ml in each well) in minimal essential medium (MEM; Gibco BRL), 
at 37 °C under 5% CO2 /95% 02. Cells were washed twice with warm MEM containing 1% 
fatty acid free BSA (Sigma), then 1 ml warm MEM containing 0.5% fatty acid -free BSA was 
added to each well. Butan -1 -ol was added to each to give a concentration of 30 mM (since 
previous experiments in this and other laboratories have shown that this concentration of 
butan -1 -ol provides optimal production of [3H]PtdBut, without adverse effects on cell viability 
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as assessed by trypan blue exclusion [18]). Various inhibitory drugs were added, 
immediately before adding the stimulating agent which was present for 30 min, unless 
otherwise stated. Reactions were terminated by removal of the 1 ml of medium and addition 
of 0.5 ml ice -cold methanol. Cells were then scraped out of wells and transferred to a 2 ml 
screw -top glass vial (Chromacol Ltd, Mundells Industrial Centre, Welwyn Garden City, Herts, 
UK). Chloroform was added to give a chloroform/ methanol ratio of 1:1. Tubes were mixed 
and left for 15 min, before distilled water was added to give a chloroform/ methanol/ water 
ratio of 1:1:0.8. The vials were shaken vigorously and centrifuged for 5 min to separate the 
two phases. The top aqueous phase was carefully aspirated and discarded while the lower 
organic phase was left in the vial and dried under vacuum in a centrifugal evaporator 
(Gyrovap; V.A. Howe, Banbury, UK) for approximately 50 min at 30 °C. Once the lower 
organic phase had evaporated the residue was resuspended in 50 µl chloroform/ methanol 
(19:1) and then spotted onto Whatman LK5D thin layer chromatography plates with pre - 
scored lanes (silica 250 µm). The plates were developed using the organic phase of a 
mixture: ethyl acetate /2,2,4 -trimethylpentane /acetic acid /water (110:50:20:100). In this 
system, PtdBut (Rf = 0.3) is well separated from PtdOH (Rf = 0.1), major phospholipids (Rf = 
0) and neutral lipids (Rf = 0.7- 0.95). The region containing PtdBut, and corresponding to a 
[14C]PtdBut standard (gift from R. Randall, Wellcome Research Laboratories, Kent, UK) was 
scraped off the plate and counted by liquid scintillation counting. 
Preparation of Pervanadate 
Sodium orthovanadate was added to divalent cation -free Earle's balanced salt solution 
containing HEPES (30 mM) to a final concentration of 5 mM. The pH was adjusted to 7.4 
with NaOH, then H202 (1 M) was added to give a concentration of 1 mM and the solution was 
then left for 15 min before 4 mg of catalase (Sigma) was added to remove excess H202. The 
solution remained clear throughout the above procedure. 
Antiphosphotyrosine Immunoblotting 
Confluent cultures of T3 -1 cells were incubated with the LHRH receptor agonist buserelin 
(100 nM; [D- Ser(tBu)6, DesGly10] LHRH ethylamide), 300 nM PDBu, 30 µM ionomycin 
or 
saline (control). Reactions were terminated after 20 min by scraping cells into a buffer 
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containing 20% (w /v) sodium dodecyl sulphate and 5% (v /v) 2- mercaptoethanol, then heating 
to 100 °C for 5 min. Cellular proteins were separated on 7.5% homogeneous microgels which 
were run on a PhastSystem electrophoresis apparatus (Pharmacia, Milton Keynes, Bucks, 
UK), then electroblotted onto Immobilon -P membranes (Millipore, Watford, Herts, UK). The 
membranes were then probed with the 4G10 monoclonal antibody (Upstate Biotechnology 
Incorporated, TCS Biologicals, Botolph Claydon, Bucks, UK), which recognises 
phosphotyrosine, or with antibody blocked with 1 mM o- phospho -L- tyrosine (Sigma). An 
HRP- labelled secondary antibody (Scottish Antibody Production Unit, Carluke, Lanarks, UK) 
and enhanced chemiluminescence (ECL; Amersham International plc, Little Chalfont, Bucks, 
UK) were employed to visualise antibody binding. 
Data analysis 
All concentration -response curves were analysed by a non -linear, error -weighted 
direct fitting program, modelling on Hill kinetics (P.fit, Elsevier Biosoft, Cambridge). 
RESULTS 
The production of [3H]PtdBut in aT3 -1 cells incubated with LHRH for 30 min showed a 
marked increase over the very low levels in control cells and clear concentration dependence 
(Figure la). Under these conditions, the EC5Ó for PLD activation by LHRH was 16 ± 5 nM 
and reached a maximum by approximately 100 nM. A concentration of 100 nM LHRH was 
therefore used in most of the other experiments in this study, in order to elicit a large (but not 
supra maximal) PLD response. 
The time course (up to 40 min) of [3H]PtdBut accumulation elicited by LHRH (100 nM) 
or PDBu (1 µM) is shown in Figure 1 b. In the LHRH -stimulated cells there was a lag of 
between 5 and 10 min before [3H]PtdBut production could be detected. The rate of 
[3H]PtdBut accumulation appeared to be approximately constant between 5 and 40 min. In 
PDBu- stimulated cells there was an even longer lag of between 10 and 15 min before 
[3H]PtdBut levels were detectable. The activation of PLD by PDBu appeared to occur at a 
rate comparable to the LHRH -stimulated activity only for around 10 min before the rate of 
[3H]PtdBut accumulation declined. Thus at all times, especially the longer time points, PDBu 
(1 µM) caused a much lower level of [3H]PtdBut accumulation than LHRH (100 nM). 
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The LHRH receptor antagonist [ Ac- D- p- CI- Phe1,2,D- Trp3,D- Arg6,D- AIa10] -LHRH (1 .iM) 
[19], completely prevented activation of PLD by LHRH (100 nM); whilst the antagonist itself 
caused no detectable activation of PLD. The biologically- inactive phorbol ester isomer, 4a- 
phorbol 12,13 -dibutyrate (4a -PDBu, 1µM) [20] elicited no increase in PLD activity at a 
concentration of 1 µM. The Cat+ ionophore, ionomycin [21] (30 µM) caused no significant 
activation of PLD by itself, although it did slightly augment the PDBu -stimulated PLD activity 
(Table 1). A combination of LHRH (100 nM) and PDBu (1 µM) elicited approximately additive 
levels of [3H]PtdBut production (Table 1), even though the large accumulation due to 100 nM 
LHRH was maximal on its own concentration -response curve. To address the possibility that 
the lag in [3H]PtdBut production was due to a requirement for protein synthesis in the 
mechanism of PLD activation, experiments were carried out in the presence of cycloheximide 
(30 µM), but this clearly had no effect on LHRH- induced PLD activity (Table 1). 
In order to assess the role of PKC in LHRH- induced PLD activation, we utilised two 
approaches; firstly employing a number of selective PKC inhibitors and secondly, down - 
regulating the PKCs in aT3 -1 cells by prolonged preincubation with a phorbol ester [22] prior 
to LHRH stimulation. Over a 30 min incubation with LHRH (100 nM), the selective 
bisindolylmaleimide PKC inhibitor Ro 31 -8220 [23] completely inhibited the evoked PLD 
activity with an IC50 of 460 ±180 nM (Figure 2a). In cells stimulated for 30 min with PDBu (1 
µM), Ro 31 -8220 again completely inhibited PLD activity but with an IC50 of 62 ±30 nM (Figure 
2b). Another highly -selective bisindolylmaleimide PKC inhibitor GF 109203X completely 
inhibited PLD activity stimulated by LHRH (100 nM), with an IC50 of 1.0 ± 0.2 µM (Figure 2c), 
PDBu- induced PLD activity was more potently inhibited by GF 109203 X, with an IC50 of 161 
± 19 nM (Figure 2d). This represents an approximately eight fold greater potency of Ro 31- 
8220 and GF 109203 X when PDBu was used as a stimulus instead of LHRH. A PKC 
inhibitor of another structural class, 1 -(5- isoquinolinyl sulphonyl) -2- methyl- piperazine (H7) 
[24] inhibited LHRH induced PLD activation with an IC50 of 232 ± 25 nM (Figure 2e). The 
slope factor of the concentration -inhibition curve (1.27 ± 0.15) was consistent with a single 
component to the inhibition. However in cells stimulated with PDBu (1 µM) (Figure 2f), H7 
inhibited the response over a very wide concentration range (slope factor = 0.56 
± 0.05). 
This is consistent with multiple components being involved in the inhibition. The 
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concentration -inhibition curve gave a much better fit to a 2 component Hill equation than to a 
one site model with component parameters of IC50(i) = 12.5 ± 1.9 µM (45% of sites) and 
IC50(ii) = 635 ± 85 µM (55% of sites). Down -regulation of PKC isoforms over a 24 hour 
period using 300 nM PDBu resulted in a major attenuation of the LHRH- and PDBu- induced 
PLD activation (82 ± 9% and 72 ± 5 %, n =4), no change was seen in the basal [3H]PtdBut 
accumulation. 
In order to assess whether tyrosine phosphorylation was involved in LHRH signalling 
and in PLD activation in this pathway, we used a number of compounds known to inhibit or 
enhance cellular tyrosine phosphorylation and employed anti -phosphotyrosine 
immunoblotting to determine tyrosine phosphorylation of cellular proteins in response to 
stimulation. Over a 30 min stimulation with LHRH (100 nM) the highly selective tyrosine 
kinase inhibitor lavendustin A [25] inhibited approximately 60% of the PLD response with an 
IC50 of 133 ± 17 nM (Figure 3a). Even at concentrations up to 20 µM, lavendustin A caused 
no further inhibition of PLD. Lavendustin A had no effect on PLD activity elicited by 30 min 
stimulation with PDBu (1 µM) (Figure 3b). Another tyrosine kinase inhibitor, piceatannol [26] 
also inhibited LHRH- induced PLD activity with an IC50 of 35 ± 5 µM (Figure 3c). Piceatannol 
also caused some inhibition, albeit with lower potency, of PDBu -stimulated PLD activity, with 
an IC50 of 155 ± 50 µM (Figure 3d). A further tyrosine kinase inhibitor, genistein [27] inhibited 
the LHRH- induced PLD activity with an IC50 of 92 ± 34 µM (Figure 3e), whilst causing only 
minor inhibition of PDBu- induced PLD activity (Figure 3f). 
Pervanadate, the peroxide of the tyrosine phosphatase inhibitor vanadate, is reported 
to elevate levels of tyrosine phosphorylation, presumably by inhibiting tyrosine phosphatases 
and unlike vanadate is cell -permeable allowing it to be used in whole cell assays [28, 29]. 
Pervanadate (1 mM) was able to induce PLD activation over a 30 min period to a level similar 
to that evoked by PDBu (1 µM). Pervanadate and PDBu had an additive effect on [3H]PtdBut 
accumulation, whereas ionomycin substantially blocked the PLD response elicited by 
pervanadate. The PKC inhibitor Ro 31 -8220 (1 µM) was ineffective at blocking pervanadate- 
induced PLD activity (Table 1). 
When protein -tyrosine phosphorylation in aT3 -1 cells was investigated by 
immunoblotting with an antibody which recognised phosphotyrosine, the LHRH- receptor 
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agonist, buserelin ([D- Ser(tBu)6,DesGly1(] -LHRH ethylamide), was observed to induce 
tyrosine phosphorylation on many proteins of molecular mass -60 to >170 kDa, but 
especially notable was a broad band at around 128 kDa and a diffuse band at around 76 kDa 
(Figure 4) whose phosphorylations were maximal within 10 min. By varying exposure 
conditions during development of the immunoblot reaction, it could be seen that each of 
these bands consisted of at least 2 proteins. Similar phosphorylations of protein- tyrosine 
were also evident with PDBu (Figure 4), but 30 µM ionomycin reduced the level of 
phosphorylation below that observed in control cells, indicating that the effects of buserelin 
and PDBu were not mediated by alterations in intracellular Cat +. 
DISCUSSION 
The results of the present study indicate that LHRH brings about the activation of PLD in 
T3 -1 cells by a process involving both PKC and a tyrosine kinase, that does not require 
protein synthesis, and cannot be mimicked to any significant degree simply by elevation of 
cytosolic Cat+ levels. 
Despite being clearly coupled via G- proteins to phosphoinositide hydrolysis, the LHRH 
receptor is an atypical member of the family of such receptors since it lacks an extended C- 
terminus [30]. There is evidence that phosphorylation of the C- terminal tail of several G- 
protein linked receptors contributes importantly to receptor desensitisation [31]. Therefore 
the lack of a C- terminal tail on the LHRH receptor may be an important factor in the complete 
lack of desensitisation seen in the PLD response to LHRH over the 40 min time course used 
in this study (Figure 1 b). 
LHRH- induced PLD activation proceeded after a lag of about 5 min (Figure 1 b). This 
result is similar to that of a previous study carried out on aT3 -1 cells, in which it was 
proposed that PLD activation required a particularly high receptor occupancy; dictating a lag 
before PLD activity could be detected [32]. However our observation of an even more 
pronounced lag in activation by PDBu suggests that the delay is mainly due to some factor 
other than the rate of receptor occupation by an agonist. Our experiments with 
cycloheximide indicate that the lag in activation of PLD by LHRH is not due to the synthesis 
of an intermediary activating protein. 
9 
It is unclear why the mechanism through which PDBu causes activation of PLD 
becomes so markedly attenuated after 10 min of activity, although it is known that even quite 
short incubations of cells (including cxT3 -1 cells) with high concentrations of phorbol esters 
lead to down -regulation of many PKC isoforms [33], and as has been previously shown, 
phorbol esters will have a more profound down -regulatory effect than agonists of cell surface 
receptors [34]. The delay before PDBu caused PLD activation compared to LHRH is also 
unexplained. It is of course possible that PDBu is activating isoforms of PKC not normally 
involved in the LHRH receptor activation of PLD, or that a different isoform of PLD may be 
activated through the PDBu -stimulated pathway. The additive effect of LHRH and PDBu on 
the PLD response supports the theory that these two stimuli do use different biochemical 
pathways, at least to some degree, in order to bring about the activation of PLD. 
Increasing the concentration of intracellular calcium with ionomycin was not sufficient 
by itself to activate PLD. Furthermore ionomycin was not able to potentiate to any great 
extent the PLD response elicited by PDBu. Both a and 131 isoforms of PKC have been 
implicated in PLD activation in different systems [35, 36, 37], so it is entirely possible that 
they are also involved here, as LHRH receptor activation increases intracellular calcium 
levels within the cells [16, 38] which could contribute to activation of such Cat + -dependent 
PKC isoforms. Some studies on PLD have concluded that Cat+ is essential for PLD 
activation [10], but interestingly a recent report has described inhibition by Cat+ of guanosine 
5'- 0- (3- thiotriphosphate) -induced PLD activation in permeabilised NG 108 -15 neuroblastoma 
X glioma cells [39]. 
The present results provide strong evidence for an obligatory role of PKC in LHRH- 
induced activation of PLD, since this response was greatly attenuated by PKC down - 
regulation and fully blocked by selective PKC inhibitors. The bisindolylmaleimide PKC 
inhibitor Ro 31 -8220 was about eight times more potent against PDBu- induced PLD 
activation than against LHRH- induced PLD activation. Similar results have been reported for 
bombesin- induced PLD activation in Swiss 3T3 cells [9]. Since all phorbol ester -sensitive 
PKC isoforms are likely to be activated by the relatively high concentration of PDBu used (1 
PM), it is possible that a form of PKC relatively resistant to Ro 31 -8220 may be activated in 
response to LHRH, compared to the consensus of those activated by PDBu. It has 
been 
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reported that a bisindolylmaleimide related to Ro 31 -8220 shows selectivity for the Cat+ - 
dependent PKCs compared to PKC E [40]. We have shown previously that aT3 -1 cells 
express a, E and isoforms at high levels [41]. Evidence has been provided both for and 
against a role for PKC E in receptor- evoked PLD activation [42, 43] Interestingly, the atypical 
Cat + -independent isoform, PKC Ç does not have a phorbol ester binding domain; and is not 
activated by phorbol esters , it also shows a relative resistance to bisindolylmaleimides and 
related indolocarbazoles compared to other PKC isoforms [44]. Whilst the relatively high 
potency of Ro 31 -8220 and GF 109203X on LHRH responses does suggest that some form 
of PKC is involved, it is of course possible that an unknown kinase (other than a PKC 
isoform) with some sensitivity to bisindolylmaleimides is mediating LHRH responses. 
Another PKC inhibitor H7 also inhibited both the LHRH and PDBu- induced increases 
in PLD activity. LHRH- induced PLD activity was inhibited in a monophasic fashion, 
suggesting either that only one PKC isoform is involved, or that all the ones that are involved 
have the same low sensitivity to H7. Compared to the potency of inhibition of various PKC 
isoforms by H7 in cell -free assays, the LHRH- induced PLD activity and one of the two 
components to PDBu -induced PLD activity were insensitive to H7; in particular PKCs a -'y 
and E are known to be sensitive to inhibition by H7 [45]. It has been reported that there is a 
distinct H7- resistant form of PKC in the rat anterior pituitary gland, that may represent either 
a novel or modified PKC isoform, although it is clear that this species is phorbol ester - 
activated and can be clearly separated from PKC - by ion -exchange and hydroxyapatite 
chromatography [46]. It is a possibility that this species of PKC is involved in the pathway of 
PLD activation by LHRH. There appear to be multiple components to the inhibition by H7 of 
PDBu- evoked PLD activity. Interestingly this suggests that PLD activation by stimulation with 
phorbol esters involves more than one isoform of PKC, and whilst it has already been shown 
using overexpression studies that the Cat + -dependent PKC isoforms a and ß1 are potentially 
involved in PLD activation [36, 37] it now seems likely that further species of PKC can also 
contribute. 
As well as PKC, our results strongly suggest the involvement of tyrosine 
kinases in the 
activation of PLD by LHRH. Similar results indicating the concurrent involvement 
of PKC and 
tyrosine kinases in receptor activation of PLD have recently been reported 
in the response to 
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endothelia -1 of A10 vascular smooth muscle cells [13]. In our experiments lavendustin A 
was able to inhibit with high potency the majority of the LHRH- induced PLD response, 
leaving a residual PLD activity that was unaffected by further elevating the lavendustin A 
concentration. The portion of the LHRH- induced response insensitive to lavendustin A may 
represent a separate pathway of PLD activation. Lavendustin A had no effect on the PDBu- 
induced PLD activity; raising the possibility that PDBu utilises the same pathway as the 
lavendustin A- insensitive portion of the LHRH response. However both LHRH and PDBu 
responses were fully sensitive to PKC inhibitors; consistent with the idea that the lavendustin 
A- sensitive, presumably PDBu- insensitive component of LHRH action may be mediated by a 
PDBu- insensitive PKC isoform, such as Ç. In a mixed micelle assay of PKC activity on 
isoforms from midbrain cytosol, there was no evidence that lavendustin A (10 µM) could 
inhibit either PDBu -evoked or basal activity which appears to include PKC Ç under these 
conditions [41; our own unpublished observations]. Another tyrosine kinase inhibitor, 
piceatannol was able to inhibit completely the LHRH- evoked PLD activity, but also affected 
PDBu- induced PLD activity at a much higher concentration, so its additional effect may 
therefore be non -specific. The tyrosine kinase inhibitor genistein also displayed greater than 
10 fold selectivity towards LHRH- induced PLD activation, compared to the PDBu- induced 
response, where only minor inhibition was observed at the highest concentration tested. 
The peroxides of vanadate have been shown to be potent enhancers of tyrosine 
phosphorylation in intact cells, and in this study pervanadate (1 mM) caused marked 
stimulation of PLD activity, supporting the evidence that tyrosine phosphorylation participates 
in the pathway of PLD activation in aT3 -1 cells. Pervanadate- induced PLD activation was 
unaffected by the PKC inhibitor Ro 31 -8220, making it unlikely that the tyrosine kinase step 
can be upstream of PKC in the activation pathway of PLD activation. The additive effect on 
[3H]PtdBut accumulation of co- stimulation with pervanadate and PDBu points towards a 
necessity for both a tyrosine kinase and PKC for maximal activation of PLD. Interestingly, 
ionomycin drastically reduced the PLD activation elicited by pervanadate, as indeed it 
prevented LHRH agonist- induced tyrosine phosphorylation of aT3 -1 cell proteins (Figure 
4), 
consistent with the Cat + -induced activation of tyrosine phosphatases. The effects of Cat+ on 
tyrosine phosphorylation may depend on cell type since an increase in intracellular Cat+ 
has 
12 
been reported to increase tyrosine kinase activity in angiotensin -II stimulation of GN4 liver 
epithelial cells [47], whereas in Swiss 3T3 cells depletion of intracellular Cat+ did not affect 
lysophosphatidic acid (LPA)- induced tyrosine phosphorylation [48]. In contrast, PKC rather 
than Cat+ appears to be a necessary (though not solely sufficient) intermediary in endothelin- 
1 stimulated tyrosine phosphorylation and mitogenesis in kidney glomerular mesangial cells 
[49]. Interestingly, elevation of Cat+ levels in epidermal keratinocytes leads to activation of c- 
src through a mechanism involving tyrosine dephosphorylation (consistent with Cat+ - 
activation of a tyrosine phosphatase) but leads concomitantly to the inactivation of the related 
c -yes tyrosine kinase activity [50]. 
Since many of the tyrosine phosphorylations induced here by LHRH could also be 
elicited by PDBu (Figure 4), it is possible (if there is only one tyrosine kinase step involved) 
that LHRH and PDBu can both activate this component. The protein- tyrosine 
phosphorylations induced in aT3 -1 cells by the LHRH- receptor agonist, buserelin, appear 
remarkably similar to those induced by lysophosphatidic acid (LPA), bombesin and 
endothelin in Swiss 3T3 cells and in Rat -1 fibroblasts, with proteins of 70 -80 kDa and 110- 
130 kDa being the main phosphorylation targets [48, 51, 52]. In each of the above cases, as 
well as in the present study, the administration of a phorbol ester appears to induce protein - 
tyrosine phosphorylations similar to those observed with the ligands. In Swiss 3T3 cells 
however, it seems unlikely that any typical PKC directly mediates the receptor- induced 
tyrosine phosphorylation since neither prolonged exposure to phorbol ester (which induces 
PKC downregulation) nor administration of GF109203X were able to inhibit this response 
[48]. PDBu- induced activation of PLD was largely unaffected by tyrosine kinase inhibitors, 
suggesting that although PKC activation of tyrosine phosphorylation clearly can occur, PDBu- 
induced activation of PLD does not rely on an intermediary tyrosine kinase, but occurs in 
parallel through a direct route. 
PDBu- induced activation of PLD rapidly becomes desensitised, consistent with the 
activator -induced down -regulation of PDBu- sensitive PKC isoforms [53]. In contrast, 
although blocked by selective PKC inhibitors, LHRH -induced PLD activation showed 
no 
desensitisation through 40 min; suggesting that a PKC isoform resistant to down 
-regulation 
(Perhaps ) was involved. It is thus feasible that a tyrosine kinase (activated 
by the LHRH 
13 
receptor through PKC -like species, and perhaps additionally by PDBu- sensitive PKCs such 
as a and ß) can lead to PLD activation. Agonist activation of the LHRH receptor may lead to 
activation of the former pathway (through a PKC t -like species), whereas PDBu stimulation is 
likely to lead largely to the triggering of the latter pathway. It is of course possible that other 
more complex mechanisms may be responsible for the results observed, in fact the loss of 
the vast majority of LHRH- induced PLD activation following down -regulation of PDBu- 
sensitive PKCs may count against the major involvement of a PDBu- insensitive PKC such as 
ç Nevertheless, since the PKC down -regulation protocol involves intense activation of 
PDBu- sensitive isoforms in the initial stages which could lead to profound secondary effects 
within the cell, the interpretation of the down -regulation result must require a degree of 
caution. 
The question remains as to which tyrosine kinase or kinases are involved in the LHRH 
receptor activation of PLD. Since the LHRH receptor is a classical G- protein linked receptor, 
with no tyrosine kinase domain, downstream involvement of non -receptor tyrosine kinases 
clearly must occur. It has been reported that agonists that directly or indirectly activate PKC 
in platelets increase the activity of the c -src non -receptor tyrosine kinase [54] . Similarly 
another member of the src family of tyrosine kinases fgr, is activated in response to fMLP- 
stimulation in neutrophils [55], and c -src is also activated as a result of endothelin -1 receptor 
activation in mesangial cells [49] and of lysophosphatidic acid receptor stimulation in N1 E 
115 neuroblastoma cells [56]. Phospholipase D activity was shown to be elevated in BALB /c 
3T3 cells transformed by v -src (a constitutively active form of c -src) [57 ]. As src has been 
shown to be activated by G- protein linked receptors in previous studies, and also to bring 
about PLD activation, a member of the src family of non -receptor tyrosine kinases is 
currently the most likely candidate for the tyrosine kinase participating here in LHRH receptor 
signalling. 
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(a) Concentration -response curve for LHRH- induced activation of PLD (ie [3H]PtdBut 
accumulation) over a 30 min incubation. (b) Time course of PLD activation by LHRH 
(100 nM) and PDBu (1 µM). Values are means ± SEM from 4 -8 separate determinations. 
Typical basal dpm/ assay are 1000 -2000, with no increase in this basal activity over the time 
course. Error bars on some of the points are obscured by the point symbol. 
Figure 2 
The effects of protein kinase C inhibitors on stimulus- induced PLD activation. Concentration - 
dependent inhibition of responses to LHRH (100 nM; in a, c and e) and to PDBu (1 µM; in b, 
d and f) is shown for PKC inhibitors Ro 31 -8220 (a, b), GF 109203X (c, d), and 1 -(5- 
isoquinolinesulphonyl)-2- methylpiperazine H7 (e, f). Values are means ± SEM from 4 -8 
separate determinations. Curve fitting analysis indicated an unusually low Hill coefficient 
(0.56 ± 0.05; consistent with the contribution of multiple components) in the case of H7 
inhibition of PDBu- evoked PLD activity but not in other cases. Error bars on some of the 
points are obscured by the point symbol. 
Figure 3 
The effects of tyrosine kinase inhibitors on stimulus- induced PLD activation. Concentration - 
dependent inhibition of responses to LHRH (100 nM; in a, c and e) and PDBu (1 µM; in b, d 
and f) is shown for tyrosine kinase inhibitors, lavendustin A (a, b), piceatannol (c, d) and 
genistein (e, f). Values are the means ± SEM from 4 -8 separate determinations. Error bars 
on some of the points are obscured by the point symbol. 
Figure 4 
Anti -phosphotyrosine immunoblots of aT3 -1 cells, using the 4G10 anti -phosphotyrosine 
antibody. Lanes 1 and 8, control (saline); 3 and 6, the LHRH receptor agonist buserelin ([D- 
Ser(tBu)6, DesGlyi0] LHRH ethylamide; 100 nM); 2, PDBu (300 nM); 7, ionomycin (30 µM); 4 
and 5, buserelin- treated cells immunostained with phosphotyrosine -blocked antibody. 




% of control LHRH- induced 
[3H]PtdBut accumulation 
LHRH (100 nM) 
LHRH antagonist (1 µM) 
LHRH (100 nM) + LHRH-antagonist (1 µM) 
413-PDBu (1 µM) 
4a-PDBu (1 µM) 
lonomycin (30 µM) 
Pervanadate (1 mM) 
LHRH (100 nM) + 4ß-PDBu (1 µM) 
LHRH (100 nM) + cycloheximide (30 µM) 
4ß-PDBu (1 µM) + ionomycin (30 µM) 
Pervanadate (1 mM) + ionomycin (30 µM) 
Pervanadate (1 mM) + 413-PDBu (1 µM) 
Pervanadate (1 mM) + Ro 31-8220 (1 µM) 
100 ± 6 (8) 
0 ± 1 (4) 
1 ± 0.5 (4) 
54 ±4 (8) 
0 ± 1 (4) 
1 ± 0.4 (4) 
22 ±4 (8) 
131 ±9(4) 
98 ±4 (4) 
64 ± 4 (4) 
7 ±3(4) 
78 ±7 (4) 
21 ±4 (4) 
Effects of agents modifying various cellular signalling pathways on [3H]PtdBut accumulation 
in aT3 -1 cells. Values are the means ± SEM from the number of experiments indicated in 
parentheses. Neither cycloheximide nor Ro 31 -8220 had any effect on unstimulated 
[3H]PtdBut accumulation. 
17 














































































































































































































































































































O.OI_ 0.1 1 10 










































































































































































































































Piceatannol () -1000 
References 
Billah, M.& Anthes, J. C. (1990) Biochem. J. 269, 281-291 
2. Billah, M., Eckel, S., Mullmann, T.J., Egan, R.W., Siegel, M.I. (1989) J. Biol. Chem. 
264, 17069 -17077 
3. Van Blitterswijk, W. J., Hilkmann, H., De Widt, T.& Van der Bend, R. (1991) J. Biol. 
Chem. 266, 10344 -10355 
4. Billah, M. (1993) Current Opinion in Immunology 5, 114 -123 
5. Huang, K. (1989) Trends in Neurosciences 12, 425 -432 
6. Nishizuka, Y. (1992) Trends in Biochemical Sciences 17, 414 -417 
7. Pettitt, T.& Wakelam, M. (1993) Biochem. J. 289, 487 -495 
8. Bowman, E., Uhlinger, D.& Lambeth, J. (1993) J. Biol. Chem. 268, 21509 -21512 
9. Cook, S., Briscoe, C.& Wakelam, M. (1991) Biochem. J. 280, 431 -438 
10. Bocckino, S. B., Blackmore, P., Wilson, P.& Exton, J. (1987) J. Biol. Chem. 262, 
51309 -15315 
11. Purkiss, R.& Boarder, M. (1992) Biochem. J.287, 31 -36 
12. Uings, I. J., Thompson, N. T., Randall, R. W., Spacey, G. D., Bonser, R. W., Hudson, 
A. T.& Garland, L. G. (1992) Biochem. J. 281, 597 -600 
13. Wilkes, L., Patel, V., Purkiss, J.& Boarder, M. (1993) FEBS Lett. 322, 147 -150 
14. Windle, J., Weiner, R.& Mellon, P. (1990) Mol. Endocrinol. 4, 597 -603 
15. Andrews, W.& Conn, P. (1986) Endocrinol. 118, 1148 -1158 
16. Limor, R., Ayalon, D., Capponi, A., Childs, G.& Naor, Z. (1987) Endocrinol. 120, 497- 
503 
17. Dan -Cohen, H., Sofer, Y., Schwartzmann, M., Natarajan, R., Nadler, J.& Naor, Z. 
(1992) Biochem. 31, 5442 -5448 
18. Randall, R.W., Bonser R.W., Thompson, N.T., Garland, L. G (1990) FEBS Lett. 264, 
87 -89 
19. Neckola, M., Horvath, A., Ge, L., Coy, D.& Schally, A. (1982) Science 218, 160 -165 
20. Blumberg, P. M. (1980) Crit. Rev. Toxicol. 8, 153 -198 
21. Kaufmann, R., Taylor, R.& Pfeiffer, D. (1989) J. Biol. Chem. 255, 2735 -2739 
22. McArdle, C.& Conn, P. (1989) Meth. in Enzymol. 168, 287 -301 
18 
23. Davis, P. (1992) J. Med. Chem. 35, 994 -1001 
24. Hidaka, H., Inagaki, M., Kawamoto, S.& Sisaki, Y. (1984) Biochem. 23, 5036 -5041 
25. Hsu, C., Persons, P., Spada, A., Bednar, R., Levitzki, A.& Zilberstein, A. (1991) J. 
Biol.Chem. 266, 21105-21112 
26. Geahlen, R.& Mclaughlin, J. (1989) Biochem. Biophys Res. Comm. 165, 241 -245 
27. Akiyama, T., Ishida, J., Nagagawa, S., Ogawara, H., Watanabe, S., Itoh, N.& Fukami, 
Y. (1987) J. Biol. Chem. 262, 5592 -5593 
28. Fantus, G., Kadota, S., Deragon, G., Foster, B.& Posner, B. (1989) Biochem. 28, 
8864 -8871 
29. Kadota, S., Fantus, I., Deragon, G., Guyda, H.& Posner, B. (1987) J. Biol. Chem. 
262, 8252 -8256 
30. Tsutumi, M., Zhou, W., Millar, R., Mellon, P., Roberts, J., Flanagan, C., Dong, K., Gillo, 
B.& Sealfon, S. (1992) Mol. Endocrinol. 6, 1163 -1169 
31. Probst, W., Snyder, L., Schuster, J., Brosius, J.& Sealfon, S. (1992) DNA Cell Biol. 
11, 1 -20 
32. Netiv, E., Liscovitch, M.& Naor, Z. (1991) FEBS Lett. 295, 107 -109 
33. Johnson, M., Simpson, J.& Mitchell, R. (1993) J. Endocrinol. Invest. 16, 17 
34. Lutz, E. M., Mitchell, R., Johnson, M. S.& MacEwan, D. (1993) FEBS Lett. 316, 228- 
232 
35. Conricode, K., Smith, J., Burns, D.& Exton, J. (1994) FEBS Lett. 342, 149 -153 
36. Eldar, H., Ben -Av, P., Schmidt, U. -S., Livneh, E.& Liscovitch, M. (1993) J. Biol. 
Chem. 268, 12560 -12564 
37. Pai, J. -K., Pachter, J. A., Weinstein, I. B.& Bishop, W. R. (1991) Proc. Natl. Acad. 
Sci. (USA) 88, 598 -602 
38. Anderson, L., Milligan, G.& Eidne, K. (1992) J. Endocrinol. 136, 51 -58 
39. Liscovitch, M.& Eli, Y. (1991) Cell Regul. 2, 1011 -1019 
40. Wilkinson, S., Parker, P.& Nixon, J. (1993) Biochem. J. 294, 335 
41. Johnson, M., MacEwan, D., Simpson, J.& Mitchell, R. (1993) FEBS Lett. 333, 67 -72 
42. Pfeilschifter, J. & Huwiler, A. (1993) FEBS Lett. 331, 267 -232 
43. Kiss, Z. & Anderson, W.H. (1994) Biochem. J. 300, 751 -756 
19 
44. Martiny- Baron, G., Kazanietz, M., Mishak, H., Blumberg, P., Kochs, G., Hug, H., 
Marme, D.& Schachtele, C. (1993) J. Biol. Chem. 268, 9194 -9197 
45. Schapp, D.& Parker, D. (1990) J. Biol. Chem. 265, 7301 -7307 
46. Ison, A., Johnson, M., MacEwan, D., Simpson, J., Clegg, R., Connor, K.& Mitchell, R. 
(1993) Biochem. Soc. Trans. 21, 386s 
47. Huckle, W. R., Dy, R. C.& Earp, H. S. (1992) Proc. Natl. Acad. Sci. (USA) 89, 8837- 
8841 
48. Seufferlein, T.& Rozengurt, E. (1994) J. Biol. Chem. 269, 9345 -9351 
49. Simonson, M.& Hermar, W. (1993) J. Biol. Chem. 268, 9347 -9357 
50. Zhao, Y., Sudol, M., Hanafusa, H.& Krueger, J. (1992) Proc. Natl. Acad. Sci. (USA) 
89, 8298 -8302 
51. Hordijk, P., Verlaan, I., VanCorven, E.& Moolenaar, W. (1994) J. Biol. Chem. 269, 
645 -651 
52. Rankin, S.& Rozengurt, E. (1994) J. Biol. Chem. 269, 704 -710 
53. Hug, H.& Saare, T. (1993) Biochem. J. 291, 329 -343 
54. Liebenhoff, U., Brockmeier, D.& Presek, P. (1993) Biochem. J. 295, 41 -48 
55. Gutkind, J. S.& Robbins, K. C. (1989) Proc. Natl. Acad. Sci. (USA) 86, 8783 -8787 
56. Jalink, K., Eichholtz, T., Postma, F., van Corven, E.& Moolenar, W. (1993) Cell 
Growth and Differentiation 4, 247 -255 
57. Song, J.& Foster, D. A. (1993) Biochem. J. 294, 711 -744 
20 
INVOLVEMENT OF A NOVEL FORM OF PKC AND 
TYROSINE KINASE IN THE ACTIVATION OF PLD BY 
LHRH, Myles Fennell, James Simpson, Rory Mitchell, Neil Thompson* 
and Lawrie Garland *, MRC Brain Metabolism Unit, 1 George Square, 
Edinburgh and *Wellcome Research Laboratories, Langley Court, 
Beckenham, U.K. 
The aT3 -1 gonadotrope cell line was used to study signalling pathways 
associated with the LHRH receptor, including phospholipase D (PLD) 
and the src family of tyrosine kinases. [3H]palmitate was used to label 
membrane phospholipids and cells were incubated with butan -1 -ol 
(30 mM) in order to assay PLD activity as production of 
[3H]phosphatidylbutanol (PtdBut). PLD activation by LHRH (100 nM) 
proceeded with a lag of about 5 -10 min. After this the rate was 
approximately constant up to 40 min, which was the longest time point 
examined. In phorbol 12,13 -dibutyrate (PDBu) (1 .tM)- stimulated cells, 
activation of PLD occured after a delay of 10 -15 min, but had virtually 
stopped by 25 min. After a 30 min stimulation the accumulation of 
PtdBut was approximately 10 -fold and 4 -fold over basal for LHRH and 
PDBu respectively. Ionomycin (30 p.M) did not activate PLD. 
Ro 31 -8220 (a selective PKC inhibitor) inhibited PLD activity elicited by 
30 min incubations with PDBu or LHRH, displaying IC50s of 62 ± 30 nM 
and 460 ± 180 nM respectively. H7 inhibited PDBu- induced PLD 
activity in a manner that indicated there are multiple components to the 
inhibition. LHRH- induced PLD activation was inhibited with low 
potency by H7 with an IC50 of 240 ± 14 p.M. Another PKC inhibitor GF 
109203X also inhibited the LHRH- stimulated PLD activity with an IC50 
of 1 ± 0.1 .tM. The tyrosine kinase inhibitor lavendustin A inhibited 
approximately 70% of the PLD response co LHRH with an IC50 of i33 
17 nM. Lavendustin A (0.1 -3 p.M) had no effect on the response elicited 
by PDBu. Another tyrosine kinase inhibitor piceatannol also caused 
partial inhibition of LHRH- stimulated PLD at concentrations up to 
100 p.M. In addition, the tyrosine phosphatase inhibitor, pervanadate 
(1 mM) caused significant activation of PLD. LHRH was also shown by 
antiphosphotyrosine immunoblots to induce tyrosine phosphorylation of 
numerous proteins of molecular mass 63 to >170 kDa. A number of 
these phosphorylations were also elicited by PDBu but not by ionomycin. 
Phosphorylation of proteins >170 kDa increased continuously over 3 -60 
min, whereas other phosphorylations were maximal at 10 min. 
Immunoblotting experiments showed that aT3 -1 cells contain src and fyn 
(but not fgr, hck, lyn or yes) tyrosine kinases and preliminary results 
using an immunoprecipitation /kinase assay have shown that fyn is 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































UNCONVENTIONAL SIGNALLING BY THE LHRH RECEPTOR. R. Mitchell, 
M.S. Johnson, J. Simpson, P.J. Sim, W.B. Wolbers, M. Fennell and A.J. Ison. 
MRC Brain Metabolism Unit, University Department of Pharmacology, 
1 George Square, Edinburgh EH8 9JZ, Scotland 
The LHRH receptor is a member of the family of G protein -linked receptors 
coupled to hydrolysis of phosphoinositides. The dependence of LHRH- 
induced gonadotrophin secretion upon phospholipase C activity has however 
been questioned. In view of the unique ability of the LHRH receptor to elicit 
the phenomenon of self -priming, we have sought to define unconventional 
signals emanating from this receptor that may not be generated by other 
members of the receptor family. 
The phenomenon of LHRH self -priming is dependent upon an apparently 
novel species of PKC (with a pituitary- selective distribution) that we have 
partially purified and characterised. Amongst the cellular targets of a PKC 
with these properties are PLA2 and PLD. 
Signalling by means of tyrosine kinase and MAP kinase cascades is 
classically associated with growth factor receptors. Nevertheless we have 
shown that each of these is strongly activated by LHRH both in normal 
pituitary tissue and in the aT3 -1 gonadotroph cell line. LHRH- induced 
production of phosphotyrosine -immunoreactive proteins is mimicked in part by 
phorbol esters but not by ionomycin and is essential for LHRH- induced PLD 
activation and LH secretion. LHRH- induced MAP kinase activation correlates 
strongly with the ability of gonadotrophs to demonstrate self -priming and 
occurs through a PKC- dependent rather than Cat + -dependent or tyrosine 
kinase- dependent mechanism. Since MAP kinase is involved in the regulation 
of transcription, translation and cytoskeletal organisation, it is a strong 
candidate for a central role in the self -priming phenomenon which is reliant on 
the rapid induction of protein synthesis and cytoskeletal changes. 
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VNERGISTIC ACTIVATION OF PHOSPHOLIPASE D (PLD) IN PERMEABILIZED PLATELETS 
BY GTP(S1 ANrkPHORBOL ESTER OR BY GTP(SJ AND Cat ; CLOSE CORRELATION WITki SECRETION. 
J.R. Coorssen a d R.J. Haslam, Department of Pathology, McMaster University, Hamilton, 
Ontario, Canada t8.3Z5. 
Human platelets wereNkabeLled with 13lljarachidonate and (14Cjserotonin (5 -HT), 
electropermeabilized and incubated with GTP(SJ and /or phorbol 12- myristate 13- acetate 
(PMA) in the absence or presence of Ca2' (pCa > 9 or 6). PLD activity was determined 
from the accumulation of (3lljphesphatidate (PA) and [3H1phosphatidylethanol (PEt) in 
incubations without and with ethanol., respectively, and secretion from the release of 
5 -HT. At pCa > 9, CTP[SJ and PMA acted synergistically to stimulate the formation of 
either PA or PEt, but had little or no effect on (3llJdiacylglycerol (DAG) levels. 
Secretion correlated with PA or PEt formation and was partially inhibited by ethanol. 
BAPTA, a known inhibitor of Ca2'- independent secretion from permeabilized cells, 
suppressed PLD activity. At pCa 6, GTP(S) alone greatly stimulated PA, PEt and DAG 
formation; PMA had no effect on PA or PEt accumulatiótr, but inhibited that of DAG. 
These increases in PA were largely attributable to PLD actlty and those in DAG to 
the action of phospholipase C. Secretion correlated with PA an of DAG levels. The 
results indicate that in platelets, a G protein, protein kina e,.0 and Ca24 all 
contribute to the activation of PLD, and suggest that PA generated by PLD may act 
directly or indirectly to promote secretion. (Supported by MRC Grant MT -5626) 
LHRH ACTIVATES PHOSPHOLIPASE D BY A PKC- INDEPENDENT 
MECHANISM IN aT3 -1 CELLS. M. Fennell, E. Lutz, R. Mitchell, L. Garland', MRC Brain 
Metabolism. Unit, 1 George Square, Edinburgh, 'Wellcome Research Laboratories, 
Beckenham. 
The gonadotrophe- derived cell line, aT3 -1, was used as a model system to study signalling 
mechanisms in pituitary gonadotrophes. The induction of phospholipase D (PLD) activity in 
aT3-1 cells in response to phorbol 12,13- dibutyrate (PDBu) or LHRH was assessed. Cells 
were preincubated with 5 µdi /ml [9.10 -3H] palmitate for 2 hours. Butan -t -ol was used as 
the nucleophilic acceptor in the transphosphatidylation reaction carried out by PLD. 
Phosphatidylbutanol was separated by TLC and quantified by scintillation counting. 100 nM 
LHRH and 1 }.IM PDBu caused a similar level of PLD activation in aT3 -1 cells. The selective 
PKC inhibitor Ro31 -8220 was used to determine the involvement of PKC in PLD activation 
induced by PDBu and LHRH. Ro31 -8220 caused complete inhibition of PDBu stimulated 
PLD activity in aT3 -1 cells with an IC90 of 500 ± 80 nM, similar to the IC50 for Ro31 -8220 
on PKC activity in mixed- micelle histone IIIS phosphorylation assays (IC50 of 210 ± 20 nM). 
However, in LHRH- stimulated aT3 -1 cells, Ro31 -8220 (10 nM - 10 fiM) had no effect on a 
major proportion of the induced PLD activity. It would appear that LHRH is activating PLD 
(at least in part) via a PKC -independent mechanism in aT3 cells. 
DIFFERE IIAL TEMPORAL DEPENDENCY OF THE IGE- DEIi'F..NDENT DIACYIGLX ?OL (My) 
Ii?ODUCTION ON 'Y INE EINAti9E (TY) ACTIVA ICN IN RBL 2H3 uNsr mods s , P. in-, 
K -S. Huang3, G. W.iggani, J.P. Kochan , H. Kado- Fong, Repetto , S. 
Lid, W.J. - Fung3, and A.M. Gilfillanl. Depts. Pharmacology , Molecular 
Genetics 2, and Protein Bi Zahemistry3, Hoffmann -La Roche, Nutley', NJ 07110, USA. 
FcERI aggregation on the urface of mast cells re.Gults'in a biphasic increase in 
phosphatidic acid (PA) and L1AG\ production leading to protein kinase C activation 
and degranulation. TO disect ou specific signalling mechanisms, chimeric human 
FcERIc< receptors (see related ) were stably transfected into RBL 2113 cells. 
While aggregation of the wild type ptor leads to both phases of DAG production 
and TK activation, at least two cell lines`.8HA3 and 3/4A3) transfected with Chimer - 
ic receptors produced the initial ,phase of DAG production in the absence of TK 
activity. To support these findings, sensiti RBL 2H3 cells were triggered with 
'ITIP -OVA (long /m1) in the absende or presene of a TK inhibitor, tyrophostin 48 
TEI inhibited IgE- dependent phosphatidyldli+-le- specific phospholipase D 
(PC -PLD) activation and thé second, but not the initial, increase in DAG produc- 
tion. Taken together, the above results demonstrate thh.t,although the ;nit_ai in- 
crease in PA and DAG' production is independent of TK a tivation, the secondary 
increase in PA and- DAG production, which is dependent or" -PLD activation, is 
directly influemedAoy TI: activation. 
ieumanlsms as targets ror new arugs, `r 
London, September 1992, P10. 
PROTEIN KINASE C AND A TYROSINE KINASE ARE 
INVOLVED IN PHOSPHOLIPASE D ACTIVATION BY THE LHRH 
RECEPTOR IN aT3 -1 CELLS 
M. Fennell, R. Mitchell, L. Garland* 
MRC Brain Metabolism Unit, 1 George Square, Edinburgh. 
*Wellcome Research Laboratories, Beckenham. 
The gonadotroph -derived cell line, aT3 -1 was used as a model system to 
study signalling mechanisms in pituitary gonadotrophs. The induction of 
phospholipase D (PLD) activity in aT3 -1 cells in response to 10M phorbol 
12,13 -dibutyrate or 100nM LHRH was assessed. Cells were preincubated 
with 5µCi/ ml [9,10 -3H] palmitate for 2 hours. Butan -1 -ol was used as a 
nucleophilic acceptor in the transphosphatidylation reaction carried out by 
PLD. Phosphatidylbutanol was separated by TLC and quantified by 
scintillation counting. 
In quiescent aT3 -1 cells the protein kinase C (PKC) inhibitor 
Ro 31 -8220 completely inhibited the PLD activity elicited by PDBu or LHRH, 
with ICs0s of 62 ±68 nM and 460 ±180 nM respectively. In quiescent aT3 -1 
cells the highly selective tyrosine kinase inhibitor Lavendustin A inhibited 
LHRH -induced PLD activity down to about 35% of its maximum with an ICso 
of 133 ±17 nM. When PLD activity was elicited by PDBu, Lavendustin A had 
no inhibitory effect. These results suggest that PKC and a tyrosine !dnase are 
both involved in PLD activation via the LHRH -I receptor, with the tyrosine 
kinase step coming before PKC in the activation pathway. 
In contrast, in growing aT3- i ceils Ro 31 -3220 only partially inhibited 
LHRH stimulated PLD activity. it therefore seems likely that another (PKC - 
independent) pathway can participate in LHRH -induced PLD activation. 
